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Few are those who see with their own eyes 
and feel with their own hearts 
 
Albert Einstein 
 
 
Reading after a certain age diverts the mind 
too much from its creative pursuits. Any man 
who reads too much and uses his own brain 
too little falls into lazy habits of thinking 
 
Albert Einstein 
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ABBREVIATION 
 
CHD:  coronary heart diseases; 
HDL:  high density lipoprotein; 
LDL:  low-density lipoprotein; 
NO:  nitric oxide; 
VCAM: vascular cell adhesion molecule; 
ICAM:  inter-cellular adhesion molecule; 
MCP:  monocyte chemotactic protein 
ACS:  acute coronary syndrome; 
ACE:  acute coronary event; 
SMC:  smooth muscle cell; 
Ox-LDL: oxidized low-density lipoprotein; 
ECM:  extracellular matrix;  
PDGF:  platelet-derivated growth factor 
TGF:  transforming growth factor; 
FITC:  fluorescein isothiocyanate;  
NZW:  New Zealand White;  
WHHL: Watanabe heritable hyperlipidemic;  
PDGF:  platelet-derivated growth factor; 
TNF:  Tumor necrosis factor; 
IC50:  inhibitory concentration;  
OCT:  optimal cutting temperature;  
H&E:  hematoxylin and eosin; 
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NI:  neointima; 
M:  media; 
Ad:  adventitia; 
Fig:  figure; 
DAPI:  4’,6-diamidino-2phenylindol. 
 CAD:  coronary artery diseases 
 
 AD-HIES autosomal dominant hyper IgE Syndrome 
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THESIS SUMMARY 
 
This thesis is aimed at evaluating a newly developed αvβ3 integrin targeted optical probe 
(ITOP) for the early detection of atherosclerotic plaque. It is equally aimed at better 
understand the molecular signature associated with the probe labeling and the associated 
mechanisms present in the context of the ITOP labeling. This thesis has been conducted 
under the direction of Professor Jacques Ohayon of the cellular dynamic team 
(DynaCell), laboratory TIMC-IMAG (techniques of medical engineering and of 
complexity, and of informatics, mathematics and applications of Grenoble), and Dr. 
Roderic I Pettigrew, of the National Institutes of Health, laboratory of integrative 
cardiovascular imaging science. The tools developed during this thesis have been used 
for the molecular and biological characterization, both in vitro and in vivo of the 
atherosclerotic plaque. This work has for problematic the evaluation of early 
atherosclerotic plaque detection with a novel αvβ3 ITOP, in different animal and human 
models, as WHHL (Watanabe heritable hyperlipidemic) rabbits, human with coronary 
arteries disease, and an AD-HIES (autosomal dominant hyper IgE syndrome) patient. 
Different techniques of pathological staining, immunohistofluorescence and 
immunohistochemistry has been used to better comprehend the link between the αvβ3 
ITOP labeling and the molecular and cellular characteristic of the plaque with an 
emphasis on the plaque vulnerability. The ultimate goals of the study focus on the 
evaluation of the αvβ3 ITOP for vulnerable plaque labeling, and the better 
comprehension of vulnerable plaque characteristic and possible mechanism of plaque 
instability. 
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To serve this purpose, the introduction will be focusing on the description of the 
atherosclerotic processes and pathophysiology, the description of the clinical imaging 
techniques allowing the detection of those atherosclerotic plaques, and the biomarkers of 
plaque instability. Angiogenesis and integrin will then be discussed more extensively, 
with an emphasis on αvβ3 probes, which was the ITOP used in this work to target 
atherosclerotic plaque. The introduction will also present the different animal and human 
models used in the thesis with their associated pertinence. 
 
The first chapter will be describing the results of an in vitro study with the αvβ3 ITOP in 
a WHHL rabbit model. This chapter will allow to determinate the potential of the probe 
for the detection of atherosclerotic plaque. In this chapter, results on molecular 
characterization of the probe will also be presented. 
 
The second chapter will be focusing on the in vivo confirmation of the results obtained in 
the in vitro study. This chapter will also describe some pathological and morphological 
findings related to the ITOP probe labeling. 
 
The third and fourth chapter will present in vitro results of the ITOP probe labeling on 
human coronary arteries, from respectively human with CAD and human with AD-HIES. 
Because of the importance and the difficulty to obtain human samples, there will be a 
more extensive pathological study in those two chapters. 
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The third chapter will be devoted to confirm the specificity of the αvβ3 ITOP labeling for 
the atherosclerotic plaque, in human coronary arteries from patients with CAD. There 
will be a pathological and immunological characterization of the samples, in order to 
associate the αvβ3 ITOP signal with plaque morphology and molecular markers. 
 
The fourth chapter will evaluated the same αvβ3 ITOP, in coronary arteries from a patient 
with AD-HIES. This human model is extremely rare and possesses several characteristics 
that rendered it very precious for the evaluation of our αvβ3 ITOP. First, previous 
imaging study reported a paucity of atherosclerosis in those patients. Second, they also 
reported an unusual prevalence of tortuosity, ectasia and aneurysms. Since vulnerable 
plaques and aneurysms are both associated with αvβ3 expression, it rendered AD-HIES 
model very pertinent for the evaluation of our ITOP. It is like having a knockout animal 
model, but with the pertinence of human biology. Very often, evaluation of another 
pathology in the context of understanding a disease, can lead to important discoveries. 
 
Finally, some theories will be exposed to feed further discussion, and a general 
conclusion and some limitations will be presented, as well as future perspectives.  
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INTRODUCTION 
 
 
1.1 ATHEROSCLEROSIS  
 
  
 1.1.1 Incidence and statistics 
 
Despite all the recent technological advances, cardiovascular disease remains the leading 
cause of death in the Western World. Atherosclerosis disease develops through the life 
course, beginning as early as adolescence, and often progresses silently before the 
development of its later sequelae of myocardial infarction, angina or stroke. Over the past 
years, cardiovascular disease has become the leading cause of death in United State 
adults, accounting for over 40% of deaths in both men and women[1, 2]. It is estimated that 
in the United States alone, more than 1 million person die annually from the 
complications of these conditions. According to the World Health Organization, in 2003, 
it was estimated that over 16 million people around the globe died of cardiovascular 
diseases (CVD), which represent over 29% of all deaths globally. Although CVD affects 
approximately 30% of both men and women at age 50, the prevalence reaches 75% by 
age 75. Overall, the lifetime risk for coronary heart disease (CHD) is approximately 40% 
in men and 30% in women. This leads to at least 20 million people surviving heart 
attacks and strokes every year, with many that will require continuing and costly clinical 
care. In the end, the cost of treating these diseases exceeds 360 billion dollars US and 
continues to rise importantly. These statistics reinforce the importance of developing 
newer methods of assessment that will allow the detection of subclinical atherosclerotic 
disease. 
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 1.1.2 Pathophysiology and Inflammation 
Until recently, atherosclerosis was considered as a simple lipid metabolism disorder 
resulting in build-up of fatty materials (cholesterol) in arteries. Mostly, atherosclerotic 
plaque was seen as “plumbing” issue and the treatment of choice was to try to break up 
these fatty build-ups to reestablish proper blood flow in the luminal area. There is now an 
extensive body of literature showing the complexity of atherosclerosis mechanism, and 
involving various key determinants. Inflammatory processes are known to play a major 
role in this process. There is also a consensus pointing out atherosclerosis as a 
multifactorial process that is largely influenced by risk factors[3] (smoking, high blood 
pressure, elevated blood levels of cholesterol) and resulting in a chronic inflammatory 
response (Fig. 1)[4]. Actually, there is a predominant theory, according to the fact that 
atherosclerosis is initiated by the endothelium in response to an injury (dysfunctional 
endothelium)[5, 6]. Effectively, endothelial cells are exposed to many stimuli: free radicals, 
reactive oxygen species, low-density lipoprotein (LDL) uptake and oxidation, mechanical 
forces (shear stress), nitric oxide (NO) diminution, etc. Then, the endothelium reacts by 
expressing various “adhesion molecules” at their surface, as VCAM (vascular cell 
adhesion molecule) and ICAM (inter-cellular adhesion molecule) and selectin, as well as 
cytokines like monocytes chemotactic protein (MCP)-1. These adhesion molecules 
trigger the recruitment of lymphocyte and monocytes, their adhesion to the arterial wall 
and their translocation into the vessel wall. Inside the arteries, monocytes will become 
activate by the ox-LDL, which lead to the expression of scavenger receptor and foam 
cells formation. This inflammatory state also contributes to the release of many cytokines 
(MMPs, interleukin-1, interleukin-6, tumor necrosis factor α, interferon, etc.) and growth 
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factors (macrophage colony stimulating factor, colony stimulating factor) by the activated 
macrophages and T-cells. These growth factors will then be responsible of the 
recruitment and the proliferation of smooth muscle cells (SMCs), their migration from 
media to intima, and their proliferation into the intima. They will be a subsequent 
extracellular matrix (ECM) production and deposition by the activated SMCs, and the 
fibrous cap formation. The presence of oxidized LDL (ox-LDL), inflammatory 
 
Reproduced from website: www.laddmcnamara.net 
 
Figure 1 Events leading to atherosclerotic plaque formation 
 
It is difficult to represent sequentially the events leading to atherosclerotic plaque 
formation, because of the complex crosstalk between plaque constituents and 
molecules. Nevertheless, plaque formation can be summarized as following: 1. LDL 
entrance and oxidation. Activated endothelium. 2.  Monocytes adhesion to 
endothelium by VCAM, ICAM. 3. Monocytes extravagation inside vessel wall. 4. 
Cytokines activation. Monocytes differentiation. Scavenger receptors expression. 5. 
Lipid accumulation and transformation into foam cells. 6. SMCs activation and 
migration to form fibrous cap. Release MMPs and Tissue factor (TF). 7. Necrotic core 
formation and plaque growth. Note that 6 and 7 are concomitant processes and that 
imbalance between proteolytic activity and SMCs proliferation can lead to plaque 
rupture and thrombus. 
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mediators, cytokines, foam cells, and apoptosis, contribute to plaque growth and 
instability. All these key molecules feed two major processes in plaque formation. The 
first one is intimal thickening caused principally by the constant lipid accumulation 
coming from the trapped intraplaque modified LDL and the absence of proper 
phagocytosis system that would remove extracellular debris from macrophages apoptosis 
and foam cells presence. The second one, caused by the presence of all the cytokines, 
growth factors and inflammatory mediators activated by ox-LDL that will lead to 
neointima formation (SMCs proliferation, migration, and ECM synthesis), and plaque 
healing.  
 
 1.1.3 Plaque Histology and Morphology 
Normal arteries are generally composed by five different categories of tissue: 
endothelium, muscle cells, elastin, collagen and ECM[7]. The first layer of cells in contact 
with the lumen is the endothelium, and it represents a barrier between the blood and the 
arterial wall. It is composed by a monolayer of epithelial cells. SMCs are another type of 
cells present in arteries and are, in conjunction with ECM, responsible for the elastic 
properties of the vessel wall. Coronary arteries possess multilayers of SMCs, which are 
responsible for the secretion of elastin, a protein that constitutes an important part of the 
arteries. The elastin is present on a polymerized form inside the wall, which constitutes a 
fiber network that can sustain high tension and constraints. Another major protein present 
in the arteries and also secreted by SMCs is the collagen. Collagen fibers are bounded to 
each other and they are responsible for the mechanical resistance of the tissue. Finally, all 
these various components are hold together by a matrix called ECM. The ECM provides 
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structural support to the tissue, is very viscous, and principally composed by 
polysaccharides and proteoglycans. Structural proteins (elastins and collagen) as well as 
specialized proteins (fibronectin, vitronectin, laminin, etc.) also composed the ECM. 
In arteries, these constituents are organized in 3 different layers: the tunica intima, the 
tunica media, and the tunica adventitia (Fig. 2). In textbook, the ideal representation of 
the intima is composed by a monolayer of endothelial cells embedded in ECM, and held 
together by junctional complexes. In reality, there is no ideal single monolayer of 
endothelium in arteries[8]. In fact, early in life, the intima differentiates into a thicker, 
 
Figure 2 Representation schematic of the constituents of the coronary wall 
 
In arteries, these constituents are organized in 3 different layers: the tunica intima, the 
tunica media, and the tunica adventitia. In textbook, the ideal representation of the 
intima is composed by a monolayer of endothelial cells embedded in ECM, and held 
together by junctional complexes. In coronary arteries, there are also two membranes 
separating the intima from the media and the media from the adventitia: the internal 
elastic lamina (IEL) and the external elastic lamina (EEL). These two membrane, as 
their name indicate, are constituted by elastic fibers. 
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better-developed intimal layer, because of the environment it is exposed to (mechanical 
stress, free radical, LDL). Indeed, all humans are carriers of a certain degree of 
hyperplasia, although this phenomenon is benign, resulting in resident SMCs into the 
intima. The media is principally composed by multilayers of SMCs, and bundles of 
collagen fibers and elastic fibrils, all embedded in the ECM. Finally, the adventitia, 
which is considered the most variable layer of the artery, is a relatively thin connective 
tissue layers. Fibroblasts are the predominant cell type, but there are also macrophages. 
The adventitia contains collagen, dense fibroelastic fibers (not lamellae), nutrient vessels 
(vasa vasorum), and nerves. In coronary arteries, there are also two membranes, 
constituted by elastic fibers, separating the intima from the media and the media from the 
adventitia: the internal elastic lamina (IEL) and the external elastic lamina (EEL). Often, 
the EEL will be use as a measurement of the total vessel area, because the adventitia 
layer is sometime difficult to delineate. 
In atherosclerosis, there is an important thickening of the intima layer[9]. This is 
principally due to the infiltration and retention of LDL, which after being oxidized, are 
trapped inside the wall. These process lead to the recruitment of monocytes, 
differentiation into macrophages and ultimately, formation of foams cells and what is 
called necrotic core (lipids, foam cells, cellular debris). Cytokines and growth factors 
released by macrophages and T-cells will activate SMCs into the media, which will 
secrete more ECM, and will eventually cause the migration of SMCs into the intima, for 
the formation of the fibrous cap. In some circumstances, the adventitia layer will also 
thicken, mostly because of the neovascularization and the presence of inflammation.  
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 1.1.4 Vulnerable Plaque and Positive Remodeling 
It is very difficult to predict the rupture of an atherosclerotic plaque, and the definition of 
these types of plaques has been debated for decades. Most of the time, cardiovascular 
events are sudden and unpredictable. There are, although, some morphological, cellular, 
and molecular features that can be related to plaque vulnerability[10, 11]. A vulnerable or 
unstable plaque is an atherosclerotic plaque, which is liable to complications and is prone 
to thrombus. For a long time, it has been postulated that plaques that were clinically 
relevant was the one with an important degree of stenosis (Fig. 3). Now, it is generally 
accepted that plaque composition, rather than luminal stenosis is considered the major 
determinant of plaque vulnerability[12, 13]. Although vulnerability is difficult to define, the 
majority of vulnerable plaques share the same characteristics. Most importantly, it has 
been reported that the majority of plaque ruptures occur in a segment with low-grade 
stenosis, but presenting outward or positive remodeling[14-16]. Effectively, as elegantly 
demonstrated by Glagov[17], at early stages of plaque development, arterial vessels 
enlarge in relation to plaque area, and lumen stenosis is delayed until the lesion occupies 
approximately 40% of the potential lumen area. This phenomenon is called compensatory 
enlargement of the vessel wall. According to this theory, for values above 40% stenosis, 
the lumen diminishes markedly and in close relation to the percentage of stenosis. Glagov 
findings demonstrated for the first time that despite presenting an adequate or normal 
lumen area, coronary arteries could present advanced atherosclerosis (Fig. 4). His 
findings were also the premises for the discovery of positive remodeling, which is 
defined by an outward bulging or expansion of the arterial wall. As mentioned before, 
this phenomenon has been largely associated with plaque vulnerability and rupture, as 
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opposed to negative remodeling, which are associated with vessel shrinkage and higher-
grade stenosis, but more stable phenotype. 
 
Reproduced from www.intranet.tdmu.edu.te.ua 
 
Figure 3 Representation schematic of plaque formation versus clinical 
events 
 
Schematic representation of atherosclerotic plaque progression, from normal coronary 
vessel to vessel with highly stenosed plaque. Before the plaque reaches the stenotic 
phase, the vessel goes into a positive remodeling phase. For a long time, it has been 
postulated that plaques that were clinically relevant was the one with an important 
degree of stenosis. It is now understand that plaque composition, rather than luminal 
stenosis is the major determinant of plaque vulnerability. It is becoming accepted that 
plaque rupture often occur in the presence of low-grade stenosis, and that stenosis is 
not a good predictor of ischemic events.  
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Apart from being in a positive remodeling stage, vulnerable lesions also possess some 
common morphological features[18]. First, these plaques possess a thin fibrous cap, 
usually less than 65µm, with very few collagen fibers. Since the fibrous cap is a dynamic 
structure, its thickness depends on the collagen synthesis by VSMCs as well as on the 
collagen degradation by MMPs. Secondly, these plaques have a very large lipid core area, 
usually more than 40% of the neointima. Moreover, the lipid core contains a large 
 
 
Adapted from Glagov et al. N Engl J Med 1987; 316(22):1371-1375. 
 
Figure 4 Compensatory enlargement of coronary artery as described by 
Glagov 
 
At early stages of plaque development, arterial vessels enlarge in relation to plaque 
area, and lumen stenosis is delayed until the lesion occupies approximately 40% of the 
potential lumen area. This phenomenon is called compensatory enlargement of the 
vessel wall. According to this theory, for values above 40% stenosis, the lumen 
diminishes markedly and in close relation to the percentage of stenosis. Glagov 
findings demonstrated for the first time that despite presenting an adequate or normal 
lumen area, many persons have advanced atherosclerosis. His findings were also the 
premises for the discovery of positive remodeling, which is defined by an outward 
bulging or expansion of the arterial wall. 
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amount of cholesterol esters and is soft, which present a higher propensity to rupture than 
fibrotic plaques. Among the factor contributing to plaque instability and rupture, plaque 
inflammation, both local and systemic, is considered to be the most important one. 
Inflammation plays a major role in plaque formation, progression, instability and rupture, 
although the importance of the key players is often debated. Nevertheless, a large number 
of macrophages are another characteristic of unstable plaques. Indeed, the number of 
infiltrated macrophages in the thin fibrous cap is often greater than 25 cells per high 
power field (40X, field diameter 0.3mm). Macrophages are often distributed at the 
shoulder region of the lipid core in fibrous plaques (type V), but are distributed diffusely 
in vulnerable plaques[19, 20]. In the neointima of vulnerable plaques, there is generally a 
smaller number of VSMCs. Another important factor in plaque vulnerability is the 
increased plaque thrombogenecity, which is characterized by an increase in plasminogen 
activator inhibitor (PAI), plasma fibrinogen, tissue factor (TF), and platelet activation and 
aggregation. Finally, a diminution of elasticity is also an important factor for plaque 
instability. Effectively, as seen in aneurysm, absence of collagen and elastic fibers lead to 
positive remodeling and can causes rupture of the vessel wall. Microcalcifications have 
also been linked to plaque instability[21]. 
Finally, after the initial plaque formation or rupture, there are two possible fates: one is 
the healing and sealing of the plaque and the other one in an acute coronary event (ACE). 
Again, at this stage, there is a number a different biological and physical/mechanical 
factors that will determinate which event will take place (Fig. 5). 
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There is an extensive body of literature and images on plaque progression and instability, 
and the clinical event associated with them. It is often difficult and confusing to navigate 
through them, because of the absence of definition or because of the conflicting 
representation. Plaque progression, clinical events, and coronary artery disease (CAD) 
severity are often associated with luminal stenosis, without taking into account plaque 
composition or compensatory lumen enlargement described by Glagov (Fig. 6A). Over 
 
Reproduced from Libby P. Nature 2002; 420(6917):868-874. 
Figure 5 Events leading to atherosclerotic plaque rupture or healing 
 
After the initial plaque formation, there are two possible fates: the plaque can either 
stabilize or develop into a vulnerable plaque. In the same way, after the rupture, the 
plaque can either be sealed and healed, or it can produce a thrombosis and causes a 
coronary event. 
 
 
 
Page 28 of 246 
 
the recent years, it has become clearer that this schematic representation of plaque 
progression might be bias. In fact, advanced atherosclerotic plaque and thrombosis events 
are often seen in vessel wall with very minimal stenosis (Fig. 6B). In the other hand, 
plaque’s healing response often lead to increased collagen accumulation and SMCs 
 
 
(A) Open-source image from http://en.wikipedia.org/wiki/Atherosclerosis 
Adapted from Pepine CJ. Am J Cardiol. 1998; 82(Suppl.10A): 23S-27S. 
(B) Libby P. Circulation 2001; 104(3):365-372. 
 
Figure 6  Stage of endothelial dysfunction in atherosclerotic plaque 
formation 
 
The sequence of events leading to progression of atherosclerosis, related to lumen 
stenosis and clinical event. (A) Representation schematic of plaque progression with 
lumen narrowing and absence of positive remodeling. (B) Representation schematic 
of plaque progression with positive remodeling and absence or minimal lumen 
stenosis. There is an extensive literature on plaque progression that related plaque 
progression, and clinical events to stenosis (A). There are currently many evidences 
supporting that advanced atherosclerosis is present without or with minimal lumen 
narrowing, and that thrombosis is often associated with little lumen encroachment (B). 
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growth. This mechanism transform fibrofatty lesion into advanced fibrous and often 
calcified plaque, which may causes significant stenosis[22]. In agreement with this theory, 
despite being in their early stage, plaque can present advanced atherosclerosis and 
vulnerability to rupture, as opposed to healed plaques that can show important stenosis. 
In fact, as elegantly schematized by Naghavi et al, among the numerous types of 
vulnerable plaques, most of them are characterized by an absence of very little lumen 
narrowing (Fig. 7)[23]. Therefore, it becomes imperative to develop imaging modalities 
that take this important phenomenon into account. 
 
 
 
 
Reproduced from Naghavi M et al. Circulation 2003; 108(14):1664-1672. 
 
Figure 7  Different types of vulnerable plaque as underlying cause of acute 
coronary events (ACS) and sudden cardiac death (SCD) 
 
(A) Rupture-prone plaque with large lipid core and thin fibrous cap infiltrated by 
macrophages. (B) Ruptured plaque with subocclusive thrombus and early 
organization. (C), Erosion-prone plaque with proteoglycan matrix in a smooth muscle 
cell-rich plaque. (D), Eroded plaque with subocclusive thrombus. (E) Intraplaque 
haemorrhage secondary to leaking vasa vasorum. (F) Calcific nodule protruding into 
the vessel lumen. (G) Chronically stenotic plaque with severe calcification, old 
thrombus, and eccentric lumen. 
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1.1.5 Histological classification of atherosclerosis 
As mention earlier, atherosclerotic plaque classification is not an easy task. Nevertheless, 
in the nineties, Stary HC and al. produced a series of 3 reports, published in both 
Circulation journal and Arteriosclerosis, Thrombosis, and Vascular Biology journal, 
aiming at describing and defining the characteristic components of atherosclerotic 
plaques by types[19, 20, 24-27]. They also try to correlate the appearance of lesions noted in 
clinical imaging with histological lesion types, and corresponding clinical symptoms. 
Those reports where the backbone of many other publications and attempt at 
classification. Unfortunately, in many subsequent reports and publications, there is a 
tendency to related stenosis with advanced atherosclerosis and clinical complications 
(Fig. 3, Fig 6A). In the original report, 6 principal types of plaques were described (Type 
I to Type VI), with type II that can be divided into type IIa and IIb, and the type V that 
can be divided into type Va, Vb and Vc (Table 1). The 3 first types are considered early 
lesions, although type I and type II are not generally precursors of more advanced 
atherosclerosis and can be seen in adults. Type III is the intermediate lesion forming the 
bridge from early to more advanced atherosclerosis. Type IV lesions are the first lesion 
considered as advanced atherosclerosis. It is also the first one considered to become 
clinically overt. Type V is generally constituted by an intima thickened by substantial 
reparative fibrous tissue (mainly collagen). The presence of fibrous connective tissue and 
lipid core(s) characterized type Va (fibroatheroma), and the predominant presence of 
calcification into a fibrolipid lesion characterized type Vb (calcific). Type Vc (fibrotic) 
only has minimal lipid and no calcification. Type VI lesions are lesions with thrombus, 
hematoma, and surface defect. 
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According to this classification, type IV lesions can be seen as the vulnerable plaques that 
are extensively described in the literature. Therefore, as illustrated in the diagram of 
Table 1, type IV lesion can either rupture to produce a clinical event, or healed and 
 
Reproduced from Arterioscler Thromb Vasc Biol 1995; 15(9):1512-1531. 
 
Table 1 Evolution and progression of human atherosclerotic lesions 
 
Flow diagram in center column indicates pathways in evolution and progression of 
human atherosclerotic lesions. Roman numerals indicate histologically characteristic 
types of lesions. From type I to type IV, changes in lesion morphology occur 
primarily because of increasing accumulation of lipid. The loop between types V and 
VI illustrates how lesions increase in thickness when thrombotic deposits form on 
their surfaces. 
 
Page 32 of 246 
 
become a more stable type V lesion. Type IV lesions, and sometime type V lesions, can 
rupture, healed and become a type VI lesion. It can also be noted that type VI lesion can 
also healed and evolve into type V lesion. In summary, a vulnerable plaque can rupture 
and produce symptoms, or it can heal and become stable. The plaque rupture can also be 
sealed and become more stable. 
Lesion from type I to III are not considered to thicken the arterial wall and do not 
produce lumen narrowing. Type IV lesions are considered minimally obstructive and do 
not produce significant lumen narrowing. Type V lesions produced different degrees of 
lumen narrowing, while type VI lesions are often very obstructive. Inasmuch, it is not 
unreasonable to think that lumen narrowing and stenosis is a result of a process of plaque 
healing. Therefore, when representing plaque progression, the phenomenon of 
compensatory enlargement previously described by Glagov[17], one of the author of those 
reports, has to be taken into account. Also, it has to be noted that the type of plaques 
described into those publications does not necessary represent a linear progression of 
atherosclerosis evolution. For example, type I and II lesions are not necessary the 
precursor of more advanced lesions. In the same way, type IV lesions can either rupture 
and create a coronary event, healed and become a more stable plaque (type V), or rupture 
and healed creating a type VI lesion. Moreover, type VI lesion can regressed into a more 
stable type (type V). 
It is consequently imperative to pursue the challenge of characterizing atherosclerotic 
lesions in the context of clinical situations. This clinical classification will allow 
depicting the plaque histology as closely as possible, and specifically targeting the 
problematic lesions with appropriate treatments. 
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1.2 IMAGING THE PLAQUE[28] 
 
 1.2.1 Current diagnostic medicine 
Angiography has been used for decade to evaluate patients with atherosclerosis and is 
seen as the conventional method for imaging the plaque. Nevertheless, with the recent 
insight regarding plaque composition and the better understanding of plaque biology, it 
has become imperative to find new imaging techniques that rely on plaque constituents, 
rather than degree of stenosis (Fig. 8). Effectively, there is growing evidences that the 
 
Reproduce from Sanz J and Fayad ZA. Nature 2008. 451(7181):953-957. 
 
Figure 8 Molecular imaging of the atherosclerotic plaque 
 
With the recent advances in plaque composition and the better understanding of 
inflammation processes in plaque formation, there is a broad development of targeted 
probes for the detection of vulnerable plaques. 
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events leading to coronary disease and sequelae appeared at an earlier stage of 
atherosclerosis, and that it is poorly correlated with the degree of stenosis. Thus, a 
number of new biomarkers and imaging techniques has been developed to detect 
atherosclerosis at an earlier stage and better predict plaque rupture. 
 
 1.2.2 Angiography 
Despite its numerous limitations, X-ray angiography is considered as the current “golden 
standard” regarding the detection of advanced atherosclerotic lesions and measurement of 
degree of stenosis (Fig. 9). The major limitation of angiography is the fact that it is 
 
 
Figure 9 Conventional angiogram of LAD in left anterior oblique views 
 
76-year-old male with none-significant stenosis (A) in the proximal LAD (yellow 
arrow) and significant stenosis (B) in mid LAD (red arrows) seen by conventional 
angiogram 
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simply based on imaging the vessel’s lumen, thus it fails to detect atherosclerotic lesion 
that does not protrude into the lumen, or the one with positive remodeling, which are 
considered important in term of vulnerability. This imaging method also provides very 
little information about plaque composition. These important limitations prevent 
angiography to differentiate between stable and unstable plaque, therefore rending it 
unable to assess or predict the risk of plaque rupture. Consequently, the main value of 
angiography will be to delineate the causative lesions in a symptomatic patient, making it 
a mostly “symptom driven” imaging technique.  
 
1.2.3 IVUS 
Intravascular ultrasound (IVUS) is an invasive imaging modality in which a small 
ultrasound probe mounted on a catheter is passed through the blood vessels. It allows 
direct imaging of the vessel area and atheroma, as well as a cross-sectional image of the 
complete plaque and vessel wall (Fig. 10). Thus, unlike angiography, IVUS can detect 
non-stenotic atheromatous plaques. It also allows plaques to be categorized as soft, 
fibrous or calcified. In spite of its utility for the detection of plaques otherwise missed by 
angiography, IVUS has major drawbacks: it is invasive, expensive, and demand more 
level of expertise than the other imaging modalities to be performed. In USA, it is mostly 
confined to research and determining the success of interventions, but in European 
countries, it is practice more often for the exploration of patients already considered at 
risk. Despite all these drawbacks, IVUS can be useful to detect plaque that are in a 
positive remodeling stage and considered as vulnerable. 
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Reproduced from www.natcomp.liacs.nl 
 
Figure 10 Cross-section of a coronary artery seen by IVUS 
 
In vivo imaging of a coronary artery by IVUS, showing the different constituent of the 
atherosclerotic plaque: calcification, necrotic core, and lumen. Unlike angiography, 
IVUS can detect atherosclerotic plaques that are not stenotic. 
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 1.2.4 PET 
Position emission tomography (PET) is the use of a radioactive tracer, administered 
intravenously, to detect its accumulation at a site of interest (Fig. 11). After a certain 
amount of time (depending of the radiotracer used), the tracer’s level became sufficiently 
low in the blood, and high in the target site, allowing a favorable target to background 
signal. PET is an imaging technique currently functional at the molecular level. The 
sensitivity of the modality is several orders higher than MRI, however, the resolution 
achieved is significantly less. Another drawback of the PET is that it requires the use of 
ionizing radiation. 
 
 
Reproduced from Rudd JH et al. Circ 2002; 105(23):2708-2711. 
 
Figure 11 Imaging by PET scan with 18FDG  
 
The upper row (left to right) shows PET, contrast CT, and co-registered PET/CT 
images in the sagittal plane, from a 63-year-old man who had experienced 2 episodes 
of left-sided hemiparesis. Angiography demonstrated stenosis of the proximal right 
internal carotid artery; this was confirmed on the CT image (black arrow). The white 
arrows show 18FDG uptake at the level of the plaque in the carotid artery. As 
expected, there was high 18FDG uptake in the brain, jaw muscles, and facial soft 
tissues. The lower row (left to right) demonstrates a low level of 18FDG uptake in an 
asymptomatic carotid stenosis. The black arrow highlights the stenosis on the CT 
angiogram, and the white arrows demonstrate minimal 18FDG accumulation at this 
site on the 18FDGPET and co-registered PET/CT images. 
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 1.2.5 CT 
Computed tomography (CT) is an imaging modality that uses X-ray beam to image a 
patient in thin sections. The computer generates an image based on different densities 
with multiple detectors, after the beam has traversed the patient. CT is an excellent 
imaging technique for soft tissue contrast and discrimination, so it allows to determinate 
plaque composition. It also allows imaging deep structures like coronary arteries, with a 
relatively high degree of resolution (Fig. 12), but it is not a functional technique for 
molecular imaging or plaque vulnerability assessment. Although CT is useful to image 
small vessels, it is a very expensive imaging technique and it involves the use of 
radiations and contrast agents that introduce risks of nephrotoxicity and anaphylaxis. 
 
 
Figure 12  320-detectors CT scan of coronary arteries 
 
(A) 3D reconstruction of a CT scan, showing RCA, LAD, and LCX. (B) 76 year old 
male with none-significant stenosis in the proximal LAD (yellow arrow) and 
significant stenosis in mid LAD (red arrows) seen by maximum intensity projection 
(MIP) in left anterior view of the LM/LAD. 
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 1.2.6 MRI  
Magnetic resonance imaging (MRI) is a method of choice for the first screening of 
atherosclerosis: it is non-invasive, does not involve ionizing radiation, and provides high-
resolution images of multiple vascular territories. Unlike CT, MRI contrast agents are 
well tolerated and less likely to alter kidney function or to cause an allergic reaction. The 
major technical advantage of MRI is the capacity of characterizing and discriminating 
among tissues using their physical and biochemical properties (Fig. 13). Thus, it allows 
 
 
Figure 13 Comparison between MRI and CT of a cross-section of a coronary 
  artery 
 
CT scan (upper panel) compare to MRI (lower panel) of coronary artery wall. MRI 
showed some of the constituents of the coronary artery wall at a plaque area. The 
lumen, vessel wall, coronary branch, and a necrotic core can be visualized. 
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differentiating between different constituents of the plaque (lipids, calcium, fibrous 
tissue, hemorrhage, necrotic core…). In the other hand, one of the most important 
challenges of MRI is the motion of the heart, rending the scan more difficult and time-
consuming. It is also a relatively expensive imaging modality and is probably the imaging 
modality the most technically challenging. Also, due to the resolution, it is difficult to 
detect plaques at the stage of positive remodeling. 
 
 1.2.7 Optical Imaging 
The perfect imaging modality for atherosclerosis would be easy to use, has a limited cost, 
and could be integrated with traditional laboratory techniques. Optical imaging 
(bioluminescence, fluorescence molecular tomography…) can fulfill these requirements 
and is an attractive imaging method for scientists without extensive knowledge (Fig. 14). 
Indeed, optical imaging apparatus are less expensive to purchase, easier to maintain, and 
does not require radiation permits or shielding. Moreover, optical imaging agents are 
usually harmless and nontoxic, plus they do not decay, so they can be stored on the shelf. 
Optical imaging also integrate very well with other laboratory techniques, as imaging 
agents can be use ex vivo for FACS or immunofluorescent histology, after in vivo 
imaging. Unfortunately, one of the major drawbacks of optical imaging is the low 
penetration of imaging agents, making it difficult to use for deep tissue like heart, or 
necessitating invasive procedures as catheterization.  
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 1.2.8 Multimodality Imaging 
It is becoming clear that there is no such thing as the perfect imaging modality for the 
detection of early or vulnerable atherosclerosis. Indeed, all the imaging modality are 
complementary, in a way that one modality can compensate for the lack of the others. By 
combining the different imaging modalities, which can overcome the limitations of some 
of them by using their respective strengths (Fig. 15). Heart is probably the most 
challenging structure to image, as it is deep inside the body, in constant movement, and 
contains arteries that are relatively small and difficult to visualize. By combining high-
 
Adapted from Farouc AJ et al. Circ 2007; 115(17):2292-2298. 
 
Figure 14 In vivo optical imaging of cathepsin K in carotid atherosclerotic 
plaques of ApoE-/- mice 
 
(A) Fusion in vivo image of a carotid vessel (5X magnification; 13X13 µm in-plane 
resolution; 10 µm slice thickness) demonstrating focal cathepsin K signal (green) in 
an atherosclerotic lesion (arrowhead). (B) Fusion image of a carotid plaque 
(arrowhead) in the control group demonstrating minimal NIRF signal in the cathepsin 
channel. 
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resolution imaging and good soft tissue contrast that give us information about anatomic 
structures, with high sensitivity technique that provide us with molecular information, we 
can probably achieve the challenge of detecting atherosclerotic plaque, before the 
apparition of the clinical symptoms, rupture and heart attack or stroke. 
 
 
 
Adapted from Makowski MR et al. Eur Heart J 2008; 29(18):2201. 
 
Figure 15 Multimodality imaging of angiogenesis 
 
Cardiac MRI with delayed enhancement (arrows) extending from anterior wall to 
apical region in 4-chamber (A) and 2-chamber (D) views. Identically reproduced 
location and geometry with severely reduced myocardial blood flow obtained with 
13N-ammonia, corresponding to regions of delayed enhancement on cardiac MRI 
(arrows) (B and E). Focal 18F-RGD signal colocalized to infarcted area. This signal 
may reflect angiogenesis within healing area (arrows) (C and F). LA = left atrium; LV 
= left ventricle; RA = right atrium; RV = right ventricle.  
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1.3 BIOMARKERS OF INSTABILITY 
 
 1.3.1 Angiogenesis 
1.3.1.1 Integrin 
Integrin are glycoproteins belonging to a family of heterodimeric transmembrane 
receptors, each consisting of an α (alpha) and a β (beta) polypeptidic chain[29-31]. The role 
of integrin is to mediate cell-to-cell and cell-to-extracellular matrix (ECM) interactions 
and communication, so they are involved in many mechanisms like cell grow, cell 
division, cell survival, cell differentiation and apoptosis. Thus, the two main functions of 
integrin are: attachment of the cell to the ECM and signal transduction from the ECM to 
the cell. To date, there are 19 alpha and 8 beta mammalian subunits that have been 
identified. The pairing of these different subunits provides a combination of 25 unique 
integrins. Electron microscopy studies about the basic structure of integrins revealed that 
these proteins consist of a very large extracellular N-termini domain with a membrane–
spanning region and a very small cytoplasmic tail (about 40-70 amino acids). Both α and 
β subunit contain separate cytoplasmic tails penetrating the plasma membrane. The 
molecular mass of the subunits can vary from 90 kDa to 160 kDa. Both α and β subunits 
contain binding sites for several divalent cations. The β subunit also contains four 
cysteine-rich repeated sequences. In a non-activated environment, integrins exist in bent 
“closed” conformations, which have low affinity for the ligand. When the environment 
become favorable (triggers by cellular event), the integrin become activated and the 
structure can be unfolded to facilitate visualization of the domain leading to better 
receptor affinity for the ligand. When activated, integrin can also form clusters of hetero-
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oligomers. Integrin activation is a complex multi-steps process that require the 
participation of many factors and that is controlled by different mechanisms (Fig. 16). 
This activation is achieved by reversible changes in the conformation of the extracellular 
domain of the integrin heterodimer, which leads to an increased affinity for the ligand. 
 
Reproduced from www2.unil.ch/cepo_research/introduction.html 
 
Figure 16 Proposed model of integrin activation 
 
In a non-activated environment, integrins exist in bent “closed” conformations, which 
have low affinity for the ligand. When the environment becomes favorable, integrins 
become activated and the structure can be unfolded to facilitate the binding of the 
ligand. When activated, integrin can also form clusters of hetero-oligomers. This 
activation is achieved by reversible changes in the conformation of the extracellular 
domain of the integrin heterodimer, which leads to an increased affinity for the ligand. 
The association with another protein called Talin also regulates it activation by 
separating the two intracellular subunits of the integrin and by opening the binding 
site. 
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The association with another protein called Talin also regulates it activation, by 
separating the two intracellular subunits of the integrin and opening the binding site. The 
tight regulation of integrin activation is highly important, as these molecules are involved 
in many key mechanisms like tumor metastasis and embryonic development. In 
atherosclerosis only, they play many different roles, being involve in leukocyte 
trafficking[32], cell migration[33], angiogenesis[34], and thrombus formation[35]. 
 
1.3.1.2 αvβ3 
The αvβ3 integrin is composed of two subunits: one αv (CD51 protein) subunit and one 
β3 subunit (CD61 protein). αvβ3 integrin is also called vitronectin receptor. Even though 
the high-resolution structure of integrin proved to be challenging to discover, the 
complete extracellular domain of the αvβ3 integrin structure was obtained in 2001 by X-
ray crystallography[36]. A more recent study by the same team elucidated the entire 
ectodomain by crystallography[37]. Unlike all the postulated molecular models, the X-ray 
structure showed the molecule folded into an inverted V-shape (Fig. 17), which was a 
surprise compare to the predicted structure. This inverted V-shape brings the ligand-
binding site very close to the cell membrane. This structure poses many challenges in 
regard of the ligand binding and signal transduction. Effectively, the ligand-binding site, 
which is directed toward the C-terminal of the integrin will be obstructed, especially 
considering that integrin ligands are large and massive molecules, also cross-linked to the 
ECM. Although the crystal structure remains surprisingly the same after the ligand 
binding (in this case cilengitide), the current hypothesis is that integrin function involves 
conformational changes, which moves the binding site away from the cell surface, into a 
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more accessible site. Thus, integrin activation is a necessary process for ligand binding. It 
is postulated to be accomplished by a protein named Talin, which bind the β tale of the 
molecule and triggers a change in the integrin shape[38]. The most convincing evidence 
supporting this theory is that some antibodies only recognize integrin in their activated 
form, when they bonded with their ligands[39]. The mechanism of integrin activation and 
their inside-out/outside-in signaling is very sophisticated and complex. Inasmuch, it is 
 
Reproduced from Xiong JP et al. Science 2001. 294(5541):339-45. 
 
Figure 17 Crystallography structure of the ectodomain of the integrin αvβ3  
 
Unlike all the postulated molecular models, the X-ray structure showed the molecule 
folded into an inverted V-shape, which was very different from the predicted 
structure. Because this structure is hiding the catalytic domain close to the cell 
membrane, it has later been postulated that an activation step is necessary for the 
binding of the ligand. 
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beyond the scope of this study to explain those mechanisms. Vitronectin, fibronectin, 
fibrinogen, osteopontin and Cyr61 are some of αvβ3 ligands[36, 40]. The variety of ligands 
explains its large distribution among melanoma, glioblastoma, activated endothelial cells, 
smooth muscle cells and macrophages. In the context of atherosclerosis alone, αvβ3 
integrin is involved in many processes. Effectively, the vitronectin receptor mediates 
several biological events that are critical to the formation of the neointima[41, 42]. First, 
αvβ3 promotes SMCs migration[43]. Effectively, it as been previously shown that, by 
outside-in signaling, the occupied αvβ3 receptor enables the platelet-derivated growth 
factor (PDGF) to activate a series of event that will ultimately lead to cell migration[44]. 
Secondly, αvβ3 increases transforming growth factor-β (TGF-β) activation, by a 
mechanism still unknown[45]. In fact, in normal condition, TGF-β is expressed as an 
inactive complex that necessitate activation for binding to its receptor and be effective. In 
vitro, αvβ3 integrin has been shown to bind latent TGF-β and liberate an active form of 
the cytokine. Interestingly, αvβ3 expression can also be upregulated by TGF-β, 
suggesting a possible feed-forward loop that might drive further TGF-β activation.  
Another implication of αvβ3 in neointima formation involves its effect on apoptosis. In 
recent studies, it has been shown that the presence of αvβ3 receptor inhibits foam cell 
formation and apoptosis, and promotes cell survival[46]. For example, ligation of αvβ3 
integrin in macrophages down-regulates the expression of scavenger receptor CD36 and 
SRA, which in turn decreases lipid accumulation and foam cell formation.  In a different 
manner, expression of αvβ3 integrin in VSMC prevents the down-regulation of PINCH-
1, a survival protein linked with integrin and the cytoskeleton[47]. This stabilization of 
PINCH-1 prevents the disruption of the cytoskeleton and ultimately leads to cell survival. 
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Finally, another role of αvβ3 in neointima formation is the enhancement of 
neovascularization[48-50]. Effectively, vasa vasorum angiogenesis and medial infiltration 
provides nutrients to the developing and expanding neointima, which contribute to plaque 
growth in early lesions[51]. Also, in more advanced lesions, the constant infiltration of 
inflammatory cells and the concomitant production of numerous pro-angiogenic and pro-
inflammatory cytokines could lead to an unstable rupture-prone environment.  
 
 1.3.2 Matrix Metalloproteinases (MMPs) 
MMPs proteins are belonging to a family of proteases known as metzincin 
superfamily[52]. There are numerous forms of MMPs with various substrate specificities, 
even though there is overlapping substrate specificity in many of them. MMPs are zinc-
dependent endopeptidases involve in the degradation of different kinds of extracellular 
matrix proteins as well as the process of bioactive molecules. They are involved in many 
cellular processes as in the activation and inactivation of chemokines and cytokines, the 
cleavage of cell surface receptors, as well as the release of apoptotic ligands such as FAS 
ligand. MMPs are also known to play a major role in cell behaviors such as proliferation, 
migration, differentiation, angiogenesis, apoptosis and host defense. Dysregulation of 
MMPs has been linked to abnormal arterial remodeling, plaque instability and aneurysm 
formation[53]. MMPs can either be synthetized and secreted, or membrane-associated[54], 
and can be found in macrophages[55], SMCs[56] and epithelial cells[57]. All the MMPs 
share a common three domains structure: the pro-peptide, the catalytic domain, and the 
haemopecxin-like C-terminal domain. The structure is also composed of a hinge region 
that links the catalytic domain and the haemopecxin-like C-terminal domain together. 
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MMPs are always synthetized in a latent form called Zymogen that will require a further 
extracellular activation to become fully functional. This activation can be accomplished 
by different proteases, like serin proteases (plasmin) as well as other MMPs (mutual 
activation). These proteases are allowing the cleavage of the pro-peptide domain, which 
contains a conserved cysteine residue interacting with the zinc in the active site and 
keeping the enzyme in an inactive form (cysteine switch). After cleavage, the zinc 
dependent catalytic domain can exercise his function on the substrate. MMPs substrate 
can be classified into two different categories: matrix substrates and bioactive substrates. 
Bioactive molecules comprise other MMPs and pro-cytokines as pro-TNF-α, whereas 
matrix substrates include collagen, elastin, fibronectin and vitronectin.  
Inside the atherosclerotic plaque, MMPs presence and inhibition by TIMPs (Tissue 
inhibitor of matrix metalloproteinases) are representing a very critical balance. In one 
hand, MMPs expression allow tissue repair and even seem to be beneficial in certain 
circumstances. Effectively, in a study on apolipoprotein E knockout (apoE0), they 
demonstrate that transgenic mice expressing MMP-1 surprisingly shown a decreased in 
lesion size compare to their littermates that didn’t express MMP-1[58]. They also notice 
less extensive and immature lesions, fewer cellular layers and a diminished content of 
fibrillar collagen and no evidence of plaque rupture. This all point out to a beneficial role 
of MMP-1 expression in the progression of lesions by the remodeling of the neointimal 
extracellular matrix. In the other hand, MMPs can lead to extensive tissue damage and 
plaque instability. Convincing evidences have demonstrated that MMPs contribute to the 
extracellular matrix loss in the fibrous cap and have been implicated in promoting the 
plaque rupture, which lead to the related vascular events[53, 59, 60]. In summary, inside the 
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atherosclerotic plaque, the delicate balance between MMPs and TIMPs is compromised 
and the extensive damage that can be induce by this unbalance will eventually destabilize 
the plaque and promote plaque instability and rupture, as well as clinical acute vascular 
events. 
 
 1.3.3 Macrophages  
Inflammation and macrophages and well know biomarkers of plaque instability[18].  
Effectively, one of the first events to occur following damage to the endothelium is the 
recruitment of macrophages at the site of injury[4, 61, 62]. Because endothelial cells are the 
primary barrier between blood and tissue, there are a large number of events that can 
initiate endothelial cells injury and ultimately lead to the biological cascade that 
constitute the pathological response. Among the myriad of factors affecting vascular 
integrity, there is direct tissue injury, genetic defect, infection, disturbed hemodynamic 
flow, dyslipidemia, ischemia, hypoxia, and oxidative stress. As mentioned earlier, those 
factors will activate endothelial cells that will in turn express adhesion molecules like 
VCAM and ICAM. Blood monocytes will then be rolling and retained at the surface of 
the epithelium and be extravagated into the arterial wall. Although macrophages 
infiltration is a necessary phenomenon and essential for the removal of ox-LDL, as lipids 
accumulate, they will eventually transform into foam cells and be responsible for the 
formation of the necrotic core. Macrophages also release numerous proinflammatory 
cytokines that are believed to further exacerbate the inflammatory response, like TNF-α 
and IL-1β. They are also responsible of the secretion of more ROS, which will contribute 
to feed the oxidative stress/inflammatory state. Moreover, macrophages will release 
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MMPs, another major key player in the atherosclerotic process. Most importantly, MMP-
9 will play an important role in plaque instability and vulnerability, by stimulating 
monocytes infiltration as well as matrix degradation. In the other hand, as mention 
before, ECM degradation by macrophages will clear the path for the SMCs migration, 
and formation of the fibrous cap, which will stabilized the plaque (type V). Also, 
macrophages and lymphocytes T cross-talk can lead to neointima formation, stenosis and 
plaque healing (type VI). Nevertheless, because of the numerous roles of macrophages in 
plaque vulnerability, macrophages infiltration is considered to be a histological marker of 
unstable plaque. Indeed, plaques with thin fibrous cap and macrophages count (CD68 
positive) > 25 cells per high power field (40X, field diameter 0.3mm) are considered 
vulnerable to rupture[3]. Macrophages localization in plaques is often at the shoulder area 
of the necrotic core, although in vulnerable plaques, they are believed to have a more 
diffuse distribution[19, 20]. 
 
 1.3.4 Vascular Smooth Muscle Cells Apoptosis 
Vascular smooth muscle cells (VSMCs) are another very important component of 
atherosclerotic plaques, as they are responsible for the promotion of plaque stability in 
advanced lesions[63]. Effectively, VSMCs apoptosis has numerous deleterious effects on 
the atherosclerotic process, like inflammation, calcification, vessel remodeling, and 
ultimately plaque rupture. Indeed, as the plaque grow, VSMCs will migrate from the 
media into the neointima to form the fibrous cap, which prevent blood molecules from 
being in contact with the thrombogenic material of the necrotic core. However, as the 
necrotic core enlarge or in the presence or certain conditions, the balance between 
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VSMCs proliferation and apoptosis is compromised. Because VSMCs are also 
responsible for the formation of collagen into the fibrous cap, VSMCs apoptosis is 
associated with the thinning of the fibrous cap in the neointima, by both diminution of the 
muscle cells content and diminution of the ECM and collagen content. The consequence 
of that will be the formation of thin fibrous cap atheromas (TFCAs), which are the 
prevalent type of plaques causing most fatal heart attacks. Also, it is worth to mention 
that microcalcifications, a product of VSMCs apoptosis and cellular death, although still 
debated, have been described as a major contributor to plaque instability and 
vulnerability to rupture[64]. Interestingly, calcium crystals themselves have been link to 
the induction of VSMCs death and atherosclerotic plaque destabilization[65]. Moreover, 
VSMCs apoptosis has also been linked to vascular remodeling[66, 67], and aneurysm 
formation[52, 64, 68]. Thus, VSMCs are playing a very important role in maintaining the 
integrity of the endothelium as well as a physical barrier between blood and 
thrombogenic material of the necrotic core. As a consequence, VSMCs apoptosis is 
related to plaque instability and a marker of plaque vulnerability to rupture. 
  
1.4 STATE OF THE ART: αvβ3 TARGETED PROBES 
 
1.4.1 αVβ3 Probes Development and Historic 
αVβ3 targeted probes has been largely used for imaging different pathologies. Since 
αVβ3 receptor is upregulated in many pathological conditions including osteoporosis[69], 
rheumatoid arthritis[48], cancer angiogenesis[34], and atherosclerosis[41], it represents a 
target of choice for imaging these diseases. Many research groups have developed αVβ3 
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targeted nanomaterials for imaging[70] and even dual system that allows detection of the 
disease as well as delivery of therapeutic drugs[71]. In the case of atherosclerosis, previous 
studies has shown the great potential of targeting αVβ3 for the development of contrast 
agents enhancing the detection of the plaque[49] and for therapeutic use[72]. Effectively, 
human atherosclerotic lesions, albeit very different in plaque composition, show 
expression of αvβ3[41], which plays a role in thrombus formation[73], cell migration[32], 
neovascularization[34, 74] as well as many other processes.  They have been some studies 
correlating the vulnerability of the plaque with neovascularization[11]. Some other studies 
have controversially linked plaque vascularization with ischemic repair, negative 
remodeling and plaque stabilization[75]. Although αvβ3 is expressed on a variety of cells, 
its expression seems to be predominant in smooth muscle cells[41], endothelial cells[76], 
and macrophages during foam cells formation[46].  Most interesting is the fact that αvβ3 
expression seems to be an early event in plaque formation[77, 78] and is also correlated 
with plaque instability[11, 79]. For all of those reasons, αvβ3 has been the target of growing 
interests for the molecular imaging of atherosclerosis.  
In 2003, Winter et al published a paper in Circulation were they fed New Zealand White 
rabbits with an atherogenic diet and they imaged them with αvβ3-Integrin-targeted 
paramagnetic nanoparticles injected intravenously[77]. They reported the specific 
detection of neovasculature within 2 hours, at a clinically relevant field strength (1.5T), 
by MRI. The same team published another paper in Atherosclerosis, Thrombosis, and 
Vascular Biology, in 2006, where they combined molecular imaging and drug therapy[49]. 
In this study, they imaged cholesterol-fed rabbit at 1.5 T using integrin-targeted 
paramagnetic nanoparticles that incorporated fumagillin and demonstrated a decreased in 
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MRI enhancement among fumagillin-treated rabbits with a single dose (30µg/kg) of 
integrin-targeted paramagnetic nanoparticles, when readministrated after 7 days. 
Although there is many studies using MRI based probe, there is also other examples of 
probe based on imaging modalities like fluorescence, PET, and SPECT. For example, in 
2008, Wadeck et al published a paper in the Journal of Nuclear Medicine, with a αvβ3-
targeted Arg-Gly-Asp (RGD) peptide labeled with cyanine 5.5 (Cy 5.5) dye[80]. They 
reported the imaging of atherosclerotic plaques in apolipoprotein E-deficient mice after 
24 hours injection of the probe by fluorescence reflectance imaging. A more recent study 
in the Journal of Nuclear Medicine, in February 2012, reported the imaging of Winstar 
rats that underwent coronary ligation, with a 18F-galacto-RGD probe[81]. 18F-galacto-RGD 
is a PET tracer binding to αvβ3 integrin receptors that are upregulated after myocardial 
infarction (MI) as part of the healing process. They showed that one week after MI, 18F-
RGD uptake was increased in the defect area as compared with the remote myocardium 
of MI rats or sham-operated controls. Finally, as mentioned before, since there is no 
perfect single modality that is sufficient to obtain all necessary information, there is a 
growing interest into the development of multimodality imaging of αvβ3. For that matter, 
a very interesting review has been published in 2011 in Theranostics journal, which 
focused on dual modalities imaging (PET and optical, SPECT and fluorescence, PET and 
MRI, SPECT and MRI, and lastly, MRI and fluorescence) and their synergetic 
advantages over any modality alone[82]. Those multimodality probes can build on the 
strength of one imaging modality and compensate the lack of the other, which open up 
new avenues in the field of research. For example, MRI can compensate for the low 
resolution of PET imaging, and inversely, PET can compensate for the low sensitivity of 
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MRI, which might translate some day into better detection, treatment or follow up of the 
beneficial effect of therapy of vulnerable plaques. 
Apart from the numerous imaging studies on animal model of atherosclerosis with αVβ3 
directed probes, there is an even more extensive literature on αVβ3 probe with animal 
models of cancer. In fact, αVβ3 targeting for cancer imaging has been reported with 
virtually every imaging modality possible (optical[83], PET[84, 85], PET/CT[86], SPECT[87], 
MRI[88], fluorescence[89]). Moreover, the probe that we used in this study has already been 
tested on nude mice bearing receptor-positive M21 human melanoma xenografts using a 
micro-SPECT single photon emission computed tomography system (A-SPECT, Gamma 
Medica Instruments, Northridge, CA) with a 2 mm pin-hole collimator for high resolution 
animal imaging[90]. More interestingly, this same molecule, labeled with 68Ga and linked 
with NODAGA[91], has been recently used to efficiently detect cancer in human 
(unpublished results). In this first human study in a breast cancer patient, they reported 25 
integrin ανβ3 positive lesions detected by the probe (THERANOST cRGD™), versus 12 
by 18F FDG. They also pointed out many advantages over 18F and 64Cu labeled RGD 
peptides, like the availability of 68Ga, the convenient radiolabelling, the high stability and 
the good imaging properties.  
 
1.4.2 αVβ3 integrin-targeted probe synthesis 
The αvβ3 integrin targeted optical probe (ITOP) 4-[2-(3,4,5,6-Tetrahydropyrimidin-
2ylamino)ethyl-oxy]benzoyl-2-(S)-[N-(3-amino-neopenta-1-carbamyl)]-
aminoethylsulfonylamino-β-alanine fluorescein thiourea was synthesized as previously 
described[92].  Briefly, ITOP was developed from a potent fibrinogen receptor antagonist 
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(3-amino-2(S)-arylsulfonylaminopropionic acid derivative)[93] and further structural 
modifications and optimization followed by conjugation to fluorescein isothiocyanate 
(FITC) led to the targeted probe (Fig. 18).  This conjugation of the fluorophore to the 
integrin antagonist did not alter the binding affinity or selectivity to integrin αvβ3.  This 
compound represents the first example of a non-peptidic integrin αvβ3 targeted optical 
probe. For in vivo studies, the probe was labeled with 111In. For that purpose, the amino 
terminus of IA or IAC (10-20 mM) was reacted with 2-(p-isothiocyanatobenzyl)-DOTA 
(Macrocyclics, Inc., Dallas, TX; SCN-Bz-DOTA; 1-2 mM) in 40 µl of 0.1 M sodium 
bicarbonate at pH 8.4 for 2 days at room temperature. The product formation was 
monitored by reverse-phase HPLC. In the binding assays as well as in the cell adhesion 
inhibition assays, this compound showed very high binding affinity (3nM) and selectivity 
to αvβ3 compared to αIIbβIIIa, αvβ5 and αvβ6. 
 
 
Figure 18 Representation schematic of the ITOP 
 
Structure of integrin αvβ3 targeted optical probe: 4-[2-(3,4,5,6-Tetrahydropyrimidin-
2ylamino)ethyl-oxy]benzoyl-2-(S)-[N-(3-amino-neopenta-1-carbamyl)]-
aminoethylsulfonylamino-β-alanine fluorescein thiourea. 
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1.4.3 αVβ3 probe characterization on cancer model 
Recently, an ITOP was synthesized and has been shown to efficiently target the αvβ3 
receptor with high affinity in an in vivo mouse model of cancer[92].  The probe is a small 
non-peptidic carbamate integrin antagonist (RGD mimic), which is fluorescently labeled 
and targets the αvβ3 integrin.  Compare to nanoparticles ranging in sizes of hundreds of 
nanometers (nm), this probe is much smaller (<1nm), which should translate into better 
clearance from blood and better diffusion into the targeted tissue.  In vitro, this labeled 
compound has very high affinity for αvβ3 (IC50 of 3nM) and greater selectivity towards 
αvβ3 compared to αIIbβIIIa, αvβ5 and αvβ6 (IC50 > 100µM).  When incubated with 
commercially available αvβ3, the same compound labeled with 111In produce a shift in 
HPLC peak to a higher molecular weight, with a retention time identical to that of 
integrin αVβ3 in a concentration-dependent manner. The percent bound was 6%, 40% and 
72%, respectively, when incubated with 0.08, 0.4 and 0.8 µM αVβ3. The receptor binding 
was completely blocked by a 25 times molar excess of cold IA to integrin αVβ3. This 
synthetic probe has at least 20 times higher binding affinity for αvβ3 compared to the 
commercially available cyclic peptide c[RGDfv]. In vivo, the αvβ3 probe has been 
labeled with 111In and injected intravenously in tumor bearing mice and detected by 
micro-SPECT single photon emission computed tomography system (A-SPECT, Gamma 
Medica Instruments, Northridge, CA) with a 2 mm pin-hole collimator[90]. The ITOP 
persisted in the tumor for more than four hours, while disappeared from most of the other 
tissues within an hour, demonstrating that its biodistribution is conducive for use in 
imaging. The tumor uptake (5.3±0.6 %ID/g) of the 111In-labeled probe was significantly 
inhibited (1.4±0.3 %ID/g) after 1 h co-injection with the cold probe, whereas there was 
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no inhibition by the control lysine co-injection, indicating that the tumor uptake was 
receptor mediated. Another preliminary study with the same compound showed in vitro 
promising results for the development of a dual imaging probe/drug delivery systems 
targeting αvβ3[50]. As neovascularization is also an important mechanism in plaque 
formation, in this study, we have explored the utility of this ITOP to probe the molecular 
processes involved in atherosclerosis, in a Watanabe rabbit model. 
 
 
1.5 ANIMAL MODEL OF ATHEROSCLEROSIS[94] 
 
1.5.1 Mice and Rats 
There are a variety of different animal models allowing us to mimic human 
atherosclerosis plaque development and study different target molecules. Currently, there 
is no single golden standard animal model of vulnerable plaque. The most common 
animal model known and used in laboratory for atherosclerosis study is probably the 
apolipoprotein E (apoE) knockout mouse. In fact, since mice do not develop 
atherosclerosis without genetic modifications, genetically engineered mice with disorders 
of lipid metabolism has been developed, such as apoE knockout mice. These mice have 
been genetically modified, so they do not express the glycoprotein apoE that mediates the 
binding of very low-density lipoprotein (vLDL) to the LDL receptor. The result is a 
blockade of the vLDL particles uptake in the liver and the accumulation of cholesterol 
rich particles in the plasma. These mice develop normally, but exhibit five times normal 
serum plasma cholesterol and spontaneous atherosclerotic lesions. There are also a large 
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number of other knockout mice (LDL receptor knockout, type A scavenger receptor 
knockout…) and even double knockout mice developed and useful for investigating 
atherosclerosis and plaque rupture. Unfortunately, mouse model does present some 
limitations, beside the fact that they do not develop atherosclerosis without genetic 
manipulation. First, lipid physiology in mouse is radically different from the one in 
human, as most of their cholesterol transport is accomplished by high-density lipoprotein 
(HDL)-like particles. In second hand, mice weight (25g) is some 3000 times less than the 
average human, which can lead to very different biological responses. Furthermore, mice 
transport cholesterol mostly in the form of HDL, unlike human that also transport it in 
LDL form, which constitute the problematic lipid in atherosclerosis. 
Some other models include dogs and rats, but these animals are very resistant to 
atherosclerosis and will only develop it following extensive diet modifications. 
 
1.5.2 Pigs 
Another very useful animal model is the pig. Pig can develop atherosclerosis even on a 
normal porcine diet and when fed cholesterol diet, they develop plasma cholesterol levels 
and atherosclerotic lesions very similar to humans. Some varieties of pig have also 
exhibit sudden coronary death as a response to stress. However, pigs are difficult to house 
and the cost of the maintenance is often too high for most laboratories. They require 
special facilities and more extensive knowledge beyond the capability of our laboratory. 
We therefore choose the most appropriate animal model for our goal, which appears to be 
the Watanabe heritable hyperlipidemic rabbit. 
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1.5.3 Watanabe Heritable Hyperlipidemic Rabbits (WHHL) 
Watanabe rabbit has been discovered in 1973, when Dr. Yoshio Watanabe noticed that a 
white rabbit was showing hyperlipidemia despite the fact that he was feed a normal 
standard diet[95]. Dr Watanabe later confirmed that the hyperlipidemia was inherited 
recessively from its parent. In 1980, the first mutant strain of this rabbit was established 
and called WHHL. Later on, in 1985, some other modifications have been added to the 
strain, to make it more susceptible to coronary atherosclerosis. Finally in 1992, Dr 
Watanabe developed a colony of coronary atherosclerosis-prone WHHL rabbits. The 
major characteristic of the WHHL rabbit are an in-frame deletion of 12 nucleotides that 
eliminates four amino acids from the cystein-rich ligand binding domain of the LDL 
receptor. This mutation delays the LDL receptor protein maturation and affects the 
transportation rate of the receptor to the cell surface. Ultimately, this defect will reduce 
the LDL receptor function in a manner similar to the human Familial 
Hypercholesterolemia (FH). In WHHL rabbits, average plasma cholesterol levels are 
about 1100 mg/dl at 6 months old, about 900 mg/dl at 12 months old and about 800 mg/dl 
at 18 months old. A normal rabbit will have an average plasma triglyceride level between 
150 and 300 mg/dl. Compared to mouse models (apoE-KO or LDLR-KO) fed standard 
chow, WHHL rabbits resemble human in lipoprotein metabolism (Table 2). Another 
important difference in the WHHL rabbit compare to the normal rabbit is the enzyme 
activity of the cholesterylester transfer protein (CETP), which is about 2 to 3 fold higher 
in WHHL rabbit. This plasma protein facilitates the transport of cholesteryl esters and 
triglycerides between lipoproteins, and mutations leading to its increased function have 
been link to accelerated atherosclerosis. 
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Table 2 Difference in lipid metabolism and atherosclerosis between 
WHHL rabbits, human with FH and apoE-KO and LDLR-KO mice  
 
WHHL 
Rabbits Human FH 
ApoE-KO 
mice 
LDLR-KO 
mice 
Plasma 
cholesterol 
levels 
Extremely high Extremely high Mildly high Moderate 
Main 
lipoprotein in 
plasma 
LDL LDL VLDL LDL and HDL 
LDL levels Extremely high Extremely high Moderate Moderate 
HDL levels Low Low Low High 
ApoB of 
VLDL B-100 B-100 B-48 B-48 and B100 
Expression of 
apoB-editing 
enzyme in 
liver 
No No Yes Yes 
Cholesteryl 
ester transfer 
activity in 
plasma 
Yes Yes No No 
Features of 
aortic 
atherosclerosis 
Complicated 
lesions 
Complicated 
lesions Foamy lesions 
(Not 
developed) 
Myocardial 
infarction Spontaneous Spontaneous Resistant Resistant 
Table 2 Comparison of lipid metabolism and atherosclerotic features 
between humans, rabbits and mice  
 
When compare to human FH, WHHL rabbit model has more similar features related 
to lipid and plaque metabolism than the mice models have. The pattern of lipid 
metabolism is relatively identical and the types of atherosclerotic lesion are also very 
similar, which made them a better animal model than mouse for the study of 
atherosclerotic processes 
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In WHHL rabbit, aortic lesions begin to appear around 2 months old despite feeding them 
on a normal rabbit chow diet. The lesions are first noticed at the orifices of the branches 
and expand to about 40% of the aortic surface around 6 months old, 70% around 12 
months old, and covering almost the entire surface around 18 months old. In early 
lesions, intima is composed mostly of macrophages and a few SMCs, with some 
macrophages penetrating the arterial media. Transitional lesions are, alternatively, 
composed of large foam cells derived from macrophages and located in the deeper area of 
the intima. These transitional lesions presented also a fibromuscular cap covering the 
surface of the intima. Above 18 months old, these transitional lesions become more 
advance and complex, with decreased cellular content, but increased collagen fibers, 
extracellular lipid accumulation and cholesterol cleft. Calcium accumulation can also be 
observed in some of these advanced lesions. Another important fact about WHHL rabbits 
is that a previous study has showed that they can develop plaque with outward 
remodeling[96], a feature related to plaque instability in human. 
After considering all of the above information, we decide that WHHL rabbit was the 
most appropriate and suitable animal model for our need. 
 
 
1.6 AD-HIES AND ATHEROSCLEROSIS 
 
AD-HIES disease or autosomal dominant hyper-IgE syndrome (AD-HIES) is a rare 
primary immunodeficiency caused by a dominant negative mutation in STAT3[97, 98]. It is 
characterized by various clinical manifestations such as high serum level of IgE, 
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recurrent infections, eczematous dermatitis, and connective tissue abnormalities[99]. 
Because AD-HIES is categorized as an immunodeficiency disease[99], and because it is 
characterized by less advanced stenotic plaques[100], as seen by imaging study, it is an 
extremely interesting model for the study of the atherosclerotic process. Effectively, AD-
HIES patients have an abnormal immunity system that prevents them to efficiently fight 
infections, and as a result, they develop lot of secondary infection problems[99]. On the 
other hand, they also develop abnormal exacerbated allergic response, which is observed 
by their elevated IgE blood level. One manifestation of their immunodeficiency is their 
improper T cells maturation process. It is translated into an absence of Th17 T cells 
subtype. It is well known that atherosclerosis is an inflammatory disease and T cells 
subtypes are important in plaque characterization. Indeed, while Treg subtype of T cells 
have been linked to more stable plaque, Th17 subtype have been link to more vulnerable 
type of plaque. Also, since there is an important crosstalk between inflammatory cells, 
especially macrophages and T cells, AD-HIES would be an interesting model to study 
plaque formation, inflammatory processes and stenosis. It could lead to important 
understanding on inflammatory cells crosstalk mechanism and what happens in case of 
defect. 
Recent studies in AD-HIES also described the presence of coronary aneurysm and 
ectasia, despite the uncommon presence of atherosclerosis, evaluated by luminal 
stenosis[100, 101]. Moreover, those features were also often accompanied by a general 
dilatation of the vessel wall[100]. Aneurysms can be caused by many different 
mechanisms, as vasculitis, trauma, connective tissue disorders, and most interestingly, 
atherosclerosis[68]. It is still debated if atherosclerosis is causing the aneurysms or if 
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aneurysms come before the development of atherosclerosis. The most accepted theory is 
that those two mechanisms are probably developing in parallel, because of the presence 
of inflammatory conditions, cytokines or altered blood flow[102]. In AD-HIES population, 
there is a high prevalence of coronary abnormalities, such as dilation of the coronary wall 
and aneurysm[100], but a paucity of severe atherosclerosis[100, 101]. For all these reasons, 
AD-HIES patient could be a very interesting model for the study of atherosclerosis.  
 
1.6.1 Aneurysm 
Aneurysm, by medical definition, is a sac formed by the dilatation of the wall of an 
artery, a vein or the heart, and filled with fluid or clotted blood (thrombus). An 
atherosclerotic aneurysm is defined by the weakening of the vessel wall in the case of 
severe atherosclerosis, and is usually seen in large arteries like abdominal aorta (Fig. 19). 
According to Stary HC et al, atherosclerotic lesions from type IV, V, and VI can be 
associated to, and appeared to be the cause of localized dilatations of the vascular wall 
they occupy[19, 20]. It is also mentioned that thrombotic deposits in atherosclerotic 
aneurysms can form large masses that fill the aneurysm, but usually preserving the lumen 
area of the original vessel.  
In general, for aneurysms to occur, specific conditions need to be present: degraded 
matrix fibers[103], proteolytic enzyme activity increased (wall destruction and 
remodeling)[102], and increased collagenases and elastase activity[104]. Destruction of the 
media by experimental mechanical injury has also been linked to aneurysm formation, 
especially in the presence of hyperlipidemia[105, 106]. Inasmuch, hystological features of 
aneurysms include medial necrosis, inflammatory infiltration, and elastic fibers 
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degradation (Fig. 20)[102]. It remains controversial if atherosclerosis is the direct cause of 
aneurysms, if aneurysms predispose to atherosclerosis, or if they are parallel 
phenomenon. In a recent ultrasound study by Johnsen et al, they postulated that 
atherosclerosis and aneurysm are likely to be developing in parallel, rather than 
atherosclerosis directly leading to aneurysm[107]. Unfortunately, findings from this study 
were not able to convincingly refute a role for atherosclerosis in aneurysm.   
 
Reproduced from www.mountsinai.org 
 
Figure 19 Representation schematic of an atherosclerotic aneurysm 
 
An aortic aneurysm is a dilatation, bulging or ballooning of a weakened part of the 
aortic artery wall. An aneurysm is most often the result of degeneration and 
weakening of the wall of the aorta. In addition to atherosclerosis, the risk of an aortic 
aneurysm can be increased by factors such as high blood pressure and smoking. In 
rare cases an aortic aneurysm can be caused by an infection or inflammation. All three 
tunica layers are involved in true aneurysms (fusiform and saccular). In false 
aneurysms, blood escapes between tunica layers and they separate. If the separation 
continues, a clot may form, resulting in a dissecting aneurysm. 
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Reproduced from Nichols et al, Arch Pathol Lab Med 2008; 132(5):823-828. 
 
Figure 20 Histology of a left circumflex coronary artery aneurysm 
 
(A) Tunica intima expanded by atherosclerosis (left) and tunica media attenuated and 
densely infiltrated by inflammatory cells (right) (H&E, 10X magnification). (B) 
Higher power showing the inflammatory cells to be predominantly lymphocytes, with 
a few residual smooth muscle cells (bottom center) (H&E, 20X magnification). (C) 
Verhoeff van Gieson stain showing only wisps of black elastin in the attenuated tunica 
media (10X magnification). (D) Immunostain for smooth muscle actin showing 
markedly decreased staining transitioning to totally absent staining (center, left to 
right), representing the loss of SMCs in the tunica media (10X magnification). 
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1.7 SUMMARY 
 
In previous sections, the biological processes leading to atherosclerosis have been 
explained. A particular emphasis has been put on the vulnerability of atherosclerotic 
plaques. Those plaques are generally in the positive remodeling phase and present an 
absence or low-grade stenosis. They also possess a large necrotic core with lipid crystals, 
a thin fibrous cap, heavy macrophages infiltration, important enzyme activity (MMP-9), 
and can also feature intraplaque hemorrhage and microcalcifications. It is very important 
to develop imaging techniques that will allow to detect vulnerable plaques, as they are 
often the key determinant leading to plaque rupture, and can cause coronary events and 
strokes. Because the degree of stenosis has a poor predictability for coronary events, it 
becomes essential to study the molecular mechanisms of plaque vulnerability. The 
integrin αvβ3 seems to be an important target for atherosclerotic plaque imaging, since 
αvβ3 is involved in numerous processes controlling the balance between plaque stability 
and instability (neovascularization, intraplaque hemorrhage, cell migrations, apoptosis, 
etc…). This study is aimed at evaluating the efficiency of a new synthetic αvβ3 ITOP for 
the imaging of early atherosclerotic plaque. For this purpose, a WHHL rabbit model has 
been used, considering that this model shares many common characteristics with the 
human disease. The results have also been confirmed in vitro in human. Finally, the 
probe has been tested on an AD-HIES human model. Because of the rarity of this model, 
and the important features interconnecting this disease and atherosclerosis (paucity of 
stenotic atherosclerosis, prevalence of aneurysms, connective tissues abnormalities, 
immunodeficiency), it becomes a very useful tool for the study of atherosclerosis. With 
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the help of those models and immunohistopathological studies, it becomes possible to 
better understand the mechanisms involved in plaque vulnerability and maybe develop 
imaging techniques that will allow plaque detection before the apparition of its sequelae, 
and prevent heart attacks and stroke. 
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CHAPTER 1   
IN VITRO ITOP LABELING ON WHHL RABBITS 
 
2.1 INTRODUCTION 
 
The detection of early atherosclerosis, before the development of its later sequelae of 
myocardial infarction, angina or stroke, constitutes an important challenge in current 
diagnostic medicine. Despite all the recent technological advances, cardiovascular 
disease remains the leading cause of death in the Western World and needs to be detected 
at an earlier stage to allow for more timely therapeutic intervention[1]. Therefore, one 
potential promising molecular target for the detection of atherosclerotic plaque is αvβ3, a 
widely recognized target and the basis for the development of molecular probes and the 
detection of pathological conditions like rheumatoid arthritis[48] and cancer[34]. In 
addition, human atherosclerosis lesions show extensive expression of αvβ3[41]. This 
integrin plays a role in thrombus formation[73], cell migration[32], neovascularization[34, 74] 
as well as many other processes involved in atherosclerotic plaque formation. The αvβ3 
receptor has been found on the surface of a wide variety of cells inside atherosclerotic 
plaques, but expression seems to be predominant in smooth muscle cells and endothelial 
cells[41, 76]. Macrophages also express αvβ3 during the formation of foam cells[46]. 
Moreover, most interesting is the fact that αvβ3 expression seems to be an early event in 
plaque formation[77, 78] and is also correlated with plaque instability[11, 79]. Additionally, 
previous studies had shown the great potential of targeting αvβ3 integrin for the 
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development of contrast agents that enhance the detection of plaque[49] and for the 
delivery of therapeutic drugs[72]. Consequently, these characteristics make αvβ3 a very 
attractive target for molecular imaging of early atherosclerosis. 
Recently, a fluorescein labeled integrin analog was synthesized and had been shown to 
efficiently target the αvβ3 receptor with high affinity in an in vivo mouse model of 
cancer[92]. The probe is a small non-peptidic carbamate integrin antagonist (RGD mimic), 
which is fluorescently labeled using a neopentyl linker and targets the αvβ3 integrin. In 
vitro, this compound with the fluorescein label had very high affinity for αvβ3 (IC50 of 
3nM) and greater selectivity towards αvβ3 compared to αIIbβIIIa, αvβ5 and αvβ6 (IC50 
> 100µM)[92]. This synthetic probe demonstrated at least 20 times higher binding affinity 
for αvβ3 compared to the commercially available cyclic peptide c[RGDfv][92]. When 
intravenously injected in tumor bearing mice, the probe persisted in the tumor for more 
than four hours, while disappeared from most of the other tissues within an hour, 
demonstrating that its biodistribution is conducive for use in imaging[90]. In this study, we 
explored the utility of this labeled molecule to probe the molecular processes involved in 
atherosclerotic plaque formation, particularly the overexpression of the integrin αvβ3. 
The purpose of this initial study was to investigate the potential of this new synthetic 
αvβ3 targeted optical probe to identify early atherosclerosis in a Watanabe rabbit model. 
 
 
 
 
 
Page 71 of 246 
 
2.2 MATERIALS AND METHODS 
 
2.2.1 Experiment design 
All experiments were performed on specimens taken from 3 month to 12 month old 
Watanabe Heritable Hyperlipidemic (WHHL) rabbits, 2 females and 3 males (n=5), fed a 
standard rabbit chow diet.  The animals were purchased from Brown Family Enterprises 
(Gemini Research of Alabama, Odenville, Alabama, USA).  Control aortic tissues 
without atherosclerosis were taken from New Zealand White (NZW) rabbits (n=2) and 
purchased from Zyagen (San Diego, CA, USA).  Prior to any experiment, rabbits were 
anesthetized with a ketamine (30mg/kg) and xylazine (5mg/kg) cocktail administered 
subcutaneously, and then euthanized by intravenous pentobarbital (100mg/kg) injection 
while still under anesthesia. All experiments were performed in accordance with 
protocols approved by the Animal Care and Use Committee of the National Heart Lung 
and Blood Institute. 
 
2.2.2 Cholesterol measurement 
Blood was collected before euthanasia and centrifuged at 1400g for 10 minutes, and the 
serum was frozen at -20°C, until it was assayed within 2 months after collection. Total 
cholesterol levels were measured by the Brown Family Enterprises Laboratory, at the 
Gemini Research of Alabama facility, using a cholesterol esterase/cholesterol oxidase 
colorimetric assay procedure. Total cholesterol values were expressed as mg/dL 
(mean6SEM). 
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2.2.3 Dissection 
The rabbit abdomen was open, and the aortic arch was excised and cut into different 
sections (ascending, descending thoracic, and descending abdominal).  2-3mm thick 
samples were taken from each segment, and 1 segment was put in a formalin solution, 
while the other segments were put in Optimal Cutting Temperature (OCT) media and 
quick frozen in methylbutane containing dry ice. Samples were kept at −80°C for further 
histological and immunohistological experiments.  
 
2.2.4 Histology and Immunohistology 
OCT blocks from frozen aortic tissues were cut into 7-8 µm sections with a cryostat and 
mounted onto slides.  Routine hematoxylin and eosin (H&E) straining was performed on 
frozen sections of the rabbit aortas. Expression of αvβ3 integrin in the aortic wall was 
assessed by immunohistofluorescence with the new ITOP. Briefly, sections were thawed 
for 15 minutes at room temperature, fixed 10 minutes with cold acetone, washed in 
phosphate buffer solution and then incubated with the targeted fluorescent probe for 1 
hour.  After the incubation period, the slides were washed again in phosphate buffer 
solution, mounted with VECTASHIELD mounting medium containing DAPI (Vector 
Laboratories, Inc., Burlingame, CA). An antibody against human αvβ3, anti-human 
integrin αvβ3, clone LM609 (Chemicon International, Inc, Temecula, CA, USA), was 
used to confirm the presence of the integrin and as a reference for the localization of any 
experimental fluorescence signal.  This antibody was used in conjunction with an anti-
mouse horseradish peroxidase detection kit, according to the specifications of the 
company (Chemicon International, Inc, Temecula, CA, USA). Images of staining or 
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fluorescence signal were acquired under a microscope (Nikon E1000 with a Nikon DXM-
1200 color camera or Leica DM5500B with a Leica DFC500 camera) using a visible or 
ultraviolet light source, respectively. For the ITOP (FITC labeling), the emission 
wavelength was set up at 495nm, while absorption wavelength at 521nm.  
 
2.2.5 Competition 
Slides were transferred from -80°C to -20°C for 15min, and then allowed to air dry for 
another 15min. The slides were then fixed for 10min in cold acetone (-20°C), washed 
with 3 changes of PBS (5min) and incubated with the ITOP (1,4mg/100µl) diluted 1/200 
for 2hrs. The slides were then washed with 3 changes of PBS, and incubated with the 
non-labeled ITOP diluted 1/20 for 1hr. After the incubation period, the slides were 
washed again in phosphate buffer solution, excess liquid was wipe off, and the slides 
were mounted with VECTASHIELD mounting medium containing DAPI (Vector 
Laboratories, Inc., Burlingame, CA). 
 
2.2.6 Lipid staining 
OCT blocks from frozen aortic tissues were cut into 7-8 µm sections with a cryostat and 
mounted onto slides. Slides were stored at -80°C and allowed to air dry for 30 minutes at 
room temperature (RT) prior to staining. Slides were then fixed with 10% ice cold 
Formalin for 5 minutes, rinse in water and incubate 5 minutes with Propylene Glycol to 
avoid carrying water into Oil Red O. Sections were stained 10 minutes with Oil Red O 
solution at 60°C and subsequently rinsed 5 minutes with 85% Propylene Glycol followed 
by water. Slides were then counterstained for 30 seconds in Gill’s Hematoxylin solution, 
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washed thoroughly for 3 minutes in running water and rinsed two times with water. 
Finally, sections were mounted with aqueous mounting medium (Supermount Permanent 
Aqueous Mounting Medium, Biogenex, San Ramon, CA). 
 
2.3 RESULTS 
 
2.3.1 Plaque Labeling 
Histological staining (H&E) of WHHL rabbit aortic tissues in transverse slices 
demonstrated intimal thickening of the aortic wall in some areas of the aorta, which was 
not observed in the control animals. Other WHHL rabbits did not showed any plaque in 
the intima. Examination of the aortic tissues with plaque incubated for 1 hour with the 
ITOP showed a strong fluorescent signal (Fig. 21A) in some cases, and a weaker signal in 
other parts of the aorta with plaque. Signal enhancement was predominately localized in 
the adventitia and the neointima of the vessel wall, although there was also some 
fluorescence in the media. The medial signal was associated with strong adventitial and 
neointimal labeling. As opposed to that, there was no medial labeling when the 
adventitial or neointimal labeling was weaker. In contrast, the specific fluorescent signal 
of the ITOP was absent in images from aortas of the control NZW rabbits (Fig. 21B). 
There was some autofluorescence in the aortic tissues, but it was negligible compared to 
the specific signal enhancement from the ITOP. Images from control rabbit aortas (Fig. 
21B) were taken at a higher magnification (10X), in order to see the background 
fluorescence, which was undetectable at a lower magnification (4X). 
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2.3.2 Signal Correlation with an Anti-αvβ3 Antibody 
 
A transverse image of the ascending aorta of the WHHL rabbit showed that the intimal 
thickening (neointima) of the tissue was a component of the atherosclerotic plaque (Fig. 
22). Upon comparison, the immunohistological labeling of αvβ3 (Fig. 22, right panels) 
and the fluorescence signal of the ITOP (Fig. 22, left panels) appeared co-localized to the 
same regions. Higher magnification (10X) of the neointimal region (Fig. 22C, D) 
demonstrated corresponding strong fluorescence and immunohistological signals near the 
interface of the lumen and intima. The fluorescent and immunohistological labeling were 
 
 
Figure 21 Fluorescence microscopy of descending Watanabe rabbit aorta 
sections (transverse cut) from tissue incubated with FITC-αvβ3 
antagonist 
 
(A) Image (4X magnification) of slide exposed to FITC-αvβ3 antagonist (2.8µM) for 
1 hour.  (B) Background fluorescence of the same region in slide from control NZW 
rabbit exposed to the fluorescent particle with the same conditions (10X 
magnification). Results indicated specific plaque labeling with the fluorescent 
antagonist with a very small amount of autofluorescence background from tissues.  
FITC, fluorescein isothiocyanate; Ad, adventitia; M, media; NI, neointima. 
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mostly localized in the adventitia and proximal intima of the ascending aorta. A similar 
distribution was showed in the descending aorta sections (Fig. 22). 
 
 
 
 
 
Figure 22 Co-localization study of αvβ3 expression on Watanabe rabbit 
ascending aorta sections labeled with fluorescence  
 
Immunofluorescence (A, C) or immunohistochemistry (B, D).  The upper panels 
displayed the whole aortic wall (4X magnification) while the bottom panels were 
focused on the neointimal region (10X magnification).  Both the fluorescence signal 
(A, C) and the immunohistological labeling (B, D) were co-localized predominantly 
in the adventitia and proximal neointima. Arrowheads illustrate immunohistological 
staining. Ad, adventitia; M, media; NI, neointima. 
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2.3.3 Competition 
In order to verify the specificity of the ITOP signal, the descending aorta of the rabbit had 
been incubated with the FITC labeled ITOP, following by incubation with the non-
labeled ITOP. After incubation with the labeled ITOP (Fig. 23A, C), the non-labeled 
ITOP displaced part of the signal produce by the αvβ3 probe (Fig. 23B, D). Although 
there was still some signal after the incubation with the non-labeled probe, the diminution 
of signal is clearly demonstrating the specificity of the αvβ3 ITOP. The displacement of 
the ITOP signal can be observed on the three different layers of the vessel wall (intima, 
media, adventitia), as shown in the lower panel (Figure 23C, D). 
 
 
Figure 23 Competition with non-labeled ITOP 
 
Left panel (A, B) represents results of fluorescence microscopy for two different 
parts of the descending aorta of the Watanabe rabbit labeled with the ITOP (2.8µM, 
1hr).  Right panel (B, D) represents the two same parts after a post-incubation with 
non-labeled ITOP (28µM, 1hr).  Results indicate a loss of signal after the competition 
with the non-labeled ITOP (B, D). 
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2.3.4 Adventitia Labeling  
Higher magnification images of the adventitial sections demonstrated co-localization 
between the ITOP signal and the DAPI (4’,6-diamidino-2phenylindole) labeling of cell 
nuclei, suggesting that the signal from the fluorescent particle is found close to the 
nucleus of the cell (Fig. 24). Adventitial co-localization results also showed neovessel-
like structures, located around regions delineated by cells labeled with fluorescent ITOP. 
Under microscopic examination, this was also correlated with an expansion of the aortic 
vasa vasorum in atherosclerotic rabbits compared to controls. 
 
 
Figure 24 Fluorescence microscopy of localization of the αvβ3 antagonist 
labeling inside the adventitia.   
 
Merged image showing FITC-integrin antagonist labeling and DAPI staining (nuclei 
of cells) of the same aortic region.  Smaller inset image represents the antagonist 
labeling alone.  The antagonist signal appeared to be localized on the surface of the 
cells, near to the nucleus.  There was presence of some structures similar to early 
neovessels that were labeled with fluorescence. FITC, fluorescein isothiocyanate; 
DAPI, 4’,6-diamidino-2phenylindole. 
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2.3.5 Labeling and Adventitia Thickness 
Comparison between fluorescent labeling with the αvβ3 targeted probe (Fig. 25, upper 
panel) and histological staining (Fig. 25, bottom panel) of the corresponding descending 
aorta sections demonstrated a qualitative correlation between fluorescent signal intensity 
and adventitial thickness. Indeed, histological staining (H&E) showed a range of 
adventitial thickening that was as much as 3 times greater in the thickest plaques as in 
non-atherosclerotic controls. In these plaques, the relative intensity of the optical probe 
 
 
Figure 25 Correlation between intensity of ITOP labeling and adventitia 
thickening 
 
Intensity of fluorescence staining in Watanabe rabbit descending aorta sections (A, B, 
C) correlated with adventitia thickness and plaque histology (D, E, F).  In images 
(10X magnification) of aorta sections with smaller adventitia (D, E), the level of 
labeling with the αvβ3-targeted probe was weaker (A, B).  Inversely, in the aorta 
sections with a larger adventitia (F), the signal from the αvβ3-targeted probe was very 
intense (C).  There were also some correlation between the intensity of labeling and 
the organization level into the plaque:  labeling was very intense when the media 
looked digested (C) and less intense when the media was well delineated (A, B). Ad, 
adventitia; M, media; NI, neointima.  
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qualitatively corresponded to the relative degree of adventitial thickening. Thus, a mild 
signal was present in plaques with a small adventitia thickness (Fig. 25A, B, D, E), while 
a strong signal appeared on plaques with marked adventitia thickness (Fig. 25C, F). There 
was also an inverse correlation between the intensity of fluorescence labeling and the 
organization level of the plaque. Staining was very intense (Fig. 25C) when the media 
was disorganized (Fig. 25F) and less intense (Fig, 25A, B) when the media was well 
delineated (Fig. 23D, E). In the plaque with very intense ITOP labeling (Fig. 25C), there 
was a structure resembling intraplaque hemorrhage in the intima of the corresponding 
H&E (Fig. 25F). Moreover, the H&E labeling of the same section also showed important 
inflammatory infiltrate, visualized by the typical red dot, into the adventitia, media, and 
neointima. 
 
2.3.6 Lipid Staining 
In order to characterize the lesions in the Watanabe rabbit model, a lipid staining was 
performed on the descending and ascending aortas of the rabbits. Results showed lipid 
accumulation localized throughout the entire circumference of the neointima (Fig. 26). 
Indeed, there was no real formation of a delimitated necrotic core, as seen in human 
plaques, but instead a general distribution of the lipids inside the entire neointima layer. 
Note that there was absence of lipids in the media layer. In both ascending (Fig. 26A, B) 
and descending (Fig. 26C, D) aortas, there was a region were it seemed that the media 
had completely disappeared. In the descending aorta (Fig. 26C), there was a portion of 
the vessel wall, inside the neointima, presenting signs of calcification (arrow). 
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Figure 26 Oil Red O staining of ascending and descending aorta of Watanabe 
Rabbits 
 
Oil red O staining showing lipid accumulation in Watanabe rabbit descending aorta 
sections (A, B) compared to ascending aorta (C, D).  Diffuse accumulation of lipids 
was clearly seen around the entire neointimal area, instead of a more define lipid area 
forming a necrotic core. Images on right panel are higher magnifications (20X) of 
images in left panel (4X). 
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2.4 DISCUSSION 
 
Integrin expression, particularly αvβ3, in atherosclerotic plaques is a component of the 
inflammatory process that can drive the plaque toward a more unstable state[9, 108] leading 
to plaque rupture[10, 109, 110], and its clinical complications such as stroke and myocardial 
infarction. In the other hand, it is also related to plaque stenosis and healing[42]. Many 
processes taking place during the initiation and progression of inflammatory vascular 
lesions require αvβ3 expression, including foam cell formation[46], smooth muscle cell 
migration[111] and thrombus formation[73]. These observations point towards the use of 
αvβ3 as a molecular target for imaging and early detection of atherosclerotic disease. 
In this study, we described the use of a novel synthetic high affinity and high specificity 
αvβ3 integrin targeted optical probe and confirmed the in vitro labeling of rabbit 
atherosclerotic plaques (Fig. 21 and 22). We also show that the ITOP signal was localized 
near the nucleus of the cells (Fig. 23), which indicates that fluorescence was correlated to 
cells (αvβ3 receptors are membrane-bound) instead of unspecific ECM labeling. One 
interesting observation in the present work was that the fluorescent signal of the integrin 
targeted optical probe seemed to extend from the adventitia toward the media of the 
aortic wall (Fig. 21A). The presence of fluorescent signal in the media was correlated 
with strong labeling and expansion of the adventitial layer (Fig. 21A and 24). This 
finding was probably associated with the development of angiogenic processes that first 
begin within the adventitia (vasa vasorum expansion) and then extends to the media of 
the vessel wall[112]. Most importantly, there was a strong correlation between the labeling 
with the integrin targeted probe and the thickness of the adventitia (Fig. 25). Thus, 
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adventitial thickening was characterized by a strong and widely distributed signal 
enhancement from the probe, which may signal a more advanced inflammatory state. 
Moreover, stronger αvβ3 labeling was located where the media was less organized, which 
is another sign of the presence of inflammation. Further evaluation of other biomarkers of 
inflammation inside the plaque can confirm this hypothesis and help to better understand 
the chronology of plaque development. 
In agreement with other studies[41, 49, 77], we also found that the most significant 
accumulation of αvβ3 receptors were in the adventitia of the aortic wall, a privileged site 
for the formation of neovessels. We also observed a characteristic expansion of the 
adventitia, a process that had been extensively described by others studies [49, 77, 113, 114]. 
This expansion allows angiogenesis to take place and will further attract more 
inflammatory cells and lipids into the plaque, contributing to plaque growth, instability 
and rupture, but also stenosis and healing. 
 
In addition to the adventitial localization of the signal, we also observed fluorescence 
within the neointima of plaques, close to the lumen. Previous studies had shown that 
activated or proliferative endothelial cells express high levels of αvβ3[34, 74]. This integrin 
is critical for the survival signal of these cells and is also recognized to influence 
adhesion and migration pathways[76]. Hence it is not surprising to observe evidence of 
αvβ3 within the intima. 
 
Relative to peptide-based molecules, this synthetic probe provides easier production and 
purification[92]. Moreover, its affinity as a labeled probe for the αvβ3 receptor is higher 
than the commercially available labeled cyclic peptide c[RGDfv][90, 92]. This should 
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translate into a smaller injected dose for the plaque detection and also a better sensitivity. 
In addition, our ITOP is specific to αvβ3, whereas linear and cyclic RGD peptide 
specificity is broader (αvβ3, αIIbβ3a, αvβ5)[92].   
The physiochemical characteristics of this probe are also important. As opposed to 
antibodies, this small synthetic molecule (<1nm) has less potential to induce an immune 
response and has important advantages related to the blood clearance and its diffusion 
into the targeted atherosclerotic tissue. Moreover, unlike antibodies, the probe is very 
suitable for further derivatives or structure modifications. However, future in vivo studies 
will be necessary to evaluate the labeling efficiency and kinetic uptake properties of this 
new optical probe. 
With the broad development of nanoparticles in disease detection[115, 116], we can 
extrapolate the use of this new αvβ3 integrin targeted probe for imaging atherosclerosis in 
combination with a variety of high-resolution molecular imaging techniques. The 
synthetic nature of this molecule makes it attractive for the development of various 
nanoparticle structures incorporating this molecule to target the plaque. For example, as 
demonstrated in other studies, this integrin targeted probe can be coupled with iron or 
gadolinium for magnetic resonance imaging[77], or even with fluorescent and magnetic 
particles for dual imaging techniques[117, 118]. As previously suggested, this αvβ3 targeted 
probe could also be used in systems that may carry drugs into the site of inflammation for 
simultaneous molecular imaging and drug treatment[49]. For example, this probe was 
efficiently used in a novel integrin targeted nanoparticle system for targeted drug delivery 
and imaging of cancer angiogenesis[50].  
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CHAPTER 2 
IN VIVO ITOP INJECTION ON WATANABE RABBITS 
 
3.1 INTRODUCTION 
 
In the previous chapter, in vitro labeling studies on Watanabe rabbits showed labeling of 
atherosclerosis plaques on aortic tissue samples, as opposed as an absence of labeling on 
aortic tissues from normal control New Zealand White rabbits[119]. There was also an 
absence of labeling in disease rabbits where aortic tissues do not show sign of plaque. 
Moreover, the ITOP signal seemed to correlate with the thickness of the adventitia layer, 
more than the thickness of the neointima. It also seemed that there was a correlation 
between the degree of inflammation and the presence of the ITOP in the aortic tissue.  
These in vitro results were promising, but isolated vessel wall tissue samples present a 
limited array of possible competing binding sites. Ideally a probe for plaque formation 
has to specifically bind and target atherosclerotic plaques, and nothing else in the entire 
body. In vitro tests for specificity can only reveal the affinity to competing or non-
binding entities chosen for such test, but they can give no guarantee for the absence of 
competing binding sites in the whole body. We therefore used the Watanabe Heritable 
Hyperlipidemic rabbit model to test our ITOP in vivo.  
From previous in vivo study on a mouse model[92], we evaluated the dose of ITOP to be 
injected at approximately 1mg/kg. Since we lack dose-response data for the previous 
mouse studies, we decided to inject 5mg of ITOP to each rabbit, independently of the 
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weight, to allow evaluation of the appropriate dose. Rabbits were chosen according to 
their age. Although some of them showed signs of plaques as early as 3 month old, they 
usually showed more extensive sign of atherosclerosis around 6 months age. Rabbits 
ranged in age from 3 month old to 4 year old, and from 1.5 kg to 5 kg, with an average 
weight of 4 kg. Although plaques in coronary tissue are clinically more important, we 
chose aortic vessel wall tissues as a model for plaque formation, because Watanabe 
rabbits rarely develop myocardial infarction and have a low incidence of coronary 
atherosclerosis[95]. Moreover, it is easier to manipulate aortic tissue than coronary tissue, 
and it is also easier to visualize plaque areas before dissection. We euthanized the rabbits 
2 hours after injection, to allow proper blood diffusion and retention of the ITOP into 
plaques. The 2 hour incubation time has been evaluated from a previous mouse study[92]. 
We dissected the aortic tissues and used histological staining to compare and characterize 
the ITOP labeling with histological features in the vessel walls of the Watanabe rabbits.  
 
 
3.2 MATERIALS AND METHODS 
 
3.2.1 Experimental Design (In vivo Injection) 
WHHL rabbits and NZW rabbits were fed a normal diet by the vendor company. Prior to 
any experiments, Watanabe rabbits (n=7) and New Zealand White rabbit (n=1) were 
anesthetized with a ketamine HCl (30mg/kg) and xylazine (5mg/kg) cocktail 
administered subcutaneously with a 23G butterfly needle in their hindlegs. After the 
rabbits were completely anesthetized, a catheter was put in place. Briefly, each rabbit ear 
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was cleaned, hairs from a small part of the ear were removed by gently poking the area, 
and a 21G butterfly needle was inserted through the vein. A heparin solution (10unit/ml) 
was pushed through the needle to ensure the right placement, and the catheter was 
attached. A cotton cloth was placed in the ear and the catheter was taped with it to secure 
it to the ear and prevent accidental removal. The heparin solution was then pushed again 
to verify positioning. The ITOP was then injected (5mg in 50mM Tris pH 8.0) through 
the catheter for 2hrs. During this time, rabbits received isoflurane gas through a nose 
cone to keep them anesthetized, and their heartbeats were monitored. After 2 hrs, the 
heparin solution was pushed again through the catheter to ensure it hasn’t been displaced, 
and rabbits were euthanized by intravenous injection with a solution of Sodium 
Pentobarbital (150mg/Kg) (EUTHANASIA III). All experiments were performed in 
accordance with protocols approved by the Animal Care and Use Committee of the 
National Heart Lung and Blood Institute or the National Institute of Diabetes, Digestive 
and Kidney Diseases. 
 
3.2.2 Cholesterol Measurement 
Blood was collected and centrifuged at 1400g for 10 minutes, and the serum was frozen 
at −20°C, until it was assayed within 2 months after collection. Total cholesterol levels 
were measured by the Brown Family Enterprises Laboratory, at the Gemini Research of 
Alabama facility, using a cholesterol esterase/cholesterol oxidase colorimetric assay 
procedure. Total cholesterol values were expressed as mg/dL (mean6SEM). Cholesterol 
measurements were made between a week to a month of the euthanasia. 
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3.2.3 Dissection 
The rabbit abdomen was open, and the aortic arch was excised and cut into different 
sections (ascending, descending thoracic, and descending abdominal).  2-3mm thick 
samples were taken from each segment, and 1 segment was put in a formalin solution, 
while the other segments were put in Optimal Cutting Temperature (OCT) media and 
quick frozen in methylbutane containing dry ice. Samples were kept at −80°C for further 
histological and immunohistological experiments.  
  
3.2.4 Histology and Immunohistology 
For probe’s visualization, slides were removed from −80°C and transferred to −20°C for 
15min. The slides were then air dry for another 15min before to be fixed in cold acetone 
(−20°C) for 10min, and washed with 3 changes of PBS (5 min each). Finally, the slides 
were carefully wiped off the excess of liquid, and mounted with VECTASHIELD 
mounting medium containing DAPI (Vector Laboratories, Inc., Burlingame, CA).  
 
 
3.3 RESULTS  
 
3.3.1 Plaque Labeling 
Histological staining (H&E) of WHHL rabbit aortic tissues in transverse slices 
demonstrated intimal thickening of the aortic wall and plaque accumulation in some of 
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the Watanabe rabbits, whereas others Watanabe rabbits showed no intimal thickening and 
no lipid accumulation. In the rabbits without apparent plaque formation, some samples 
presented an adventitial thickening, even in the absence of neointima. Those same 
samples did not show ITOP labeling, which seemed to indicate that the αvβ3 probe was 
related to the adventitial thickening, but only when there was a corresponding neointimal 
formation. In some of the Watanabe rabbits with plaque accumulation, examination of the 
aortic tissues incubated for 1 hour with the ITOP showed a fluorescent signal in both 
descending and ascending aorta (Fig. 27A). Signal enhancement was predominately 
localized in the adventitia and the neointima of the vessel wall, though there was also 
some fluorescence in the media. The fluorescent signal of the ITOP was absent from the 
aorta of Watanabe rabbits without plaque (Figure 27B).  
 
 
Figure 27 In vivo plaque labeling on Watanabe aorta with ITOP 
 
Left panel (A) represents results of fluorescence microscopy for the descending aorta 
of the Watanabe rabbit injected with the ITOP (5mg, 2hrs), while right panel (B) 
represents results of fluorescence microscopy for the ascending aorta. The αvβ3 
signal appeared stronger in the adventitia of both descending and ascending aorta, and 
in both parts, there was a weak associated αvβ3 signal in the neointimal layer. There 
was also an important background signal from the aortic tissues, probably caused by 
the collagen. The background signal was more important than the one in the in vitro 
experiments. 
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For the in vivo injection, a specific plaque signal enhancement could be observed from 
the probe, as in the in vitro experiment. However, the in vivo labeling produced a more 
important autofluorescence and background signal in the aortic tissues than in the in vitro 
labeling experiments. Moreover, in some of the rabbits, there was a very weak ITOP 
signal, despite the formation of a neointima (Fig. 28). The absence of signal seemed to be 
correlated with an adventitia less developed and without important inflammation, as seen 
with in vitro results. 
 
3.3.2 Neointima Labeling 
In some Watanabe rabbits injected with the αvβ3 probe, the presence of αvβ3 signal was 
more important in the neointimal area rather than in the adventitia (Fig. 29A). 
Interestingly, this signal was also visually correlated with a thinning of the SMCs layer, 
and has observed before, with a beginning of adventitial thickening (Fig 29B). In the in 
 
 
Figure 28 In vivo plaque labeling on Watanabe aorta with ITOP 
 
Left panel (A) represents results of fluorescence microscopy for the descending aorta 
of the Watanabe rabbit injected with the ITOP (5mg, 2hrs), while right panel (B) 
represents results of fluorescence microscopy for the ascending aorta. In this rabbit, 
there was a very weak αvβ3 signal in the adventitia of the descending aorta and 
absence of signal in the ascending aorta. 10X magnification. 
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vivo experiments, αvβ3 labeling seemed to be related to the complexity of the plaques. 
Effectively, the neointimal αvβ3 labeling (Fig. 29A) was also characterized by important 
calcification areas (Fig. 29C), as well as intraplaque hemorrhages (Fig. 29D). There was 
also presence of lipid crystals in the neointima, which is often seen in plaques with late 
cores. Those characteristics were also present in the in vitro experiments, in the rabbit 
with important αvβ3 signal. The neointimal labeling and thinning of the SMCs layer 
seemed to be correlated with an important acellular region in the neointima (Fig. 29D). 
 
 
Figure 29 In vivo plaque labeling on Watanabe aorta showing neointima 
labeling and plaque complexity 
 
(A) Results of fluorescence microscopy for the descending aorta of the Watanabe 
rabbit injected with the ITOP (5mg, 2hrs). (B) H&E staining of the same region, 
demonstrating the thinning of the SMCs layer and the beginning of adventitial 
thickening. On the same section of the rabbit’s descending aorta (thoracic part), there 
was an important zone of calcification (C) and some intraplaque hemorrhages (D). 
Red arrows: intraplaque hemorrhages. 10X magnification. 
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3.3.3 Adventitia Labeling 
In the in vivo experiments, as seen also in vitro, there was presence of αvβ3 probe 
labeling in the adventitia, when there was presence of adventitial thickening (Fig. 30A). 
In those samples, elastic fibers from the SMC layer seemed to be disorganized and even 
disrupted in some areas, and the neointima of the vessel was characterized by the 
presence of foam cells (Fig. 30B). Although no specific blood vessel staining was done, 
the signal seemed to be localized in zones of vessels-like structures and inflammation, as 
observed with the H&E staining. This result was also observed previously during the in 
vitro experimentation. There seemed to be an absence of medial labeling in the samples, 
although the strong background staining of the elastic fibers in the media rendered the 
specific αvβ3 ITOP signal difficult to differentiate. In some of the samples (Fig. 30B), an 
αvβ3 signal in the media cannot be excluded. There seemed to be some weak neointimal 
ITOP signal in the samples, but it is far less intense than the adventitial signal (Fig. 30A).  
 
 
Figure 30 In vivo ITOP labeling on Watanabe aorta showing adventitia 
labeling 
 
Left panel (A) show results of fluorescence microscopy for the descending aorta of 
the Watanabe rabbit injected with the ITOP (5mg, 2hrs), while right panel (B) 
represents the H&E staining of the same region, demonstrating adventitial thickening 
and disrupted collagen content into the SMC layer. In the H&E staining (B), the 
adventitia with an αvβ3 ITOP signal presented vessel-like structures that can be 
characterized as blood vessels. 10X magnification. 
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3.3.4 Labeling and Adventitia Thickness 
As seen with the in vitro samples, comparison between fluorescent staining with the αvβ3 
targeted probe (Fig. 31, upper panel) and histological staining (Fig. 31, bottom panel) of 
the corresponding descending aorta sections demonstrated a qualitative correlation 
between fluorescent signal intensity and adventitial thickness. Accordingly, there was 
presence of mild signal in plaques with a small adventitia thickening (Fig. 31A, D), while 
a stronger signal appeared on plaques with marked adventitia thickening (Fig. 31C, F). 
 
 
Figure 31 Correlation between intensity of ITOP labeling and adventitia 
thickening 
 
Intensity of fluorescence labeling in Watanabe rabbit aorta sections (A, B, C) 
correlated with adventitia thickening and plaque histology (D, E, F).  In the section 
with smaller adventitia (D), the level of staining with the αvβ3 targeted probe was 
weaker (A).  Inversely, in the aorta sections with a larger adventitia (F), the signal 
from the αvβ3 targeted probe was more intense (C).  Interestingly, when the adventitia 
was larger, but there was no plaque formation (E), there was also absence of signal. 
There was also some correlation between the intensity of labeling and the organization 
level into the plaque:  staining is very intense when the media seems digested (C) and 
less intense when the media is well delineated (A, B). 20X magnification. 
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The histological staining (H&E) showed an adventitial development as much as 10 times 
greater in some plaques (Fig. 31F) than in Watanabe rabbit without plaque (Fig. 31D). In 
these plaques, the relative intensity of the optical probe qualitatively corresponded to the 
relative degree of adventitial thickening. Notably, when there was presence of adventitial 
thickening without associated plaque (Fig. 31E), there was absence of staining. Again, as 
seen in vitro, an inverse relationship between the intensity of fluorescence labeling and 
the organization level of the plaque appeared to exist. Staining was more intense (Fig. 
31C) when the media was disorganized (Fig. 31F), and less intense (Fig. 31A, B) when 
the media was well delineated (Fig. 31D, E). As opposed to the in vitro results, there was 
no plaque with very intense αvβ3 labeling.  
 
3.3.5 Labeling and Markers of Plaque Vulnerability 
The Watanabe rabbit aortas that produced an αvβ3 signal were characterized by some 
important cytological features. First, there was adventitial thickening and extensive 
inflammatory cell infiltration in either neointima, adventitia, or both in some cases (Fig. 
32A, C, D). Interestingly, most of the rabbits producing an αvβ3 signal also presented 
heavy calcification (Fig. 32B) and intraplaque hemorrhages (Fig. 32C). The calcified 
areas also corresponded to areas of thinning of the medial layer or complete absence of 
media (Fig. 32A, B). There were also some important discontinuities in the collagen 
fibers of the media (Fig. 32E, F). In some instances, it seemed to be a localized 
discontinuity, probably due to macrophage infiltration (Fig. 32E). In other cases, there 
was an important discontinuity along the length of the media, correlated with what 
seemed to be another small upper layer of elastic fibers (Fig. 32F). 
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Figure 32 Characteristics of the Watanabe atherosclerotic plaques that 
produce an αvβ3 ITOP signal 
 
Watanabe rabbit aorta sections that showed some of characteristics of the plaques that 
has produced an αvβ3 signal. The αvβ3 ITOP signal correlated with important 
cytological characteristics: adventitial thickening and inflammatory cells infiltration 
(A, D), heavy calcification (B), intraplaque hemorrhage (C), and collagen 
discontinuities (E, F). There was also some areas without apparent media layer, 
usually correlated with calcifications (A, B). (A, D, E, F) 10X magnification. (B, D) 
20X Magnification. 
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3.4 DISCUSSION 
 
We previously reported the use of a novel synthetic high affinity and high specificity 
αvβ3 integrin targeted optical probe, in vitro on rabbit atherosclerotic plaques[119]. In this 
previous study, we showed that the majority of the ITOP signal was founded in the 
neointima and adventitia, although there was some associated medial labeling when the 
signal was important. We also reported the qualitative correlation between the intensity 
of αvβ3 labeling and the thickening of the adventitial layer. In the present study, we seek 
to correlate the in vitro results with in vivo injection to evaluate the labeling efficiency 
and kinetic uptake properties of this new optical probe. 
In this study, we showed that in vivo injection of the αvβ3 ITOP produced a specific 
signal in the adventitia and in the neointima of the Watanabe rabbits. It was in 
concordance with our previous in vitro study and also with other studies showing 
angiogenesis in atherosclerotic plaques[120]. As opposed to the in vitro results, we did not 
see intense ITOP labeling in the rabbit’s atherosclerotic plaques. This could be explained 
by the difficulty to differentiate between background fluorescence and specific signal or 
the greater accessibility of the receptor on tissue samples, as opposed to in vivo 
accessibility. Further in vivo studies on blood clearance and dose optimization would be 
necessary. Moreover, as opposed to the in vitro study, αvβ3 labeling with an antibody 
was not possible, since the ITOP was injected, an the probe is designed as an antagonist 
of the αvβ3 receptor. Consequently, ITOP binding will further prevent the binding of the 
αvβ3 antibody. 
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In this study we also showed that in some cases, beside the adventitial and neointimal 
labeling, there was an associated αvβ3 signal in the media. The aortic segments that 
produced a medial αvβ3 signal seemed to be the ones that presented early plaques. In 
those segments, there were no heavy calcification, no intraplaque hemorrhage, and no 
medial discontinuity. This can be explained by the fact that in plaques with calcification 
or hemorrhages, there were often medial necrosis and thinning, with associated 
discontinuities in collagen synthesis due to SMC death[64]. Together with the 
overexpression of MMPs, this caused digestion of ECM proteins and a diminution in 
ECM synthesis. Since αvβ3 is an integrin that play a role in cell-to-cell and cell-to-ECM 
contact and communication, it is expected that extensive medial necrosis and ECM 
degradation will lead to an absence of expression in the media. In that case, adventitial 
angiogenesis and neointima hemorrhages will be the principal site of αvβ3 expression. 
Inversely, in the event of plaque healing, there will be SMC migration and ECM 
synthesis, mechanisms that will involve the expression of αvβ3[43]. 
Another observation of the in vivo study was the absence of αvβ3 signal in the case of 
adventitial thickening without corresponding neointimal formation. Moreover, in vivo 
results also confirmed the correlation between adventitial thickening and αvβ3 signal 
intensity, as previously seen in vitro. Indeed, αvβ3 labeling seemed to be positively 
related to the degree of adventitial thickening and also with the degree of plaque 
inflammation. This observation was in agreement with other studies reporting that plaque 
neovascularization is related to both degree of inflammation and neointima formation[112]. 
Finally, in vivo results also demonstrated that there was often concomitant presence of 
vulnerability markers or stenosis markers in plaque demonstrating an αvβ3 ITOP signal. 
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Effectively, some of the Watanabe rabbits presented calcification, intraplaque 
hemorrhages, heavy inflammatory cell infiltration in both neointima and adventitia, as 
well as collagen/elastic fibers rupture and discontinuities, in some cases associated with a 
thinning or absence of the SMC layer. Interestingly, all those characteristics had been 
previously reported in the in vitro results. Indeed, the rabbit that produced the most 
extensive αvβ3 ITOP signal presented all these features, but medial thinning. While 
numerous studies have link inflammation, plaque hemorrhage, angiogenesis, and medial 
necrosis to plaque vulnerability[11, 121], the relation between calcium and vulnerability 
remain controversial. While microcalcifications had emerged as a new biomarker of 
vulnerability[21], heavy calcification is usually seen in advanced stenotic plaques, and has 
been link to more stable type of atherosclerosis[122]. In the case of Watanabe rabbits, there 
was extensive plaque calcification in the aortas that produced an αvβ3 signal. This could 
be due to discrepancy between the animal models and human atherosclerosis. Effectively, 
while rabbits have a similar lipid mechanism to human, they are less prone to plaque 
rupture[123]. In the other end, link between plaque calcification in rabbits and more 
advanced atherosclerosis have been previously reported[124]. The mechanism by which 
microcalcifications and calcifications processes may differ in rabbits and humans 
remained to be elucidated. 
In this chapter, we correlated the in vitro data of the new αvβ3 ITOP probe with in vivo 
injection on a WHHL rabbit model. We showed that the probe efficiently labeled the 
plaques when intravenously injected to rabbits. The in vivo results confirmed the in vitro 
findings that ITOP labeling seemed to qualitatively correlate with the degree of 
adventitial thickening and inflammation. We also showed that when there was labeling of 
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the media, it seemed to be related to plaque healing, as opposed as when the signal was 
only located in the adventitia and neointima. More pathological and histological studies 
will be necessary to better understand the link between the ITOP signal and the plaque 
composition, but these results indicated that ITOP labeling could be a valuable tool for 
the detection of atherosclerotic plaques, if combined with method that detect stenosis. 
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CHAPTER 3 
IN VITRO ITOP LABELING ON HUMAN 
ATHEROSCLEROTIC SAMPLES AND HISTOLOGICAL 
CHARACTERISATION 
 
4.1 INTRODUCTION 
Our new αvβ3 ITOP has been tested in vitro and showed specific labeling of 
atherosclerotic plaques in a WHHL rabbit model[119]. Labeling was found on adventitia 
and neointima layers, with associated media labeling in some cases. The in vitro study 
also suggested an association between adventitial thickening, inflammatory cell 
infiltration, and the intensity of labeling. After the in vitro study, the ITOP had been 
injected intravenously to WHHL rabbits for in vivo evaluation. The αvβ3 ITOP showed 
specific in vivo labeling of atherosclerostic plaques in WHHL rabbits, although the 
background signal was more important than in the in vitro study. Labeling of the 
adventitia and neointima was confirmed, as well as media labeling, as seen in the 
previous in vitro study. Correlation between adventitial thickening, presence of 
inflammation, and intensity of labeling was also observed. Moreover, the in vivo study 
showed that adventitial thickening without neointima formation resulted in an absence of 
αvβ3 ITOP labeling. In this part of the study, the labeling efficiency of our αvβ3 ITOP 
signal in atherosclerotic plaques will be evaluated in human coronary artery samples, and 
correlated with pathological examination. 
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4.2 MATERIALS AND METHODS 
 
4.2.1 Experimental Design  
Studies were performed on autopsy specimens from the left anterior descending (LAD) 
region of the coronary arteries from multiple cases of sudden deaths (7 atherosclerotic 
cases, 1 case with adaptive intimal thickening, and 1 case with pathological intimal 
thickening). Specimens were purchased from CVPath Institute (Gaithersburg, MD). 
Immunohistology staining, immunohistofluorescence and immunohistochemistry on 
frozen tissue sections from those specimens were then carried out.  
 
4.2.2 Histology and Immunohistology 
OCT blocks from snap frozen coronary arteries (left anterior descending) were cut into 7-
8 µm sections with a cryostat and mounted onto slides.  Routine hematoxylin and eosin 
(H&E) straining was performed on the frozen sections.  For immunohistochemistry, an 
antibody against human α-actin (ab7817, Abcam, USA), and an antibody against CD-68 
(ab955, Abcam, USA), were used, at a dilution 1/200 (PBS), to confirm the presence of 
α-actin and macrophages respectively.  These antibodies were used in conjunction with 
an anti-mouse horseradish peroxidase detection kit, according to the specifications of the 
company (Chemicon International, Inc, Temecula, CA, USA). For 
immunohistofluorescence, an antibody against human MMP-9 (ab58803, Abcam, USA), 
and an antibody against CD-40 (ab61401, Abcam, USA), were used, at a dilution 1/100 
(PBS).  These antibodies were used in conjunction with an anti-mouse secondary 
antibody conjugated to FITC, at a dilution of 1/500 (ab6785, Abcam, USA). Expression 
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of αvβ3 integrin in the aortic wall was assessed by immunohistofluorescence with our 
new αvb3 integrin targeted optical probe (ITOP). Briefly, sections were thawed for 15 
minutes at room temperature, fixed 10 minutes with cold acetone, washed in phosphate 
buffer solution and then incubated with the targeted fluorescent probe for 1 hour.  After 
the incubation period, the slides were washed again in phosphate buffer solution, and 
mounted with VECTASHIELD mounting medium containing DAPI (Vector 
Laboratories, Inc., Burlingame, CA). An antibody against human αvβ3, anti-human 
integrin αvβ3, clone LM609 (Chemicon International, Inc, Temecula, CA, USA), was 
used to confirm the presence of the integrin and as a reference for the localization of any 
experimental fluorescence signal.  This antibody was used in conjunction with an anti-
mouse horseradish peroxidase detection kit, according to the specifications of the 
company (Chemicon International, Inc, Temecula, CA, USA). Images of staining or 
fluorescence signal were acquired under a microscope (Leica DM5500B with a Leica 
DFC-500 color camera) using a visible or ultraviolet light source, respectively. For the 
ITOP (FITC labeling), the emission wavelength was set up at 495nm, while absorption 
wavelength at 521nm.  
 
4.3 RESULTS 
 
4.3.1 Histological Characterization of the Coronary Wall 
Since atherosclerotic plaques present many different characteristics, it was very difficult 
to choose a specimen representing a typical plaque.  Indeed, every atherosclerotic plaque 
is characterized by its own features, and it is difficult to draw any conclusion without 
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extensive pathological studies. For this reason, in other to test our probe in vitro on 
human samples, we chose plaques that demonstrated signs of complexity. First, all of the 
human plaque specimens were taken from left anterior descending (LAD) coronary 
arteries. The coronary wall on those samples appeared very thick (Fig. 33A) due to the 
formation of an important neointima (Fig. 33B, D). In most cases, there were associated 
adventitial thickening (Fig. 33A, C, E). Most of the plaques that were tested also 
presented some inflammatory cell infiltration (Fig. 33A, C, E). Typically, the necrotic 
 
 
Figure 33 Characteristics of the coronary artery walls of human 
atherosclerotic plaque specimens 
 
Human sections that showed some of the characteristics of the plaques that had 
produced an αvβ3 signal. Features of the tested plaques included adventitial 
thickening (A, C, E), important neointimal formation (B, D), stenosis (B), fibrous cap 
and necrotic core formation (D), and inflammatory cell infiltration (A, C, D). 
Typically, plaque did not present intraplaque hemorrhages or microcalcification. 10X 
Magnification.  
 
Page 104 of 246 
 
core thicknesses (Fig. 33D) were more than 65µm, which was not considered thin fibrous 
caps or markers of plaque vulnerability[3]. Two of the plaques tested presented signs of 
complexity, as superimposed necrotic cores (Fig. 34B, C). The human samples tested 
were also characterized by an absence of intraplaque hemorrhage or microcalcification. 
 
 
 
Figure 34 Cross-sectional view of human atherosclerotic plaque specimens 
 
Cross-sectional image of human atherosclerotic plaques showing mostly plaques with 
luminal stenosis (A, B, C), evaluated by the small lumen area. The plaque in D 
seemed to be in positive remodeling phase, although it is not possible to confirm 
without the associated adjacent segment presenting no stenosis. 1,25X Magnification.  
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Most of the plaque samples obtained seemed to be presenting stenosis, observed by the 
overall small cross-sectional areas, and the small size of the lumen areas (Fig. 34A, B, C). 
One plaque seemed in positive remodeling, although the overall morphology made it 
difficult to evaluate (Fig. 34D). The fact that the vessel area and lumen size were larger 
than the other specimens of plaque, and the oval morphology with asymmetrical plaque 
formation point out toward positive remodeling. Unfortunately, because the lumen was 
not pressurized or the vessel conformation and morphology not preserved by the method 
of fixation, it was difficult to draw any conclusion. Some plaques appeared to be fibrous 
(type V; Fig. 34A), two more complex (type VI; Fig. 34B, C), and one between fibrous 
and vulnerable (between type V and type IV; Fig. 34D). 
 
4.3.2 αvβ3 Labeling 
All of the human atherosclerotic plaque samples tested produced a certain level of αvβ3 
ITOP signal. The signal was found in the neointima (Fig. 35B, D), media (Fig. 35A), as 
well as in the adventitia (Fig. 35A, C, E). As previously found in vitro on Watanabe 
rabbits, most of the signal was localized in the adventitia and near lumen area. Medial 
labeling seemed to be sparser and was associated with intense adventitia and neointima 
labeling (Fig. 35A, B, C). The background signal on the human samples was very weak. 
As seen with the Watanabe animal model, the background appeared more intense in the 
zone where the collagen localized. One of the plaques tested was presenting a very 
intense αvβ3 signal, with ITOP labeling in the adventitia, media and near lumen areas 
(Fig. 35A, B, C). This plaque was characterized by two necrotic cores: a healed necrotic 
core with another one in development (Fig. 36B), which is characteristic of type VI 
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plaques. Moreover, there was presence of adventitial thickening on the whole length of 
the cross-sectional area. Also, this plaque was extremely stenotic. Finally, on the segment 
of the developing necrotic core, there was intense staining around structures inside the 
adventitia that look like neovascularization (Fig. 36), as well as near elongated structures 
that resemble muscle sprouts (Fig. 36A, C). The specificity of the αvβ3 binding was 
confirmed with an αvβ3 antibody. The signal was co-localized, although less intense 
with the antibody (Fig. 37). 
 
 
Figure 35 Fluorescence microscopy of human coronary artery sections from 
tissues incubated with FITC-αvβ3 antagonist 
 
Image of slide exposed to FITC-αvβ3 antagonist (2.8µM) for 1 hour. All of the 
coronary arteries tested produced an αvβ3 signal. In the samples producing an 
important intensity of signal, the adventitia (A, C), media (A, C) and neointima (B) 
were all labeled.  In the samples with a weaker signal, near lumen neointima (D) and 
adventitia (E) both produced an αvβ3 signal. Results indicated specific plaque 
labeling with the fluorescent ITOP with a very small amount of autofluorescence 
background from tissues. 10X Magnification. 
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Figure 36 Characteristics of human coronary artery section producing the 
most intense αvβ3 ITOP labeling 
 
Image of slide exposed to FITC-αvβ3 antagonist (2.8µM) for 1 hour (upper panel), 
with correspondent H&E staining (lower panel). Adventitia labeling (A, B) seemed to 
be corresponding to neovessel-like structures in H&E staining (C, D). In the 
adventitia of the segment with developing necrotic core, there was some elongated 
structures (∗) that resemble muscle sprouts (C). 10X Magnification. 
 
∗  
∗  
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4.3.3 α-Actin Labeling 
As mentioned previously, human atherosclerotic plaques are very heterogeneous. The α-
actin staining for the presence of SMCs in the coronary wall was a good illustration of 
this complexity. All of the plaques showed α-actin staining in the media and neointima 
area, but with different intensity. For example, some plaque demonstrated an important α-
 
 
Figure 37 Co-localization study of αvβ3 expression on human coronary 
artery sections labeled with αvβ3 ITOP or an αvβ3 antibody.  
 
(A) αvβ3 immunofluorescence and (B) immunohistochemistry of a human coronary 
artery labeled with the ITOP (A) and with an αvβ3 antibody (B), respectively.  The 
panel (A) displayed a portion of the aortic wall producing a fluorescent ITOP signal. 
The panel (B) displayed a higher magnification of the same area incubated with an 
αvβ3 antibody, which was necessary in order to better visualize the signal.  Both the 
fluorescence signal (A) and the immunohistological labeling (B) were co-localized 
predominantly in the adventitia and proximal neointima. The ITOP signal was 
stronger than the antibody signal, which can be explained by the better avidity of the 
ITOP toward the receptor. (A) 10X Magnification. (B) 40X Magnification. The 
asterix (*) signs displayed the zone were there was a αvβ3 signal. 
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actin staining in the medial layers, but a weak and sparse staining in the neointima layers 
(Fig. 38A, B), which typically characterized fibrous plaques (type V) or vulnerable 
plaques (type IV). As opposed to that, other plaques showed less staining in the medial 
layers with some discontinuities, associated with a more important neointima staining 
(Fig. 38C, D), which is often present in healed plaques (type VI).  
 
 
 
Figure 38 α-actin labeling on human coronary artery sections demonstrating 
the presence of SMCs 
 
α-actin labeling showing SMCs presence in the media and neointima of the coronary 
wall.  Some samples showed strong medial labeling of SMCs, associated with weak 
and sparse neointima labeling (A, B), while other samples showed weak and 
discontinuous medial labeling, associated with strong neointimal labeling (C, D). 
Strong medial α-actin labeling could be associated with young (A) or healed (B) 
plaques, while strong neointimal labeling could represent healed plaques or more 
complex type of plaques (C, D). 2,5X Magnification. 
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4.3.4 MMP-9 Labeling 
MMP-9 expression on the coronary wall of the human samples was dispersed throughout 
the entire cross-sectional areas (Fig. 39). Indeed, the MMP-9 signal appeared in the 
neointima, media, and adventitia of the plaques. Despite some variability among the 
samples, MMP-9 expression seemed relatively comparable in all the samples. Since the 
antibody used to label MMP-9 recognized both active and inactive forms, MMP-9 
presence did not necessary predicted MMP-9 activity in the samples. The background 
signal seemed to be more important in the neointima layer than in other parts, maybe 
because of the presence of collagen and elastic fibers inside the neointima. 
 
 
Figure 39 MMP-9 expression on human coronary arteries  
 
Sections of left anterior descending coronary arteries showing MMP-9 expression. In 
the atherosclerotic plaques tested, MMP-9 expression was dispersed throughout the 
neointima, media and adventitia layer. Magnification 10X. 
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4.3.5 Macrophages Labeling (CD68)  
In atherosclerosis, macrophages are often localized in the neointima, at the shoulder areas 
of the plaques. Surprisingly, even if the human plaque tested were complexes, CD68 
labeling revealed very few positive cells (Fig. 40). Most of CD68+ cells were found in 
the neointima of the plaques, around the necrotic core areas and shoulders (Fig. 40A, B), 
although that in the plaque with the most important αvβ3 labeling, there was also 
presence of CD68 labeling in the adventitia layer (Fig. 40C, D). 
 
 
Figure 40 CD68 expression on human coronary artery sections 
demonstrating the presence of macrophages in the plaques 
 
CD68 labeling showing the presence of macrophages in the neointima (A, B) and 
adventitia (C, D) of the plaques. In the human plaques tested, most of the labeling was 
found in the neointima, although the plaque with important αvβ3 labeling showed 
presence of CD68+ cells in the adventitia. 40X Magnification. 
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4.3.6 T-Cell/B-Cells Labeling (CD40) 
In atherosclerotic plaque formation, there is a very sophisticated mechanism of cross-
talking between inflammatory cells like macrophages and T-cells. Immunofluorescence 
labeling of CD40, a receptor present at the surface of T-cells and B-cells, revealed the 
presence of inflammatory infiltration in all of the plaques tested (Fig. 41). CD40 
expression was relatively important, especially in the neointima of the plaques (Fig. 41A, 
B, C). As seen previously with macrophage expression, the plaque with an important 
αvβ3 labeling also presented CD40 expression in the adventitia layer. 
 
 
Figure 41 CD40 expression on human coronary artery sections 
demonstrating the presence of lymphocyte T 
 
CD40 labeling in the coronary wall demonstrated the presence of T-cells or B cells 
mostly in the neointima of the plaques (A, B, C), with associated adventitial 
expression (D) for the plaque with the most important αvβ3 signal. 20X 
Magnification. 
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4.3.7 Elastic Fibers - Verhoeff’s Van Gieson (EVG) Staining 
In coronary arteries, there are two important elastic fiber membranes that confer arteries 
their elastic properties: the internal elastic lamina (IEL) and the external elastic lamina 
(EEL). EVG staining of the coronary plaques revealed that on the plaques with a thicker 
adventitia, the IELs were almost disappearing (Fig. 42A, C, D), while in the plaques with 
smaller adventitia, it were still present, but contained numerous discontinuities (Fig. 
42B). On the other hand, the EELs seemed intact in samples where the adventitia 
appeared to have a high density of collagen and fibers (Fig. 42A, B), while almost absent 
from the samples where the adventitia layers had less collagen and fibers (Fig. 42C, D). 
 
 
Figure 42 Elastic tissue fibers staining of the human coronary artery plaques 
with elastic Van Gieson (EVG) stain 
 
The IELs were almost absent from samples with thick adventitia (A, C, D), while it 
was present, but contained discontinuities, in samples with smaller adventitia (B). The 
EELs were intact in samples with dense content of adventitial fibers and collagen (A, 
B), while it were absent from the samples with sparse content of adventitial fibers and 
collagen (C, D). Black: elastic fibers. Magnification 5X. 
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4.3.8 Masson Trichrome Staining 
The collagen content in atherosclerotic plaques is another feature that confer the 
physicoproperties to the wall and can give information on plaque stability. Some of the 
tested plaques presented absence of staining in the necrotic core area, demonstrating loss 
of collagen into the neointimal regions (Fig. 43A, B). This is typical of late cores, with 
numerous cholesterol clefts, cellular debris and an absence of ECM, particularly collagen, 
as opposed as early cores, which show collagen interspersed with intact foamy 
macrophages. One plaque tested seemed to have the characteristics of an early core (Fig. 
43C, D), but surprisingly showed the most cross-sectional degree of stenosis. This could 
be explained by the fact that this plaque possessed two different necrotic cores: one that 
had been healed, and another one superimposed. Plaques with late cores seemed to have 
higher collagen content in the neointima (Fig. 43A, B) than the plaque with and early 
core (Fig. 43C, D), and also possessed a denser collagen content in the adventitia layers. 
In the late cores, the media layers were intact, as opposed as the early core, where the 
media layer seemed to be disorganized with an absence of SMCs in some parts (Fig. 
43D) of the wall. In the plaque that produced the most αvβ3 signal, there were SMC 
labeling in the adventitial layer, where we found most of the αvβ3 signal (Fig. 43C, 
asterisk). The SMCs were arranged in elongated structures that resembled muscle 
sprouts. In this plaque, the collagen content appeared much more sparser than in the other 
plaques, with a density much more smaller in all the different layers (neointima, media, 
and adventitia). The late cores possessed fibrous caps that showed an important 
accumulation of dense collagen. As opposed to that, the plaque with the early core 
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showed an important formation of SMC layer in the fibrous cap, but associated with a 
smaller density of collagen. 
 
 
 
 
 
Figure 43 Masson Trichrome staining of the human coronary arteries with 
plaques  
 
Upper panel showed typical late cores with absence of staining, with and associated 
high density of collagen in the vessel wall. Lower panel showed an example of 
plaque with healed core (C), and another superimposed core (D), with a lower density 
of collagen content in the vessel wall. The late core showed intact medial layer, while 
the other core presented some areas with absence of SMCs in the media. * SMC 
staining in the adventitia, resembling muscle sprouts. Blue: collagen. Red: muscle, red 
blood cells. Pink: cytoplasm. Black: Nuclei. 5X Magnification. 
 
∗ 
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4.3.9 Labeling and Adventitia Thickness 
Because of the small number of plaque tested, it was difficult to draw any conclusion on 
the correlation between the thickness of the adventitia and the intensity of αvβ3 labeling. 
Nevertheless and albeit the small sampling, the human plaques showed the same 
tendency than the previously published results on Watanabe rabbits. Effectively, it 
appeared that the area with smaller adventitia showed less intense αvβ3 ITOP labeling 
(Fig. 44A, B, D, E), as opposed to the area with thicker adventitia that showed more 
intense labeling (Fig. 44C, F). Therefore, comparison between fluorescent αvβ3 probe 
 
 
Figure 44 Relationship between intensity of ITOP labeling and adventitia 
thickening 
 
Intensity of fluorescence staining in human coronary sections (A, B, C) correlated 
with adventitia thickness and plaque histology (D, E, F).  In sections with smaller 
adventitia (D, E), the level of staining with the αvβ3 targeted probe was weaker (A, 
B).  Inversely, in sections with a larger adventitia (F), the αvβ3 signal was more 
intense (C).  There was also some correlation between the intensity of labeling and the 
organization level into the plaque:  staining was more intense in plaque with disrupted 
media (C) and less intense when the media was well delineated (A, B). 10X 
Magnification. 
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signal (Fig. 44, upper panel) and H&E staining of the corresponding coronary artery (Fig. 
44, lower panel) showed the same qualitative correlation between the intensity of signal 
and the adventitial thickening. Moreover, as also seen previously in the Watanabe rabbit 
model, there were an association between the intensity of labeling and the plaque 
morphology. Indeed, plaques with intact medial layers showed less intense labeling (Fig. 
44A, B, D, E) than plaques with discontinuous and disorganized medial layers (Fig. 44C, 
F). 
 
 
4.4 DISCUSSION 
 
In the previous chapters, we tested a new αvβ3 ITOP on a Watanabe rabbit model, both 
in vitro and in vivo. We showed that it efficiently labeled atherosclerotic plaques with 
high affinity, although there was some background signal from the in vivo injection. We 
also showed that the signal was mostly found in the adventitia and neointima layers, 
although there was also signal from the media in samples with intense signal. We also 
found that the intensity of αvβ3 ITOP signal seemed to correlate with the degree of 
adventitial thickening, as well as the level of organization of the media and collagen 
content in the media[119]. 
The goal of this chapter was mostly to show that our αvβ3 ITOP could also labeled 
efficiently human atherosclerotic plaques in vitro. Since we had a very limited amount of 
samples, we do not had the ambition to elucidate the mechanism of ITOP labeling in 
regard to the type of plaque. In this regard, our conclusions will be draw only for 
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discussion purpose, and the markers used in conjunction with the ITOP probe, only 
served to better characterized the samples tested. We kept in mind that a more extensive 
sampling will be needed to collaborate any conclusions.   
Most of the plaque samples obtained seemed to be in negative remodeling phase or 
stenosed, observed by the overall small cross-sectional areas, and the small size of the 
lumen areas (Fig. 34). Unfortunately, because the lumen was not pressurized or the vessel 
conformation and morphology not preserved by the method of fixation, it was difficult to 
draw any conclusion. In the other hand, the negative remodeling/stenotic stage could 
explain the fact that none of the tested human atherosclerotic plaques had ruptured, since 
vulnerable plaques are most likely characterized by positive remodeling[14, 16], and the 
degree of stenosis appears to be a poor predictor of cardiovascular event[22, 125]. Only one 
of the plaque tested appeared to be in positive remodeling phase, with minimal cross-
sectional stenosis. This plaque showed minimal αvβ3 ITOP labeling, with signal 
localized in neointima and adventitia. This observation seemed to correlate with the 
expression of vasa vasorum (vv) in plaque with low-grade stenosis and positive 
remodeling[126, 127]. As opposed to this plaque, the plaque with the most intense signal 
(neointima, media and adventitia) appeared severely stenosed, and possessed two 
different necrotic core areas: one healed and one superimposed. This intense labeling can 
be linked to the fact that in this particular plaque, there were two mechanisms responsible 
for the apparition of neovascularization: ischemia and hypoxia. Indeed, lumen stenosis 
produce by the healed necrotic core contributes to tissue ischemia[128, 129], in the same 
way inflammatory processes produced hypoxia[75, 130]. As mentioned before, those two 
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mechanisms are associated with neovascularization[131, 132], which might explain the 
intensity of the αvβ3 ITOP labeling in this plaque. 
Another characteristic of the plaque with the most important αvβ3 signal was the 
presence of adventitial elongated structures resembling muscle sprouts. Those structures 
were localized in the same adventitial region where an intense αvβ3 ITOP signal was 
found. Previous reports have shown that before the formation of neovessels, activated 
SMCs will sprout and form elongated structure, a phenomenon preceding the formation 
and organization of new vessels into a circular lumen[44, 133]. We could postulate that the 
intense αvβ3 labeling on the adventitia, among the elongated structures, represented 
activated SMCs that will further become neovessels. 
All of the plaques tested showed MMP-9 expression in the entire coronary wall, 
macrophage infiltration, and CD40 expression at some level of intensity. Those 
inflammatory features point out toward the presence of hypoxia[134, 135], an important 
stimulus for the formation of neovascularization[121, 136, 137], but also stenosis. 
Unfortunately, because of the small sampling, it was difficult to draw some conclusion. 
Nevertheless, it could be mentioned that the plaque with the most αvβ3 labeling, also 
demonstrated the most T-cells labeling. T-cells are important in plaque formation, 
because of their crosstalk with macrophages and other immune cells in the plaque[138-140] 
and are also involved in remodeling[141, 142] and neovascularization[143, 144], which can lead 
to stenosis and plaque healing. 
Finally, as demonstrated previously with the Watanabe rabbit model, preliminary results 
on the human plaques also seemed to point out toward a relationship between the 
intensity of labeling and the thickness of the adventitial layer. Effectively, some other 
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studies reported that angiogenesis[145] and inflammatory mechanisms involved the 
development of the adventitia into a thicker layer[146]. Although we had a very limited 
amount of samples, we did see a qualitative correlation between the intensity of the signal 
and the adventitial thickening. Results showed a tendency to have more important level 
of signal in areas of adventitial thickening, as seen in the Watanabe rabbit model. This 
also seemed to be correlated with the degree of organization into the plaques. In the 
Watanabe rabbit model, the media of the samples presenting important staining was often 
discontinuous or disorganized. In the human samples, the plaque showing the most 
important αvβ3 labeling also showed and absence of medial layer in some areas, and a 
collagen content less important than in plaques with weaker αvβ3 labeling, but also an 
important fibrous cap formation (thick layer of neointimal SMCs). This could be 
explained by the fact that plaque formation involves the migration of SMCs and 
remodeling of the vessel wall[147]. That phenomenon can be associated with a 
disorganization of the medial layer and a smaller density of collagen fiber to allow 
migration and matrix remodeling. In conjunction with the Watanabe rabbit results, it also 
seemed to point out toward the fact that healed plaques (where necrotic core has been 
replaced by fibrous tissues and the SMCs layer is disorganized) seemed to be 
characterized by an intense αvβ3 labeling. This is in contradiction with previous studies 
correlating neovascularization with plaque instability. 
The principal limitation of this study was the small number of samples. Although it has 
been possible to form some hypothesis, a larger sampling will be needed for the 
confirmation of our finding. It would also been interesting to verify the labeling 
efficiency of our probe on other models of diseases. Effectively, to understand the 
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mechanism of plaque formation or neovascularization, it is crucial to use other 
pathological models that behave differently. For example, AD-HIES patient has been 
reported to have a paucity of atherosclerosis[100, 101], as opposed to HIV patients that seem 
to develop accelerated atherosclerosis[148, 149]. It would be interesting to investigate the 
comportment of our probe on those patients and compare it with our previous results. 
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CHAPTER 4 
IN VITRO ITOP LABELING ON AD-HIES SAMPLES 
WITH MOLECULAR CHARACTERIZATON 
 
5.1 INTRODUCTION 
 
Because of the rarity of this disease, it is extremely fortunate that we had access to 
autopsy samples from an AD-HIES patient. Consequently, because of the novelty and 
scientific importance of any discovery, this chapter will be more developed and 
discussed. 
AD-HIES disease or autosomal dominant hyper-IgE syndrome (AD-HIES) is a rare 
primary immunodeficiency caused by a dominant negative mutation in STAT3[97, 98]. It is 
characterized by various clinical manifestations such as high serum level of IgE, 
recurrent infections, eczematous dermatitis, and connective tissue abnormalities[99]. Most 
of the extracellular bacterial infections in hyper IgE patient are caused by Staphylococcus 
Aureus bacteria and are characterized by milder inflammation than in normal population. 
Another important clinical aspect of this disease is the presence of connective tissue 
abnormalities and hyperextensibility. Recent studies had described an unset of vascular 
abnormalities in hyper-IgE patients, characterized by the presence of tortuosity, arterial 
aneurysms, and ectasia, despite the uncommon presence of atherosclerosis, indicated by 
luminal stenosis[100, 101]. These interesting characteristics make AD-HIES an extremely 
attractive model for the study of atherosclerotic processes. Therefore, we used 
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histological, immunohistological and immunofluorescence studies to identify coronary 
physiological features and molecular markers in an AD-HIES case.  
 
5.2 MATERIALS AND METHODS 
 
5.2.1 Experimental Design  
We took autopsy specimens of different segments of the coronary arteries (right n=2, left 
anterior descending n=2, left circumflex n=2, left main at bifurcation point n=2) from an 
AD-HIES case. Coronary artery specimens were obtained less than 24 hours after death 
and the samples were immediately processed. Briefly, 1 sample from each of the right, 
left anterior descending, left circumflex, and left main at the bifurcation point were 
dissected from the heart and keep on ice. 2 segments of each coronary artery (about 
0.5mm) were taken out, embedded in Optimal Cutting Temperature (OCT) medium and 
stored at -80°C.  The remaining tissues were put in a bag and stored at -80°C. We carried 
out immunohistology staining, immunohistofluorescence and immunohistochemistry on 
frozen tissue sections from the biopsy tissues.  
 
5.2.2 Histology and Immunohistology 
OCT blocks from snap frozen coronary arteries (right, left anterior descending, left 
circumflex, left main at bifurcation point) were cut into 7-8 µm sections with a cryostat 
and mounted onto slides.  Routine hematoxylin and eosin (H&E) straining was performed 
on the frozen sections.  Routine elastic fiber staining was performed with elastic tissue 
fibers – Verhoeff’s Van Gieson (EVG) staining. Briefly, samples were fixed with 4% 
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paraformaldehyde, and then incubated with Verhoeff’s hematoxylin for 30 minutes. After 
being washed with water, samples were differentiated with 2% ferric chloride solution, 
rinsed in water again, and then incubated 1 minute with 5% Hypo to remove iodine. 
Finally, samples were washed in water, counterstained in Van Gieson’s for 5 minutes, 
dehydrated, cleared in xylene and coverslip. For collagen staining, we used Masson 
Trichrome. Briefly, frozen samples were fixed with Bouin’s solution, washed, and 
incubated with Weigert’s iron hematoxylin for 10 minutes. After being rinse in tap water 
and washed in distilled water, samples were stained with Biebrich scarlet-acid fuchsine 
for 10-15 minutes, and washed again. Samples were then differentiated in 
phosphomolybdic-phosphotungstic acid solution for 10-15 minutes, transferred directly 
to aniline blue solution for 5-10 minutes, rinse briefly, and differentiated in 1% acetic 
acid solution for 2-5 minutes. Finally, sections were washed in distilled water, quickly 
dehydrated through 95% ethyl alcohol, absolute ethyl alcohol, clear in xylene and mount 
using resinous mounting medium. Special Movat staining was also used. Briefly, frozen 
samples were fixed in Bouin’s, rinsed in cold running water for 10 minutes, incubated in 
Sodium Thiosulfate for 5 minutes, and washed again under cold running water. Samples 
were then stained in 1% Alcian Blue for 20 minutes, and rinsed under cold running water 
again. Samples were then placed in preheated Alkaline Alcohol for 10 minutes in the 
oven, and rinsed in cold running water. Then, samples were placed in Movat’s Weigerts 
for 1 hour, washed in cold running water and rinsed with distilled water, and placed in 
Crocein Scarlet/Acid Fuchsine for 1 minute. After a rinse in distilled water, samples were 
placed 5% Phosphotungstic Acid for 5 minutes, transferred to 1% Acetic Acid for 5 
minutes, and rinsed again in distilled water. Finally, samples were dehydrated in 1 change 
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95% ETOH, 2 changes of 100% ETOH, put in Alcoholic Saffron for 20 minutes, rinsed 
with 2 changes of 100% ETOH, cleared with xylene, and mount. For 
immunohistochemistry, an antibody against human α-actin (ab7817, Abcam, USA), and 
an antibody against CD-68 (ab955, Abcam, USA), were used, at a dilution 1/200 (PBS), 
to confirm the presence of α-actin and macrophages respectively. Those antibodies were 
used in conjunction with an anti-mouse horseradish peroxidase detection kit, according to 
the specifications of the company (Chemicon International, Inc, Temecula, CA, USA). 
For immunohistofluorescence, an antibody against human MMP-9 (ab58803, Abcam, 
USA), and an antibody against CD-40 (ab61401, Abcam, USA), were used, at a dilution 
1/100 (PBS). Those antibodies were used in conjunction with an anti-mouse secondary 
antibody conjugated to FITC, at a dilution of 1/500 (ab6785, Abcam, USA). Expression 
of αvβ3 integrin in the aortic wall was assessed by immunohistofluorescence with our 
new αvb3 integrin targeted optical probe (ITOP). Sections were thawed for 15 minutes at 
room temperature, fixed 10 minutes with cold acetone, washed in phosphate buffer 
solution and then incubated with the targeted fluorescent probe for 1 hour.  After the 
incubation period, the slides were washed again in phosphate buffer solution, and 
mounted with VECTASHIELD mounting medium containing DAPI (Vector 
Laboratories, Inc., Burlingame, CA). An antibody against human αvβ3, anti-human 
integrin αvβ3, clone LM609 (Chemicon International, Inc, Temecula, CA, USA), was 
used to confirm the presence of the integrin and as a reference for the localization of any 
experimental fluorescent signal. This antibody was used in conjunction with an anti-
mouse horseradish peroxidase detection kit, according to the specifications of the 
company (Chemicon International, Inc, Temecula, CA, USA). Images of staining or 
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fluorescence signal were acquired under a microscope (Leica DM5500B with a Leica 
DFC-500 color camera) using a visible or ultraviolet light source, respectively. For the 
ITOP (FITC labeling), the emission wavelength was set up at 495nm, while absorption 
wavelength at 521nm.  
 
5.2.3 Measurements and Definitions 
Quantification of each cross-sectional section was made under non-pressurized condition. 
Measurements were made of lumen area (Luarea, mm2), neointimal area or plaque area 
(Plaarea, mm2 = IELarea - Luarea), medial area (Mearea, mm2 = EELarea- IELarea), adventitial 
area (Adarea, mm2), internal elastic lamina area (IELarea = Luarea + Plaarea, mm2), external 
elastic lamina (EELarea = Mearea + Plaarea + Luarea, mm2), necrotic core area (NCarea, mm2), 
cap thickness (Capthick: measured at the location of thin cap, µm). Cross-sectional degree 
of stenosis, according to Glagov, was calculated as 100 X Plaarea / IELarea. Luminal 
percentage of stenosis was calculated as 100 X [(Luarea at reference site – minimum 
Luarea) / (Luarea at reference site)], where lumen area at reference site is an adjacent 
segment of the same coronary artery judged to be free of plaque. Plaque burden was 
calculated as 100 X (Plaarea + Mearea)/ EELarea. Eccentricity index is calculated as 360° X 
(plaque free arc angle / total vessel circumference). Remodeling index (RI) was 
calculated as vessel area  (EELarea) at minimum lumen area / reference vessel area.  
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5.3 RESULTS 
 
5.3.1 Histological Characterization of the Coronary Wall 
Apart from the left main artery at the bifurcation point, the AD-HIES case revealed 
intimal thickening in all the region of the coronary artery (right, left anterior descending, 
left circumflex) without apparent lipid pool or necrotic core presence (Fig. 45). The 
 
 
Figure 45 H&E staining of the AD-HIES coronary arteries 
 
Section of the left anterior descending (A), right (B), left circumflex (C), and left 
main at the bifurcation point (D), coronary artery. 2,5X magnification. The vessels 
appeared to be generally dilated, as they show a mean vessel size of approximately 12 
mm2, even at pressure zero. 
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intimal thickening of the vessel mainly consisted of smooth muscle cells (SMCs) in a 
matrix of proteoglycan, similar to adaptive intimal thickening appearing with age. The 
AD-HIES case presented a generalized dilation of the vessels’ wall without plaque, as 
shown by the large vessel area even at no pressure (mean 12mm2, Fig. 45). Pathological 
examination of the AD-HIES coronary tissues showed an atherosclerotic plaque at the 
bifurcation point of the left main coronary artery, which was very unusual, and presented 
all the features of an advanced lesion, but without associated luminal narrowing or very 
mild stenosis (Fig. 46A, B). It was characterized by compensatory enlargement of the 
vessel size, or positive remodeling (Fig. 46), compared to the atherosclerotic samples 
presenting late CAD and stenosis. Interestingly, using Glagov calculation, the cross-
sectional degree of stenosis was evaluated to 60%, stage at which the vessel is known to 
be passed the compensatory luminal enlargement phenomenon, and should be presenting 
important stenosis. On the other hand, the luminal stenosis, calculated with an adjacent 
reference segment free of plaque, is evaluated to be around 3% (Table 3), which is 
considered to be very mild. Effectively, at the plaque site, the lumen appeared similar in 
size to the reference site, with only minimal stenosis. Notably, morphological evaluation 
of the plaque seemed to correlate strongly with vulnerability. First, the vessel’s localized 
dilation exceeded 1.3 times the diameter of the adjacent normal segment (Fig. 46A, B), 
with a remodeling index of 1.63 (Table 3), which correspond to positive remodeling 
(RI>1.05), and a plaque burden of 68%. There was a large necrotic core area representing 
66% of the plaque area (Table 3 and Fig. 46B, C, D), and presenting an important 
thickness (~650µm). The necrotic core was composed by lipids and small cholesterol 
clefts (Fig. 46D), microcalcifications (Fig. 46E), and small 
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Figure 46 H&E staining of the AD-HIES left main coronary artery at the 
bifurcation point  
 
Section of the left main coronary artery representing the reference site (A) and another 
adjacent section showing characteristic outward plaque accumulation (B), taken at 
1.25X magnification. (C), (D), (E), and (F) are higher magnifications of the left main 
coronary artery with plaque shown in (B): 5X, 10X, 20X, and 40X respectively. 
Boxed area in (C): region that is magnified 2X in (D). (C) Region with plaque 
showing an important necrotic core area, lipid pool, and cholesterol clefts. (D) Image 
showing 10X magnification of the plaque area, with cholesterol clefts (black arrow) 
and also intraplaque hemorrhage (red arrow). (E) 20X magnification showing 
extensive microcalcifications in the plaque. (F) 40X magnification of the shoulder 
region showing the thin fibrous cap, which appears to be smaller than 45µm. Red 
Arrow: red blood cells. Black arrow: cholesterol clefts. *: Region of 
microcalcifications. 
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hemorrhages (Fig. 46D), with an absence of collagen, a characteristic of late core. The 
cap thickness at the shoulder area was very thin, estimated to be less than 45µm (Table 3 
and Fig. 46C, boxed area, D), and heavily infiltrated by macrophages (Table 3). The 
media and adventitia layers appeared thinned below the atherosclerotic plaque, as 
opposed to the adventitia layer opposite the plaque, that showed a beginning of 
thickening (Fig. 46B).  
TABLE 3 Left Main Coronary Artery Measurements at the plaque site 
Morphological Indexes Value 
LS (%) 2.7% 
Cross-sectional DS (%) 60% 
PB (%) 68% 
NC (%) 66% 
NCT (µm) ~650µm 
CT (µm) <45µm 
RI 1,63 
EI (°) 176º 
Macrophages count by High Power 
Field 
~40 
 
 
 
Table 3 Morphological indexes of the AD-HIES left main coronary artery 
at the bifurcation point 
 
LS: luminal stenosis. DS: degree of stenosis. PL: plaque burden. NC: necrotic core 
area. NCT: necrotic core thickness. CT: cap thickness. RI: Remodeling Index. EI: 
eccentricity index 
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5.3.2 αvβ3 Labeling 
Neovascularization has been reported to play a role in plaque instability and 
vulnerability[11, 79] as well as in the aneurysm formation[150]. Expression of αvb3 was 
evaluated with an integrin targeted optical probe, which we previously published[119], and 
confirmed with an antibody against αvb3. The AD-HIES case presented a paucity of 
αvb3 expression in the asymptomatic vessel wall (samples without plaque) (Fig. 47 B, 
C), associated with a low level of expression when there is a beginning of adventitial 
 
 
Figure 47 αvβ3 labeling of the AD-HIES coronary arteries  
 
Section of the left anterior descending (A), left circumflex (B), and right (C, D) 
coronary arteries labeled with an anti-αvβ3 probe. Apart from few + cells, there was a 
paucity of αvβ3 labeling in the coronary sections of the AD-HIES case without the 
plaque. The right coronary artery seemed to present more + cells and a relative 
thickening of the adventitia. 10X magnification. 
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thickening (Fig. 47A, D). At the plaque site, there were few αvb3+ cells on the 
neointima, in the near lumen area (Fig. 48B), and inside the adventitia below the plaque 
(Fig. 48A).  
 
 
5.3.3 α-Actin Labeling  
SMCs are largely involved in numerous aspect of the vessel wall integrity, playing a role 
in matrix remodeling, vessel repair, atherosclerosis and aneurysm[102, 151, 152]. 
Immunohistochemical analysis of biopsy specimens from AD-HIES showed the presence 
of α-actin inside the media of the coronary artery wall, with associated neointimal α-
actin expression (Fig. 49). This is characteristic of normal arterial thicknening caused by 
aging, which is principally characterized by proliferation of SMCs and 
 
 
Figure 48 αvβ3 labeling of the AD-HIES left main coronary artery at  
  the plaque site  
 
Section of the left main coronary artery showing characteristic outward plaque 
accumulation labeled with an anti-αvβ3 probe. (A) A section of the plaque showing 
shoulder area is characterized by anti-αvβ3 positive cells in the adventitia layer below 
the plaque, and at the surface of the lumen. (B) The same section showing part of the 
adventitia below the plaque with few αvβ3 positive cells. 10X magnification. 
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proteoglycans/collagen deposit. AD-HIES coronary samples were characterized by a 
strong smooth muscle cell staining in the media, associated with sparse and weak 
neointimal labeling (Fig. 49). The AD-HIES coronary artery at the plaque site showed 
very few neointimal SMCs labeling, suggesting an absence of SMCs migration and cap 
formation (Fig. 50A, B, C). In atherosclerosis, we typically see a migration of the SMCs 
 
 
Figure 49 SMCs labeling of coronary arteries in the AD-HIES patient  
 
Section of the right (A), left anterior descending (B), left main at the bifurcation point 
(C), and left circumflex (D) coronary artery labeled with an antibody against α-actin. 
We can clearly see the smooth muscle cells labeling in the media layer, as well as a 
few sparse smooth muscle cells labeled in the neointima. Arrow in panel (A) 
represents smooth muscle cells surrounding a blood vessel. Magnification 10X. 
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into the near lumen area during the formation of the fibrous cap. Also, the SMC layer was 
almost absent on the arterial wall below the plaque, which point out toward medial 
necrosis (Fig. 50A, B, D). 
 
 
 
 
Figure 50 SMCs labeling of the atherosclerotic plaque in the AD-HIES 
patient  
 
Section of the left main coronary artery at the bifurcation point labeled with an 
antibody against α-actin. The plaque area seemed to label very weakly for SMCs (A). 
Few α-actin+ cells were seen in the neointima layer (B, C), as well as in the adventitia 
below the plaque (B, D). Usually, important necrotic core are characterized by the 
formation of a fibrous cap. Also, adventitial necrosis is a feature of aneurysms. (A) 
2,5X Magnification. (B) 5X Magnification. (C, D) 10X Magnification. Boxed area in 
(A) represents magnified area in (B). Boxed areas in (B) represents magnified areas in 
(C) and (D). SMCs: smooth muscle cells. 
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5.3.4 MMP-9 Labeling 
Matrix metalloproteinase 9 (MMP-9) is involved in matrix remodeling and cell 
migration[153, 154]. Immunohistofluorescence study of the expression of MMP-9 showed 
important findings in the AD-HIES case. While the expression of MMP-9 was usually 
widely distributed into the adventitia, media, and neointima in atherosclerosis, it was 
mostly confined to the adventitia region for the AD-HIES samples (Fig. 51). Despite 
 
 
Figure 51 MMP-9 labeling of the AD-HIES coronary arteries  
 
Section of the left anterior descending coronary artery (A, B) and right coronary artery 
(C, D) showing MMP-9 expression. In the AD-HIES patient, plaque free coronary 
arteries expressed MMP-9 at a low density, and mostly confined to the adventitia 
layer. Magnification 10X. 
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some variability among the samples, MMP-9 signal was stronger where there was a more 
important inflammatory cell infiltration in the adventitia. Generally, it also appeared that 
the MMP-9 expression was more important when there was a neointimal bump or 
protuberance. The left main artery at the bifurcation point (LMbp), presenting the 
symptom of an advanced atherosclerotic plaque, showed an important MMP-9 
overexpression inside the proximal neointimal region, in the near lumen of the plaque 
area (Fig. 52A). In the segment opposite to the plaque, MMP-9 expression was not 
confined to the adventitial area, but was instead widely distributed along the adventitia, 
media and neointima (Fig. 52B), which could be related to a remodeling process inside 
the coronary segment with plaque. Despite some variability among the different regions 
of the arteries, and apart from the plaque site, MMP-9 density was clearly lower in the 
AD-HIES coronary walls than in atherosclerosis. MMP-9 expression in the coronary 
walls was co-localized with macrophages expression. 
 
 
Figure 52 MMP-9 labeling of the AD-HIES left main coronary artery at the 
plaque site 
 
Section of the left main coronary artery at the bifurcation point (A, B) showing MMP-
9 expression. In the AD-HIES plaque, MMP-9 was strongly overexpressed on the near 
lumen neointima layer (A), a characteristic often seen in aneurysm. Interestingly, the 
plaque free segment on the same cross-section, showed MMP-9 expression in the 
three vessel wall layers (adventitia, media, and neointima) (B). Magnification 10X. 
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5.3.5 Macrophages Labeling (CD68) 
Monocytes and macrophages play a central role in immunity and the process of 
atherosclerosis[62, 155]. Immunohistochemical study of the expression of CD-68, a cell 
surface receptor present on monocytes/macrophages, confirmed de presence of 
macrophages almost exclusively into the adventitia of de AD-HIES patient coronary 
 
 
Figure 53 Macrophages localization in the AD-HIES coronary arteries 
 
Macrophages labeling with an anti-CD68 antibody in the left anterior descending (A), 
right (B), left circumflex (C), and left main at the bifurcation point (D) coronary 
arteries. We can clearly see that CD68+ cells are almost exclusively express in the 
adventitia layer of the coronary wall. Arrow in panel (A) shows a group of CD68+ 
cells that seems to be on the neointimal section of the coronary artery. Panel (A) was 
taken at 10X magnification to be able to visualize the entire wall. Panel (B, C), and 
(D) has been taken at 20X magnification. 
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arteries presenting no sign of plaque accumulation within the wall (Fig. 53).  
As opposed to the coronary arteries without plaque, the left main artery with the plaque 
showed an important and heavy infiltration of macrophages into the neointimal area (Fig. 
54). The macrophages count at high power field (40X) was around 40 CD68+ cells (Fig. 
54A and Table 3), which is considered as histological marker of plaque vulnerability 
(≥25 macrophages per high power field)[3]. Another interesting fact was the localization 
of the macrophages along the whole length of the plaque in the cross-sectional section 
(Fig. 54B). Effectively the CD68+ cells did not seem to be concentrated on the shoulder 
region of the plaque, but instead they were widely distributed along the near lumen area 
in front of the plaque. The adventitial layer showed only few CD68+ cells. CD-68 
expression generally co-localized with MMP-9 expression. 
 
 
Figure 54 Macrophages labeling of the AD-HIES left main coronary artery 
at the plaque site 
 
In the coronary artery segment of the left main coronary artery showing plaque 
accumulation, there was a heavy infiltration of macrophages in the neointimal area 
near the lumen. Panel (A) is showing a 40X magnification of the plaque, with a 
macrophages count of ~40 CD68+ cells. Panel (B) is showing a 5X magnification of 
the same region. Macrophages are mostly localized into the near lumen neointima, 
and diffusely distributed over the whole length of the plaque cross-sectional area. 
Boxed area in (B) represents the magnified area in (A). 
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5.3.6 T-Cell Labeling (CD40) 
CD-40 is a receptor mainly expressed on the surface of antigen presenting cells (APCs) 
responsible for the induction of a variety of downstream effects, as the induction of anti-
microbial substance from macrophages, as well as vascular remodeling and neointimal 
formation[156, 157]. The presence of CD-40 was assessed by immunohistofluorescence. All 
AD-HIES samples showed a similar pattern of CD-40 expression, mostly in the 
adventitia and neointima of the vessel wall, but the signal found was very weak  (Fig. 
55). Effectively, there were very few CD-40+ cells in the AD-HIES cases. When 
 
 
Figure 55 CD40 labeling of the AD-HIES coronary arteries  
 
Left anterior descending (A), left circumflex (B), right (C), and left main at the 
bifurcation point (D) coronary arteries labeled with an anti-CD40 antibody. Although 
there were some small differences in the density of CD-40+ cells, there was very few 
CD40 labeling in the coronary arteries of the AD-HIES case. 20X Magnification. 
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atherosclerotic lesions are associated with adventitial inflammation and stenosis, there is 
usually a high level of CD-40 expression. Similar to the other molecular markers, the 
LMbp artery presented a different pattern of expression at the plaque site, showing a 
greater density of CD-40 expression in the neointima (Fig. 56).  
 
5.3.7 Elastic fibers - Verhoeff’s Van Gieson (EVG) Staining 
The internal elastic lamina and external elastic lamina are two different layers of elastic 
fibers delimitating, respectively, the media from the intima, and the adventitia from the 
media, in the coronary arteries. Those two layers of elastic fibers are very important for 
the arteries’ biophysical properties and they have been involved in positive remodeling[12, 
158], ectasia[158], and aneurysm[159]. We used elastic Verhoeff’s Van Gieson (EVG) 
 
 
Figure 56 CD40 labeling of the AD-HIES left main coronary artery at the 
bifurcation point in the reference segment and in the segment with 
plaque 
 
Left main coronary artery labeled with an anti CD-40 antibody showed more 
important density of CD40+ cells in the segment presenting the plaque (B) than in the 
segment before the plaque (A). Although there was a difference of density between 
the segment without plaque (A) and the segment with plaque (B), the density of 
labeling in AD-HIES was weaker than CAD samples presenting stenosis. 20X 
Magnification.  
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staining to evaluate the integrity of the internal and external elastic lamina. In the AD-
HIES coronary arteries, there was a general thinning of the external elastic lamina, which 
was very difficult to localize (Fig. 57). The internal elastic lamina also appeared thinned, 
with some discontinuities in the elastic network. The left anterior descending coronary 
artery’s internal elastic lamina seemed to have completely disappeared in some region of 
 
 
Figure 57 Elastic tissue fibers staining of the AD-HIES coronary arteries with 
elastic Van Gieson (EVG) stain 
 
Right (A), left circumflex (B), left anterior descending (C), and left main at the 
bifurcation point (D) coronary arteries stained with an elastic Van Gieson stain. The 
right (A), left circumflex (B), and left main (D) coronary arteries seemed to have few 
elastic fiber breaks into the internal elastic lamina. Interestingly, the left anterior 
descending coronary artery (C) internal elastic lamina seemed to have completely 
disappeared.  In all samples, the external elastic lamina separating the media from the 
adventitia was very difficult to differentiate. Black: elastic fibers. 10X Magnification. 
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the cross-sectional section, which could be link to the fact that this artery presented the 
highest degree of dilatation. In the cross-sections with the plaque, there was a high 
number of internal elastic lamina discontinuities in the segment below the plaque (Fig. 
58B, C), and a complete absence of this layer on the wall opposite to the plaque (Fig. 
58D). This could suggest a vessel’s remodeling process in the wall opposite the plaque. 
 
 
 
Figure 58 Elastic tissue fibers staining of the AD-HIES left main coronary 
artery at the reference site and plaque site with elastic Van Gieson 
(EVG) stain 
 
Elastic fibers staining in the reference segment in the left main coronary artery at the 
bifurcation point (A) and in the same coronary artery at the plaque site (B, C, D). On 
the wall below the plaque, there were numerous discontinuities in the internal elastic 
lamina (B, C). The segment opposite to the plaque showed a complete absence of the 
internal elastic lamina (D). Black: elastic fibers. 10X Magnification.  
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5.3.8 Masson’s Trichrome Staining 
SMCs and the collagen content deposed by them is also an important feature for the 
biomechanics properties of the coronary arteries[160]. Masson staining of the AD-HIES 
coronary arteries showed that intimal thickening was principally due to SMCs 
proliferation and collagen deposition (Fig. 59). The same phenomenon has been 
 
 
Figure 59 Masson Trichrome staining of the AD-HIES coronary arteries  
 
Right (A), left circumflex (B), left anterior descending (C), and left main at the 
bifurcation point (D) coronary arteries stained with a Masson Trichrome stain. The 
right (A), left circumflex (B), and left main (D) coronary artery presented similar 
density of collagen. The left anterior descending coronary artery (C) collagen content 
appeared denser. In the near intima of the LMbp (D), there was a region with loser 
collagen content, which corresponds to the region with the plaque in the adjacent 
coronary artery segment. Blue: collagen. Red: muscle, red blood cells. Pink: 
cytoplasm. Black: Nuclei. 10X Magnification. 
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described in adaptive intimal thickening, phenomenon associated with aging. We can 
clearly identify the coronary arteries’ media layer staining red for SMCs, and the high 
collagen content in blue in the neointima, media, and adventitia layers. Notably, the left 
anterior descending presented a much more denser pattern of collagen fibers, as seen in 
relatively normal artery (Fig. 59C). As opposed to that, the left main coronary artery at 
the bifurcation point demonstrated looser collagen content in all the layers, plus a 
beginning of collagen loss into the near lumen neointima (Fig. 59D), which could be 
related to the beginning of the plaque formation seen in the adjacent segment of the same 
artery (Fig. 60). In the segment of the left main coronary artery with plaque (Fig. 60), 
there was an important loss of collagen into the neointimal region (Fig. 60A, B). This is 
typical of a late core, with numerous cholesterol clefts, cellular debris and an absence of 
ECM, particularly collagen, as opposed as an early core, which shows collagen 
interspersed with intact foamy macrophages. The SMC layer of the adventitia below the 
plaque seemed to have almost completely disappeared, and the collagen staining 
appeared weaker (Fig. 60C). The segment opposite the plaque also presented a looser 
pattern of collagen fibers in all layers, with a thinned media layer and a more 
disorganized collagen content (Fig. 60D). The thin fibrous cap (TFC) almost disappeared 
at the shoulder region, with a thickness of less than 45µm (Fig. 60B). There was an 
absence or very few SMCs labeling in the neointimal region above the plaque (Fig. 60B). 
This is uncharacteristic of a plaque with a large necrotic core, which should present SMC 
labeling in the near lumen area, usually forming the fibrous cap. 
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Figure 60 Masson Trichrome staining of the AD-HIES left main coronary 
artery at the plaque site  
 
Masson Trichrome staining in the left main coronary artery at the plaque site. In the 
necrotic core, there was absence of staining, which is characteristic of a late core (A, 
B, C), and the collagen content in the fibrous cap was extremely thinned on the 
shoulder region (B). Interestingly, the segment opposite to the plaque showed 
collagen staining, but with fibers demonstrating a looser pattern (D). The wall below 
the plaque showed thinning of the medial layer, which almost entirely disappeared, 
and an absence of the adventitial layer (C). Blue: collagen. Red: muscle, red blood 
cells. Pink: cytoplasm. Black: Nuclei. (A) 5X Magnification. (B, C, D) 10X 
Magnification.  
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5.3.9 Movat Staining 
For evaluating the biomechanical properties of the coronary wall, SMCs, collagen, elastic 
fiber content, and ground substance are important[160]. Movat staining is a very useful 
type of stain, as it allows the differentiation between all those different components. The 
elastic fiber content of the external elastic lamina in the AD-HIES coronary walls without 
plaque appeared again very low and very difficult to see (Fig. 61). In the other hand, the 
internal elastic lamina looked relatively easy to visualize, although it contained many 
discontinuities along the length of the cross-sections in almost all of the samples. Those 
results are consistent with the EVG staining, which showed the same pattern of 
discontinuities in the internal elastic lamina and very weak staining in the external elastic 
lamina of the AD-HIES samples without plaque. In the segment of the AD-HIES with 
plaque, were we saw a weak staining of the internal elastic lamina and no external elastic 
lamina with EVG, there seemed to be a total absence of both internal and external elastic 
lamina (Fig. 62). This could be due to less specific staining of the Movat stain for elastic 
fibers, or the fact that the cross-section used in the Movat staining, even if adjacent to the 
one used in EVG staining, has loss all of the elastic fibers. Interestingly, the collagen 
staining, although similar to the one with Masson, showed a slightly different pattern of 
staining. Effectively, unlike Masson stain, Movat stain allows to differentiate between 
collagen content (yellow) and ground substance and mucin (blue). Accordingly, the 
segments without plaque in the AD-HIES coronary walls stained with Movat showed 
different pattern of collagen staining than the Masson’s stain previously showed. First, in 
the left circumflex and left anterior descending (Fig. 61B, C) coronary arteries, there was 
a denser collagen content in both adventitia and neointima.   In  the other hand,   the right 
Page 147 of 246 
 
 
 
 
Figure 61 Movat Pentachrome staining of the AD-HIES coronary arteries  
 
Right (A), left circumflex (B), left anterior descending (C), and left main at the 
bifurcation point (D) coronary arteries stained with a Movat Pentachrome stain. The 
left circumflex (B) and left anterior descending (C) coronary arteries demonstrated 
similar density of collagen into the neointima and adventitia, which appeared denser 
than the other coronary arteries. The right (A) and left main (D) coronary artery’s 
collagen content was slightly less dense in the neointima, with more ground substance 
and mucin content, and much more looser in the adventitia. In both right (A) and 
LMbp (D) coronary arteries, there was a region with loser collagen content on the 
near lumen area. For the LMbp, it corresponded to the region with plaque in the 
adjacent segment of the same artery. Those results were correlated with the previous 
results with Masson staining and EVG staining, but as opposed to the Masson stain, 
the collagen content and ground substance or mucin can be differentiated. Blue: 
ground substance, mucin. Yellow: collagen, reticular fibers. Red: muscle, red blood 
cells. Bright red: fibrin. Pink: cytoplasm. Black: Nuclei, elastic fibers. 10X 
Magnification. 
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(Fig. 61A) and left main at the bifurcation point (Fig. 61D) coronary arteries presented a 
looser pattern of collagen fiber into the adventitia, with a less important collagen content 
in the neointima, visualized by the blue/greenish color of the neointimal layer. In fact, the 
very near lumen area of both coronary arteries seemed to present a total absence of 
collagen in some areas, with presence of only ground substance and mucin. For the left 
main coronary artery, it corresponded to the same area on the adjacent segment of the 
same coronary artery with plaque. It could be interesting to see if by cutting more cross-
sections of the right coronary artery, we will also find a beginning of plaque formation. It 
also has to be mention that when dissected, the pathologist identified this segment as 
possibly presenting an aneurysm. In the AD-HIES left main coronary with plaque (Fig. 
62), there was the same loss of staining in the necrotic core (Fig.  62A, B), which is, as 
mentioned earlier, characteristic of late core. There was also absence of SMC labeling in 
the near lumen neointima, in spite of the large size of the necrotic core, and an important 
thinning of the collagen in the neointimal area, with loss of collagen content in the 
shoulder region of the plaque. Instead, the collagen content was almost entirely replaced 
by ground substance and mucin (Fig. 62A, B). On the segment below the plaque (Fig. 
62C), there was a thinning of the medial layer and an absence of the adventitial layer. 
The segment opposite to the plaque also presented a mixture of ground substance, 
mucin and collagen in the neointima, associated with a much looser density of collagen 
in both neointima and adventitia. 
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Figure 62 Movat Pentachrome staining of the AD-HIES left main coronary 
artery at the plaque site  
 
Movat pentachrome staining in the left main coronary artery at the plaque site (A, B, 
C, D). In the necrotic core, there was absence of staining, which is characteristic of a 
late core (A, B), and the collagen content in the fibrous cap was extremely thinned in 
some parts of the shoulder regions, and completely replaced by ground substance and 
mucin in other parts (B). The segment opposite to the plaque showed collagen 
staining, but the fibers seemed to be looser in both neointima and adventitia (D). 
There was also presence of ground substance and mucin in the neointima of the wall 
opposite the plaque. The wall below the plaque showed thinning of the medial layer, 
which almost entirely disappeared, and absence of the adventitial layer (C). Blue: 
ground substance, mucin. Yellow: collagen, reticular fibers. Red: muscle, red blood 
cells. Bright red: fibrin. Pink: cytoplasm. Black: Nuclei, elastic fibers. (A) 5X 
Magnification. (B, C, D) 10X Magnification.  
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5.3.10 Results Summary 
The comparison between CAD plaques (Chapter 3) and AD-HIES plaques can lead to 
better understanding of the plaque formation process (Table 4). Generally, when 
compared to CAD cross-sections with plaques, AD-HIES cross-sections with plaque 
possessed many common characteristics shared with vulnerable plaques. First, in the AD-
HIES sections with plaque, there was no important stenosis, with a lumen diameter not 
significantly different from the normal adjacent vessel, but a total vessel diameter much 
larger (positive remodeling). Second, αvβ3 expression was present, but at a lesser degree 
than in plaques with important stenosis. Third, α-actin labeling showed very few SMCs 
in the neointima, consistent with the absence of fibrous cap formation. Fourth, MMP-9 
was overexpressed in the near lumen area. Fifth, there was an important infiltration of 
macrophages in the neointima. Importantly, instead of being concentrated into the 
shoulder areas as usually seen in atherosclerotic plaques, macrophages were localized 
along the entire near lumen length above the plaque. Sixth, there were very few CD40+ 
cells, consistent with the absence of stenosis. Seventh, the collagen content was very 
sparse in the necrotic core area, and near lumen area. Finally, the IEL and EEL in the 
plaque area had almost completely disappeared. It also has to be mentioned that AD-
HIES cross-sections without plaque possessed two major differences with CAD cross-
sections without plaque. First, they showed an unusual high number of macrophages in 
the adventitial layer. Second, the pattern of their elastic fibers (IEL and EEL) contained 
many discontinuities, sometime associated with complete absence of elastic fiber in parts 
of the cross-sections.  
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TABLE 4 Left Main Coronary Artery Measurements at the plaque site 
Morphological 
Characteristics 
and 
Immunohistological 
Labeling 
CAD AD-HIES 
Cross 
section 
w/o 
plaque 
Cross 
section with 
plaque 
(vulnerable) 
Cross 
section 
with 
plaque 
(stable) 
Cross section 
w/o plaque 
Cross 
section with 
plaque 
Lumen diameter = = or (-/+)< - = = 
Vessel diameter = + + or - = +++ 
Stenosis - -/+ ++ - - 
αvβ3 - + ++ - + 
α-actin -/+ -/+ ++ -/+ -/+ 
MMP-9 + +++ ++ + +++  Near lumen 
CD-68 -/+ ++ -/+ ++ Adventitia 
+++ 
Near Lumen 
Diffused 
CD-40 - -/+ +++ - -/+ 
Collagen ++ + ++ ++ -/+ 
Elastic Fiber ++ -/+ + -/+ - 
 
 
 
 
Table 4 Morphological and Immunohistological comparison between CAD 
coronary artery cross-sections and AD-HIES cross-section 
Morphological and immunohistological markers of CAD cross-sections without 
plaque, with vulnerable plaque, and with stable plaque, compared to AD-HIES cross-
sections without plaque, and with plaque. Note that the column qualifying CAD with 
vulnerable plaque has been deducted from literature, since no vulnerable plaque where 
obtained for staining. All the others column represented a summary of the findings in 
chapter 3 and chapter 4. 
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5.4 DISCUSSION 
 
The present immunohistological study revealed an atherosclerotic plaque at the 
bifurcation point of the left main (LMbp) coronary artery, a rare feature in AD-HIES 
patient. This atherosclerotic plaque is consistent with compensatory positive remodeling 
and histologically presented advanced atherosclerosis and vulnerability. We reported four 
major molecular differences inside the coronary wall tissue of the segments without 
plaque, versus the coronary wall with plaque (Fig. 63). First, the localization of the 
macrophages, which were found mostly confined to the adventitia in the AD-HIES wall 
without plaque, with the exception of the plaque area presenting important intimal 
macrophage infiltration on the near lumen area. Secondly, the presence of matrix 
metalloproteinase 9 (MMP-9) mainly located in the adventitia, with again the exception 
of the plaque, which showed an important overexpression of MMP-9 in the near lumen 
area. Thirdly, the paucity or low level of CD40 expression in all samples, with a greater 
density of CD40+ cells in the segment with plaque, although far less important than seen 
in CAD samples with stenosis. Finally, the paucity of αvb3 in the AD-HIES samples 
without plaque, associated with a low level of expression in the segment with the plaque, 
which correlated with the expression of vasa vasorum (vv) in plaque with low-grade 
stenosis and positive remodeling[126, 127]. We also observed a crucial morphological 
difference in the AD-HIES plaque: the presence of compensatory enlargement and 
positive remodeling without significant lumen narrowing, despite the 60% cross-sectional 
stenosis, and a remodeling index of 1.63, as previously described by Glagov[17]. 
Effectively, according to Glagov, after 40% cross-sectional stenosis, the balance between 
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Figure 63 Schematic representation of the AD-HIES plaque at the bifurcation 
site of the left main coronary artery 
 
The AD-HIES plaque possessed many common characteristics shared with vulnerable 
plaques. First the vessel was in positive remodeling phase. The necrotic core was very 
important and contained cholesterol clefts, microcalcifications and small intraplaque 
hemorrhages. The fibrous cap thickness was evaluated under 45µm, which is a 
criterion for vulnerability. There was a low density of αvβ3 expression, which is 
usually seen in minimally stenotic plaques. The plaque also featured some 
characteristics of an atherosclerotic aneurysm. Indeed, there was a heavy macrophages 
infiltration on the whole length of the near lumen with associated MMP-9 
overexpression. Moreover, there were very few SMCs into the neointima. The media 
and adventitia below the plaque were almost absent, and there was a lost of collagen 
into the necrotic core. Finally, there was a beginning of adventitial thickening in the 
wall opposite the plaque, which could be indicating a remodeling process in the plaque 
free segment as opposed as on the plaque segment. 
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positive remodeling and lumen preservation should quickly switch toward negative 
remodeling and lumen stenosis, as the plaque enlarges. The healing/stenosis process 
seemed to be prevented in the AD-HIES plaque. Our findings suggest that the AD-HIES 
patient presented undetectable non-stenotic low-grade atherosclerosis that caused 
weakness of the vessel wall, impaired healing, dilatation and ultimately aneurysm. We 
hypothesized that AD-HIES disease, with STAT3 mutation, is characterized by a defect 
in Interleukin-6 (IL-6) signaling via STAT3. Therefore, when there is lipid infiltration 
and beginning of atherosclerosis, an improper healing of the developing plaque (default 
in negative remodeling and stenosis), and an exacerbated positive remodeling will lead to 
dilatation of the vessel wall, and ultimately formation of an aneurysm.  
 
Effectively, although the atherosclerotic plaque could not be formally classified as an 
aneurysm, because the dilatation of the vessel at the plaque site was only 1.3 times the 
diameter of the adjacent normal segment, it could be postulated that the plaque will 
further develop into an aneurysm. This hypothesis was supported by the vessel wall 
composition, which presented many features of an atherosclerotic aneurysm, including 
compensatory positive remodeling, medial thinning and destruction, speckled 
microcalcifications, MMP-9 overexpression in the near lumen area, lipid and foam cell 
deposition, cholesterol clefts, inflammatory reaction in the adventitia, intraplaque 
hemorrhages, mild neovascularization, and absence of neointimal formation (smooth 
muscle cells and collagen forming the cap). It was also supported by the absence of 
luminal stenosis, despite the large necrotic core size (66%), and the important 
compensatory enlargement of the vessel. As mentioned before, Glagov clearly 
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demonstrated that after a cross-sectional percentage of stenosis of 40%, the lumen 
markedly decrease in close relation to the percentage of stenosis[17]. We did not observe 
this phenomenon in the AD-HIES plaque. Indeed, after more than 60% cross-sectional 
stenosis, the lumen was still almost entirely preserved, which, in conjunction with 
previous imaging studies, point out toward the formation of aneurysm[101] (Fig. 64). 
One important feature of aneurysms is the presence of medial necrosis[68]. When there is 
 
 
Figure 64 Theory of aneurysm formation in AD-HIES 
 
In Glagov scenario (upper panel), after 40% cross-sectional stenosis, the 
phenomenon of compensatory enlargement of the vessel wall is overcome and lumen 
narrows in relation to the percentage of stenosis. In the AD-HIES case (lower panel), 
this stenosis/healing process is inhibited, which ultimately lead to dilatation and 
aneurysm.  
AD-HIES 
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an injury or diminution of blood flow in a normal vessel, apoptotic VSMCs were shown 
to promote proliferation, migration, and matrix synthesis in adjacent VSMCs[67]. This 
process promotes vessel remodeling, medial repair, and neointima formation (healing) via 
a STAT3 dependent pathway, as demonstrated by previous study[161, 162]. We can 
postulate that mutation in STAT3 can lead to impaired vessel repair, formation of edema 
and eventually aneurysm. Effectively, if there is endothelial damages without appropriate 
proliferation and migration of the SMCs, no neointimal formation and matrix deposit, 
associated with apoptosis of the media, the vessel wall will gradually weaken, eventually 
leading to aneurysm formation. Moreover, VSMCs death has been reported to play a 
central role in plaque rupture, with an associated augmentation in symptomatic plaques 
compared to stable plaques[66]. In the AD-HIES plaque, there was an important medial 
atrophy below the plaque, at the point of no longer being able to differentiate between 
neointima, media and adventitia. There was also absence of neointimal formation, despite 
the important growing intimal mass represented by the necrotic core. Unlike 
atherosclerotic samples, there were few SMCs at the lumen surface, which would have 
been expected in a plaque with an important necrotic core size. In accordance to this 
theory, a previous study on Watanabe rabbit model susceptible to myocardial infarction 
(MIWHHL) have linked the invasion of atheromatous plaques into tunica media to 
coronary outward remodeling [96]. They also showed that in those areas, collagen fibers 
and the internal elastic lamina had partly disappeared and apoptotic smooth muscle cells 
were observed. 
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MMPs-9 are also key players in the process of atherosclerosis and aneurysm formation, 
because of their importance in matrix remodeling and their effect on SMCs migration[154, 
163]. Studies showed that MMP-9 expression was associated with increased proteolysis of 
the matrix in the arterial wall and can be a susceptibility factor for the development of 
aneurysms in patients with coronary atherosclerosis. Indeed, by degrading collagen and 
elastin, MMP-9 allows vessels wall dilation and outward expansion, as well as 
destabilization and loss of vessel integrity. Also, it had been shown that the loss of 
collagen in the plaque’s cap reduce tensile strength, while the absence of collagen from 
the lipid core promotes transfer of hydrodynamic stress to the cap during the cardiac 
cycle. Those two important factors will further promote plaque rupture[164]. MMP-9 
expression has been show to be dependent of ERK signaling pathway and NFκB, which 
can explain the overexpression in AD-HIES disease, despite the mutation in STAT3[165, 
166]. In the vessel wall of the AD-HIES plaque, MMP-9 are overexpressed inside the 
neointimal region, close to the lumen, which is associated with matrix degradation and 
thinning of the fibrous cap, vulnerable plaques and aneurysm formation[167]. 
 
Although Il-6 is very well known as a pro-inflammatory cytokine, a recent study linked 
the expression of IL-6 to the attenuation of the proinflammatory response[168]. They 
showed that expression of IL-6 induced by macrophage lipid loading induced ABCA1 
expression, and that ABCA1 promote cholesterol efflux from macrophages to apoA1. 
This cellular recycling of free cholesterol reduces foam cell formation and apoptotic body 
responsible of intraplaque inflammation. They also show that this atheroprotective effect 
was abolished by inhibition of the Jak-2/STAT3 signaling pathway. The corresponding 
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STAT3 mutation in Job’s patient could be responsible for the accumulation of cytotoxic-
free cholesterol and impaired cholesterol efflux. Notably, in the AD-HIES plaque, there 
was a heavy infiltration of macrophages in the neointima and necrotic core shoulder (40 
CD68 + cells by high power field) as seen in vulnerable plaques. Despite the fact that 
AD-HIES patient seems to develop less severe CAD, the plaque seen on our case 
possesses an unusually large lipid core (66% of the neointimal area) without associated 
stenosis, which would be in accord with this theory. 
 
Beside macrophages, T cells and B cells also play a role in atherosclerosis and aneurysm 
formation[169]. CD40 expression on lymphocyte T, B cells, macrophages and SMCs, had 
been involved in restenosis and VEGF induce angiogenesis[170]. Since there is a default in 
lymphocytes T maturation in AD-HIES patients, that could explain both the lower 
incidence of plaque with stenosis in those patients, and the lower expression of αvβ3 
despite the large necrotic core area and the presence of inflammation. Effectively, when 
there is arterial injury, CD40 is involved in neointima thickening. Naïve T cell 
differentiation into Th17 (lymphocyte T maturation) depends principally upon the 
cytokines profile present during the process, and IL-6 via STAT3 is essential for Th17 
differentiation[171]. Since STAT3 mutation is associated with Th17 deficiency, we can 
postulate that this could be the reason that AD-HIES patients presented a more vulnerable 
type of plaque, and developped less stenotic atherosclerosis than the regular population. 
 
Neovascularization is another important topic in atherosclerosis and aneurysm formation. 
Whereas ischemia had been associated with both arteriogenesis and angiogenesis 
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processes, hypoxia and plaque inflammation had been linked principally to 
angiogenesis[172]. As opposed to arteriogenesis that presents fully-grown capillaries to 
bring oxygen to stenotic plaques, immature vessels characterize angiogenesis. Those 
vessels can come from the adventitia and/or endothelial cells that have been activated by 
inflammation, and there is often absence of SMCs[11]. Activated endothelial cells 
expressed VEGF, which in turn can potently induce vascular permeability and can cause 
edema in ischemic tissues[173]. Ox-LDLs are also involved in the upregulation of VEGF 
expression in both epithelial cells and macrophages[174]. Leaky endothelium is associated 
with lipids infiltration, intraplaque hemorrhages and plaque vulnerability[11, 173]. 
Interestingly, even though there was a paucity of αvb3 expression in the AD-HIES case, 
there was a low level of αvb3+ cells inside the adventitia and near lumen neointima of 
the plaque. This could be link to the presence of small hemorrhages seen into the plaque, 
as well as the important size of the lipid core. We can also postulate that because of the 
presence of ox-LDLs, activated endothelial cells and macrophages will express VEGF, 
which in turn will cause vascular permeability, intraplaque hemorrhage and edema. 
Without appropriate repair response from the vessel wall, this could lead to aneurysm 
formation. Interestingly, αvb3 and neovascularization has been involved in the 
progression of advanced atherosclerosis[175]. In the AD-HIES coronary artery with 
plaque, although there is an important necrotic core size with macrophage infiltration in 
the neointima, there were very little CD40+ cells (lymphocytes T), which can support this 
theory. 
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Adventitial thickening had also been related to remodeling[15]. There is evidence 
supporting the fact that greater adventitial thickening on the wall below the plaque favor 
inward growth, negative remodeling, stenosis and plaque healing. Moreover, negative 
remodeling is characterized by medial and adventitial thinning on the wall opposite the 
plaque. In the other hand, vasa vasorum on the wall opposite to plaque formation 
associated with adventitial thinning on the wall below the plaque favor outward growth, 
positive remodeling, plaque destabilization and aneurysm. The plaque in the AD-HIES 
coronary artery presented a thickening of the adventitia on the wall opposite to the 
plaque, associated with a thinned adventitia and media layers on the wall below the 
plaque. Interestingly, αvb3 expression seemed to be localized on the adventitial layer 
below the shoulder region of the plaque and on the adventitia below the plaque. This was 
a surprising result, because we would have expected the thickness of the adventitia to 
correlate with the αvb3 expression. This could although be explained by the fact that 
αvb3 expression is AD-HIES is related to inflammation. Indeed, αvb3 expression was 
concentrated on the epithelial surface and adventitial area, the same area where we found 
most of the macrophages. Moreover, absence of luminal stenosis was reflected by low 
level of αvb3 expression, as usually seen in plaques with signs of vulnerability (type IV). 
Also, it comforted the fact that AD-HIES abnormalities in IL-6/Gp130/Jak2-mediated 
STAT3 transactivation on target genes causes absence of lymphocyte T maturation, and 
that cross-talk between lymphocytes T and macrophages is important for plaque healing 
and stenosis. 
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In atherosclerosis and aneurysm formation, the SMC content, as well as the density and 
pattern of fibers and substances present inside the coronary walls (elastic fibers, collagen, 
ground substance, mucin), will greatly influence the biomechanical characteristics of the 
vessel wall[160]. Effectively, it had been shown that loss of elastin and collagen is 
associated with outward remodeling and can favor plaque vulnerability and 
aneurysms[164]. As seen with the special staining (EVG, Masson, and Movat) in the AD-
HIES case, the very thinned external elastic lamina and discontinuous nature or total 
absence in certain areas of the internal elastic lamina, together with the large cross-
sectional vessel areas despite the zero pressure state, could all support the clinical 
imaging findings of coronary wall dilation, ectasia and aneurysms. The fact that the 
segment of the coronary with plaque presented an important thinning of the medial layer, 
a lack of adventitial thickening, a late core with few SMCs in the near lumen area, and an 
important degradation of the collagen at the shoulder and neointimal areas also point out 
toward the formation of an aneurysm. Despite the fact that atherosclerotic plaque 
accumulation as a cause of aneurysm in AD-HIES might seem contradictory to the fact 
that they presented a paucity of severe coronary disease (seen by stenosis in imaging), we 
can postulate that the lack of compliance in their arteries favor the development of 
aneurysms. For example, diabetes patients had been showing a higher susceptibility to 
atherosclerosis than the regular population[176]. Some studies have shown that arteries 
from diabetes population are much less compliant. We can extrapolate this finding to 
AD-HIES disease and postulate that the fact that they had less compliant coronary 
arteries (seen by a diminution of elasticity) makes them more susceptible to develop 
aneurysm in the context of atherosclerosis presence. Consequently, in the presence of a 
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right storm scenario, atherosclerotic plaque without appropriate healing will result in 
ectasia and aneurysm formation. 
 
The main limitation of this study is that it was limited to a report case. Although we 
based our conclusion on other AD-HIES patients that had been image by MRI and CT, 
the pathological examination has been done on only one person. Moreover, the cross-
sectional nature of the study should be taken in consideration when evaluating positive 
remodeling. Therefore, outward and inward remodeling should be considered as relative 
value, rather than absolute value. Nevertheless, difference in vessel areas between a site 
of interest and an adjacent reference site as been an arbitrary and widely used measure for 
remodeling in cross-sectional studies[177]. Also, we are well aware that atherosclerosis 
and aneurysm are multifactorial processes involving many key determinants and multiple 
regulatory pathways that can tips the balance in favor of one or another. Accordingly, we 
are limited by the number of immunological markers used. For example, MMP-9 
antibody used in this study can detect both activated and non-activated forms, so the 
presence of overexpression doesn’t necessarily means that there is more MMP-9 activity. 
Also, many inhibitor of MMPs, mainly tissue inhibitor of matrix metalloproteinase 
(TIMPs), are present in the coronary wall and can influence the degree of activity of 
MMPs, so results should be interpreted carefully. The same can be applied for α-actin 
(SMCs), CD-40 (APCs), αvβ3 (angiogenesis), CD-68 (macrophages). Those molecules 
and processes have been reported to have both beneficial and detrimental effects on 
atherosclerotic and aneurysm formation, so again, more studies with more cases and other 
markers could help clarified the role of each one. Also, it is important to take into account 
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the risk factors and presence of other clinical manifestation in the evaluation of the 
patient. It is conceivable that another patient will present a different etiology, depending 
on the presence or absence of other pathological conditions. 
In this chapter, we reported the case of an AD-HIES autopsy revealing an uncommon 
atherosclerotic plaque on the LM coronary artery at the bifurcation point. Despite the 
cross-sectional nature of the study and the fact that we are limited to a report case, we 
attempted to correlate the morphological and immunohistological features of the plaque 
with the development of aneurysm, as previously reported before in imaging study of 
AD-HIES patients[100, 101]. We postulated that despite the paucity of severe coronary 
disease in AD-HIES disease, advanced atherosclerosis process without proper healing 
mechanism (negative remodeling and stenosis), ultimately leads to aneurysm formation. 
Further imaging and histoimmunological studies will allow us to confirm this hypothesis. 
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GENERAL DISCUSSION 
 
The first goal of this study was to evaluate a new αvβ3 ITOP, previously developed for 
targeting angiogenesis in cancer, for the detection of atherosclerotic plaques. In the 
theory of damage to the endothelium, it was postulated that epithelial cells are activated 
and express adhesion molecules that will recruit blood monocytes that will engulf lipids 
and ultimately become foam cells and create a necrotic core. The first type of lesions 
considered to be advanced and to have the possibility to become overt is the type IV 
lesions. Therefore, it becomes critical to develop imaging techniques allowing detection 
of this type of vulnerable plaques. In the WHHL study, human study and AD-HIES 
study, the αvβ3 ITOP seemed to detect plaques with medial disorganization and sign of 
inflammation, a characteristic of type IV plaques. Moreover, in addition of the adventitial 
labeling, there was a neointimal labeling that can be associated to endothelial activation. 
Taken together, those observations headed toward the potential of this αvβ3 ITOP to 
detect the first type of advanced plaques, the type IV lesions. In accord with this theory, 
the AD-HIES case presenting a plaque with positive remodeling and minimal stenosis 
(type IV) has been successfully labeled with the probe. The signal was found in the 
adventitia and near lumen area, which can be related to angiogenesis formation and 
endothelial activation. In the context of clinical imaging, it can represent a potential 
target for the detection of vulnerable plaques, as long as the detection method is sensitive 
enough and does not interfere with plaque stability. Combined with an imaging modality 
that can detect stenosis, we can discriminate between plaques that are considered to be 
healed or more stable, and plaques that present a more vulnerable type (Table 5). 
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Table 5     Timeline of atherosclerotic plaque detection 
Atherosclerotic 
plaque type I II III IV V VI 
αvβ3 
expression - - - + +/- +++ 
Lumen 
narrowing - - - +/- + ++ 
Plaque 
detection 
- 
Not detectable 
+/- 
Early 
Plaque 
(Advanced 
atherosclerosis) 
+ 
Late plaque 
 
 
Another goal of this study was to understand atherosclerosis formation in the context of 
other diseases. For this purpose, an AD-HIES disease model was used to look at specific 
markers of atherosclerosis. Since AD-HIES patient had been shown to present 
unexpected high level of coronary artery dilatations and aneurysms, markers of those 
processes have been evaluated. Over the recent years, it had been largely debated if 
atherosclerosis and aneurysms were developing concurrently, or if one causes the other. 
Most imaging study concluded that the two mechanisms were likely to be developing in 
parallel, although studies were unable to convincingly refute the involvement of 
atherosclerosis in aneurysm formation. In the AD-HIES case, the hypothesis that the 
atherosclerotic plaque directly caused aneurysm formation seems to be the more plausible 
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(Fig. 65). Effectively, in a study published in Nature Medicine in 2004, it was shown that 
STAT3 inhibition by dominant negative mutation or antisense produced an augmentation 
of the proinflammatory cytokines (TNF-α, RANTES, IL-6), and inverse effects were 
observed with STAT3 activation (inhibition of RANTES and IL-6 expression)[178]. As 
seen previously, IL-6 activation via JAK/STAT3 cascade is involved in migration, 
proliferation (cell survival), remodeling and angiogenesis, ultimately leading to healing. 
In the other hand, IL-6 activation via ERK/MAPK cascade lead to MMP-9 expression, 
which is involved in compensatory enlargement (positive remodeling). Consequently, 
STAT3 mutation will lead to detrimental effects on plaque stabilization via two important 
mechanisms. First, they will be constant feeding of IL-6 cytokine, because STAT3 
mutation upregulates IL-6 production. Second, STAT3 mutation will prevent the IL-6 
response via Jak/STAT3 cascade. In conjunction, those two mechanisms will favor 
aneurysm formation. It can also be mention that the defect in lymphocyte T maturation 
(Th17 defect) caused by STAT3 mutation can further prevent proper plaque healing and 
exacerbate aneurysm formation, as cross-talk between macrophages and lymphocytes is 
important for neointima formation and stenosis processes. 
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Figure 65 Proposition of signaling pathways leading to aneurysm formation 
in AD-HIES disease 
 
STAT3 inhibition, by dominant negative mutation or antisense, lead to a pro-
inflammatory state (IL-6 production). IL-6, via MAPK cascade, upregulates MMP-9 
expression and favor compensatory arterial enlargement (positive remodeling). In the 
other hand, STAT3 mutation block IL-6 effect via JAK/STAT, which causes less 
migration, proliferation (cell survival), negative remodeling and angiogenesis. The 
consequences are detrimental to the process of healing. STAT3 mutation also prevents 
lymphocyte T maturation, which has been involved in stenosis formation. Taken 
together, the activation of the MAPK cascade and the inhibition of the Jak/STAT3 
cascade, altogether with the proinflammatory state (IL-6 production) will ultimately 
favor aneurysm formation. 
IL-6R 
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Finally, AD-HIES disease is also an interesting model for the development and study of 
the inflammatory process, because it is classify as an immunodeficiency disease. 
Effectively, those patients have recurrent bacterial infections and they have difficulty to 
clear them. It is therefore surprising to see a more vulnerable type of plaque in the AD-
HIES disease model, as advanced atherosclerosis is often linked to an exacerbated 
inflammatory process. In the other hand, as mention before, it had been shown that 
mutation in STAT3 produced a more inflammatory state (RANTES, IL-6, TNF-α), as 
opposed to STAT3 activation that seemed to block Il-6 and RANTES expression[178]. 
This paradoxical situation is also present in HIV patient. Effectively, although HIV 
patients are immunocompromised, they are predisposed to atherosclerosis. It is unclear if 
this is due to the disease itself or to the medication taken. We can draw a parallel between 
these two diseases. Effectively, inflammatory processes, although recognized as being 
central in atherosclerosis formation, are also an important part of the healing mechanism. 
Therefore, anti-inflammatory therapy for the treatment of atherosclerotic disease can also 
lead to complications like aneurysm formation, in the presence of other conditions. It is 
also to be noted that both AD-HIES disease and HIV patients develop a lymphocyte T 
deficiency, either by absence of maturation or direct viral destruction. CD40 and CD40L, 
playing an important part in the cross-talk between macrophages and lymphocytes T, had 
been largely linked to restenosis and neointimal formation[156, 179, 180]. This pathway is 
considered to be of major importance in the development of atherosclerosis progression 
and complications, and strategies to inhibit it are under investigation. AD-HIES and HIV 
model can challenge this prevailing concept and showed that CD40 signaling can also 
provide a more beneficial effect, by allowing neointimal formation and luminal stenosis, 
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both involved into the plaque healing process. Effectively, macrophages releasing MMPs 
are an important process for clearing the path for SMCs migration. In presence of 
lymphocytes T, they can play their role and allow SMCs to begin the process of plaque 
healing. In the other way, in absence of lymphocyte T, their detrimental effect on ECM 
degradation is not counterbalance by SMCs proliferation, migration and matrix 
deposition. This could lead to diminution of vessel wall integrity and can cause plaque 
rupture. Rather than being involved in plaque rupture, lymphocyte T and IL-6 cascade, 
which are usually thought to be pro-inflammatory and detrimental to plaque stability, 
could be a major determinant in plaque healing. Consequently, presence of innate 
immunity, but defect in adaptive immunity could lead to absence of atherosclerosis 
healing and plaque rupture. Rather than being an exacerbated inflammatory process, 
plaque rupture will be the result of an inflammatory process that somewhere fails to be 
completed, because of the absence of key players, especially adaptive immunity. Indeed, 
many diseases causing low lymphocyte T count have been linked to atherosclerosis. For 
example, infections (viral or bacterial), HIV, tuberculosis, neurological and autoimmune 
diseases, and drugs can all lead to low level of circulating lymphocytes T. It is interesting 
to note that all of those diseases or conditions have also been linked to atherosclerosis. 
The same parallel can be deducted from atherosclerosis and aging. After all, there is no 
doubt that atherosclerosis is and aging disease, and aging is also responsible to lessen 
efficiency of immune system response. Although atherosclerosis is a multifaceted 
disease, the numeral relationships between immune defects, especially low lymphocyte T 
count, can hardly be seen as a pure coincidence. This can bring the intricate idea that 
reestablishing the crucial cross-talk between inflammatory cells can lead to plaque 
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stabilization. This also leads us to question the way we approach cardiovascular diseases. 
It becomes clear that genetic (as in the AD-HIES case) and the concomitant presence of 
other pathologies (HIV, asthma, infection, allergies, diabetes) can affect the 
atherosclerotic process and tips the balance toward plaque rupture and MI and stroke. In 
this regard, drugs and treatment administered to patients (particularly statins, NSAIDs, 
steroids) should take those other criteria into considerations. Consequently, in the future, 
it seems important to redirect the global medicine approach toward a more personalized 
medicine and an individual assessment of the patient.  
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CONCLUSION AND LIMITATION 
 
In this study, we reported the efficiency of a new αvβ3 ITOP to specifically label 
atherosclerotic plaques both in vitro and in vivo on a Watanabe rabbit model. We also 
showed that the αvβ3 ITOP was efficiently labeling human atherosclerotic plaque in 
vitro. In both animal model and human, the intensity of the αvβ3 ITOP labeling seemed 
to be correlated with the degree of adventitial thickening. This was an important finding, 
since adventitial thickening had been previously reported in plaque neovascularization, a 
process that was also related to plaque vulnerability. Human and animal samples also 
revealed a relationship between the αvβ3 signal and some markers of vulnerability, as 
inflammatory infiltration, intraplaque hemorrhages, medial necrosis and calcifications. 
More extensive studies on the correlation between the intensity of the αvβ3 ITOP signal 
and the plaque morphology will be necessary. Moreover, in human samples, there was an 
association between the αvβ3 signal and the degree of stenosis. Effectively, angiogenesis 
and neovascularization are involved in both ischemia and hypoxia mechanisms. It seems 
intuitive that stenotic plaques will necessitate more angiogenesis to compensate for the 
lack of oxygen into the neointima. In this study, we showed that plaque with high 
stenosis demonstrated important αvβ3 ITOP labeling, and early plaque with minimal 
stenosis seemed to demonstrate a less intense αvβ3 ITOP signal. A better understanding 
of the ITOP probe in the context of plaque morphology and composition could lead to not 
only detection of advanced plaques, but also detection of plaques that have the potency to 
rupture. 
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One important limitation of this study is the absence of probe characterization. Although 
the probe had been tested on cancer model previously, there were no data on specificity 
of labeling on cell lines. This is an important step, as it allows demonstration of the 
specificity of the probe for a certain target, αvβ3 in our case, compare to other types of 
integrins, as αvβ5 for example. For example, there are different cell lines, as M21, 
MCF7, A375 or U251, that are expressing either avb3, avb5, both or neither of them, that 
can be use to evaluate the specificity of our compound. 
Another limitation is the cross-sectional nature of the study. Effectively, both in vitro and 
in vivo experiments have been done on either cross-sectional sections of aortas, or cross-
sectional sections of coronary arteries. This limit the conclusions that could be draw, 
because there is no information on the entire arterial or coronary tree. For further probe 
characterization and morphological analysis, probe imaging on the entire aortic tissue ex 
vivo, or in vivo imaging with another imaging agent, will be necessary. PET agents, for 
example, could be used. 
The present study focused on pathology and immunohistology data. We evaluated the 
efficiency of the probe by immunofluorescence, as well as characterized the morphology 
and molecular markers of the samples by histological staining, immunofluorescence and 
immunochemistry. In order to confirm the results, it would be interesting to look at other 
methods of analysis. For examples, we could use Western Blot to confirm the presence of 
αvβ3 in the aortic tissue of the Watanabe rabbit with plaque. For MMP expression, we 
could use zymography, which not only shows the overexpression of MMPs, but also the 
presence of active molecule by showing enzymatic activity. The use of in situ PCR on 
slide would be interesting to verify the overexpression of αvβ3 in human samples. 
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Electromobility shift essay (EMSA) could also have confirmed in the AD-HIES case the 
diminution of STAT3 activity. Even though the pathological data and immunological 
studies demonstrated the efficiency of our αvβ3 ITOP probe to label atherosclerotic 
plaques, confirmation of the results with other techniques is always beneficial.  
  
FUTURE PERSPECTIVES 
 
Clinical Applicability 
As mentioned before, the actual techniques for the detection of atherosclerosis are mostly 
based on plaque with stenosis. Unfortunately, it had been shown that the majority of 
ruptured plaques causing cardiovascular events are plaques in positive remodeling phase, 
with minimal degree of stenosis. Thus, it becomes very important to be able to detect 
plaque not only at an earlier stage, but also be able to assess the plaque composition and 
potency to rupture. Because of its physicochemical properties, especially high affinity 
(IC50 of 3nM in vitro) and great selectivity (IC50 > 100µM in vitro), the αvβ3 ITOP has 
great potential to detect plaques with signs of vulnerability. Moreover, it has 20X times 
higher binding affinity for αvβ3 compared to the commercially available cyclic peptide 
c[RGDfv], and the in vivo results on tumor bearing mice showed efficient and specific 
labeling. Recently, the probe had also been labeled with 68Ga and linked with NODAGA, 
and tested on human cancer with very promising results. The probe didn’t show any 
toxicity and efficiently detect cancer in human. In this first human study in a breast 
cancer patient, the study reported 25 integrin ανβ3 positive lesions detected by the probe 
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(THERANOST cRGD™), versus 12 by 18F FDG. They also pointed out many 
advantages over 18F and 64Cu labeled RGD peptides, like the availability of 68Ga, the 
convenient radiolabelling, the high stability and the good imaging properties. This could 
translate into an interesting probe to detect atherosclerotic plaques with 
neovascularization process or vulnerability markers. More importantly, we showed that 
this αvβ3 ITOP could detect in vitro the first type of advanced plaques (type IV) in an 
AD-HIES model. This plaque was characterized by positive remodeling and showed 
important signs of vulnerability. If the detection method for the ITOP is sensitive enough, 
the potential for clinical translation and applicability is promising.  
The ITOP is currently being modified by a group of chemist at the NIH (Dr. Martin 
Briechber), who are working on different possibilities for imaging modality. As mention, 
it had been labeled with 68Ga and successfully used in human for cancer detection. Since 
toxicity study in human had been done, it could be easier to translate it into nuclear 
imaging of atherosclerosis. It is also being labeled with near infrared fluorescence 
(NIRF), which possesses better sensitivity and less background than green fluorescence 
(FITC). Unfortunately, because coronary arteries are localized deeper in the body, it will 
necessitate the use of catheters. Still, with the recent development in new and more 
efficient catheters, detection of vulnerable plaques with this ITOP becomes possible.  
On the other hand, one important point has to be mention: the αvβ3 ITOP developed is 
an antagonist of the αvβ3 receptor. The possibility of inhibiting the receptor and it effects 
on angiogenesis has to be kept in mind when using it as a molecular marker for imaging. 
Effectively, as mention before, even though neovascularization has been linked to 
detrimental effects as plaque vulnerability and instability, beneficial effects on plaque 
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healing and stenosis had also been demonstrated. Further investigations will be needed to 
insure enough sensitivity for efficient detection of atherosclerotic plaques, without 
producing any adverse effect on plaque stability. Nevertheless, chemical modifications 
and changes in design can be use to improve safety, if it becomes a concern. It can also 
be noted that the αvβ3 ITOP could be better suitable as a molecular tool for the analysis 
of atherosclerosis, as it seemed to response with more sensitivity to the αvβ3 receptor 
than the commercially available antibody. Nevertheless, its use in cancer detection and 
treatment remains appropriate. 
 
Future Investigation on Pathology and Plaque Morphology 
The field of atherosclerosis and plaque characterization involves a variety of specialties, 
and necessitates an important degree of general knowledge in a variety of field. Indeed, 
mathematical models, biological characterization, pathological observation, and imaging 
modalities, all come together to help elucidate the complex phenomenon involved in 
plaque vulnerability, plaque destabilization, and their clinical outcomes. During the past 
few years, important emphasis had been made on the understanding and characterization 
of the vulnerable plaques. Continuing this fundamental work is very important, as it can 
lead to early detection of atherosclerosis, and prevent the apparition of the clinical 
sequelae. Importantly, future investigations on plaques characterized as “vulnerable” will 
allow the development and perfecting of imaging techniques, and put the emphasis on the 
molecules with the most impact on plaque vulnerability. For example, understanding 
signaling pathways involved in vascular remodeling, particularly positive remodeling, 
will be a major advancement, since it is often seen in plaque rupture, and it is extremely 
Page 176 of 246 
 
difficult to observe by the actual imaging modalities. Also the association between 
immunodeficiency and plaque formation would be an interesting field to look at, as in the 
AD-HIES case, atherosclerosis seems to be linked to aneurysm formation. A link 
between immunodeficiency and atherosclerosis can also be observed in HIV patient, who 
had been reported to be susceptible to atherosclerosis. This suggests an important role of 
the adaptive immunity in atherosclerotic plaque healing. Another important player, as 
seen in this study, will be plaque neovascularization and its impact on plaque 
vulnerability. It is all the more important since advancement in imaging technique as 
MRI and CT, with the help of contrast agent, now allow us to better visualized the 
adventitia layer of the coronary artery. If we can better understand the association 
between neovascularization and vulnerability, we can develop imaging technique to 
assess plaque instability. It is also important to understand the different mechanisms of 
plaque vascularization, depending of the cytokine profile and growth factors involved, as 
it can tip the balance in favor of plaque stabilization or in an opposite way toward 
instability. This fundamental work to understand the basic molecular processes associated 
with atherosclerosis progression and plaque vulnerability is crucial, as it can provide 
molecular targets to develop and perfect all the different imaging modalities. 
 
Clinical Work in Atherosclerosis Field 
In this study, we emphasized the importance of working closely with clinicians to better 
understand and detect vulnerable plaques. In fact, imaging modalities combined with 
pathological data can lead to important advances in the detection of atherosclerotic 
plaques. Animal model can be very helpful to help elucidating important mechanism of 
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plaque ruptures/healing (positive remodeling, intraplaque hemorrhage, inflammation, 
etc.), but they are also limiting, in a sense that there is no perfect animal model that 
completely mimic human atherosclerotic processes, each one presenting its own strengths 
and weaknesses. Indeed, no animal model can recreate the phenomenal complexity of 
human atherosclerotic processes. Ultimately, we need to test our hypothesis on human 
and in a clinical setting, so we can validate the finding of animal studies. Also, human 
samples from autopsies from different populations and genetic background are extremely 
useful to help understanding atherosclerosis. Indeed, it is the evaluation and 
characterization of atherosclerosis in patients with other pathologies, as seen in AD-HIES 
and HIV diseases, that will allow us to progress with the ultimate goal of detecting 
atherosclerotic plaques before the clinical outcomes. Moreover, cell based studies on 
cells extracted from different patients are becoming a very efficient tool to investigate 
atherosclerotic diseases. It allows better understanding of the cytokine profile for 
different type of cells in a more clinical setting than with cell culture, because cells are 
extracted directly from human tissues or blood. In this regard, combining autopsy 
samples or blood analysis, research data and clinical reports will constitute a powerful 
tool for future investigation and discovery. 
 
Other Probe Design (ox-LDL) 
The focus of this thesis was the characterization of a new optical imaging probe targeting 
αvβ3 receptors, in diverse atherosclerotic models (animals, humans, STAT3 genetic 
disease). As documented in the chapter about the biomarkers of instability, there are other 
molecular targets that we can use to develop probes. MMPs are one example of 
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molecules playing an important role in plaque destabilization and vulnerability. There are 
already an important number of publications showing successful use of MMP probes in 
the detection of atherosclerosis, particularly MMP activatable probes. Macrophages are 
also of interest for the development of probes, because they definitively play a central 
role in the development of atherosclerosis, and being natural phagocytes, they are easily 
labeled. Most importantly, there is a growing interest into oxidized LDLs, as potent 
markers of atherosclerotic disease. Indeed, since LDL oxidation appears to be one of the 
first steps of plaque accumulation and also the one causing most of the vascular damages, 
we can postulate that ox-LDL will be an interesting target to look at. On the other hand, 
structural component of the vascular wall can also be use as imaging probe. For example, 
elastic fibers forming the internal and external elastic lamina in coronary arteries are 
crucial for tissue integrity and the degradation of those fibers can lead to a diminution of 
arteries’ elasticity, positive remodeling and plaque ruptures. Accordingly, imaging elastic 
fibers as well as plaque lipids can be a good method to predict possible rupture. These 
molecular targets are usually strongly correlated with plaque instability, but there is also a 
multitude of other possible players that need to be evaluated for developing probes, as 
well as many probe designs (monomer, polymer, nanoparticle, antibody, etc.…). 
In order to overcome the challenge of detecting atherosclerosis before the clinical 
outcome of heart attack and stroke, it becomes essential that basic research scientists and 
physicians collaborate closely together to develop a better understanding of plaque 
vulnerability and apply it to perfect the actual imaging techniques. Effectively, with the 
major contribution of clinicians and their access to patients with different pathologies, 
basic research will allow to identify important targets in plaque development and rupture 
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that can be further incorporated into imaging techniques. Indeed, the studies of patients 
with different genetic background can greatly help elucidating the mechanism of 
atherosclerosis and plaque ruptures. Therefore, it is fundamental that we continue to 
strengthen the collaboration between researchers and clinicians, and that we develop 
more bench-to-bedside projects.  
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ANNEX I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rabbit Protocol 
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NATIONAL INSTITUTES OF HEALTH 
ANIMAL STUDY PROPOSAL 
 
(See NIH Manual 3040-2) 
 
 
________________________________________
A. ADMINISTRATIVE DATA: 
 
Institute or Center NIDDK Principal Investigator Ahmed M. Gharib, Ph.D. 
Building/Room 10/CRC/3-5340 E-Mail agharib@mail.nih.gov Tel 301-451-8982 
FAX 301-480-3166 
Emergency Treatment and Animal Care instructions shall be provided on the attached form at the end of this document. 
Division, Laboratory, or Branch National Institute of Biomedical Imaging and Bioengineering 
Project Title αvß3-targeted Imaging of Early Atherosclerosis in Watanabe 
Heritable Hyperlipidemia (WHHL) Rabbits with a New Integrin Antagonist 
Initial Submission [ X ] Renewal [ ] or Modification [ ] of Proposal Number  
List the names of all individuals authorized to conduct procedures involving animals under this proposal and identify key 
personnel (i.e., Co- investigator(s)): A brief summary of the training and/or experience for procedures each individual will be 
expected to perform in this ASP must be documented and available to the ACUC. The name(s) of the supervisor, mentor, or 
trainer who will provide assurance each individual is/has achieved proficiency in those procedures shall be included in that 
documentation. 
Ahmed M. Gharib, Ph.D., Principal Investigator, 301-451-8982, PI refresher 
course 12/17/2009 Julie Heroux, Contract Technician, 301-451-9092, user 
refresher course 4/27/2009 Mary B. Angstadt, Technician (CC), 301-594-0050, 
user refresher course 7/9/2008 Zu-Xi Yu, Ph.D., Visiting Fellow, (NHLBI), 301-
496-5035, user refresher course 7/31/2007 
________________________________________________________________________ 
B. ANIMAL REQUIREMENTS: 
 
Species Rabbits Age/Weight/Size 10-25 months/ 3-5 Kg Sex Male & Female 
Stock or Strain New Zealand White (NZW); Watanabe (WHHL) Source(s) Brown 
Family Enterprises, LLC., dba Gemini Research of Alabama, Harlan Holding 
Locations(s) Bldg 14F Animal Procedure Location(s) Bldg 10/B1D315 (MIF), Bldg 
10/B1D221 (Procedure Room), Bldg 10/B1D200-202 (Imaging Facility) 
Estimated Number of Animals: 
32  14  14  60 
Year 1 Year 2 Year 3 TOTAL 
________________________________________________________________________ 
C. TRANSPORTATION: Transportation of animals must conform to all NIH and Facility guidelines/policies. If 
animals will be transported between facilities, describe the methods and containment to be utilized. If animals will be 
transported within the Clinical Center, also include the route and elevator(s) to be utilized. 
On arrival, rabbits will be housed in Building 14F and transportation will be 
carried out by a qualified individual using approved transport boxes in 
accordance with applicable regulations. On the day of experiment, rabbits will be 
delivered to the B1 loading dock of Building 10 and carried out to the procedure 
room or imaging location room B1D200-202 and B1D315 (MIF). When 
 Leave Blank 
PROPOSAL #K037-NIBIB-10  
 
APPROVAL DATE 10/6/2010  
 
EXPIRATION DATE 10/6/2013  
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transporting the rabbits in Bldg 10, animals will be transported in NIH approved 
filtered cardboard carriers, following NIH Guidelines, via stairwells or elevators 8, 
9, 16, 21, 28 or 38. 
________________________________________________________________________ 
D. STUDY OBJECTIVES: Provide no more than a 300 word summary of the objectives 
of this work. Why is this work important/interesting? How might this work benefit 
humans and/or animals? This should be 
written so that a non-scientist can easily understand it. Please eliminate or minimize 
abbreviations, technical terms, and jargon. Where they are necessary, they should be 
defined. 
 
Aim: 
The goal of this study is to evaluate the potential of a new molecular marker 
(αvß3 integrin antagonist) in the detection of the vulnerable atherosclerotic 
plaque by fluorescence, magnetic resonance imaging (MRI) and dual modality 
imaging. 
 
Rationale of the study: 
Previous studies have shown the great potential of targeting αvß3 integrin for the 
development of contrast agent that enhance the detection of the plaque and can 
also be used for the delivery of therapeutic drugs1-2. From these results, we 
investigated the possibility of targeting αvß3, in vitro, on rabbit aortas, with a new 
fluorescent labeled (FITC) integrin antagonist developed in a collaborating 
laboratory3. This study clearly demonstrated a specific signal enhancement into 
the vasculature of the disease animal model (Watanabe Heritable Hyperlipidemic 
rabbit) compare to the control animal model (New Zealand White rabbit). 
 
The present study has three objectives: 
 
1) To assess ex vivo, by histological techniques, the possibility of specifically 
label the early atherosclerotic plaque with fluorescence (FITC) labeled αvß3 
integrin antagonist. 
2) To evaluate in vivo, by MRI, the possibility of specifically label the early 
atherosclerotic plaque with the same αvß3 integrin antagonist labeled with 
gadolinium and then compare the results with other known MRI contrast agents 
(Gadofluorine, Feridex, Gadolinium, etc.). 
3) To investigate the feasibility of combining both MRI and Fluorescence imaging 
modality in a MRI guided fluorescence imaging system that could be further used 
for the delivery of drugs specifically in the atherosclerotic lesion. 
 
________________________________________________________________________ 
E. RATIONALE FOR ANIMAL USE: 1) Explain your rationale for animal use. 2) Justify the 
appropriateness of the species selected. 3) Justify the number of animals to be used. (Use additional sheets if necessary.) 
 
1) We would like to use animals for our study because only animal models can 
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reflect the complexity of the atherosclerosis disease. Since the study is about 
optimizing the imaging technique for the detection of atherosclerotic plaque, 
neither cellular models or computational models can reproduce the in vivo 
environment necessary for the evaluation of these imaging techniques. 
Moreover, because the contrast agent that will be used in this study (αvß3 
integrin antagonist) has already been studied with in vitro experiments and  
proved to target the plaque, we would like to test it in an in vivo experiment. 
 
2) We choose rabbits because of the availability of a genetic model that mimics 
the atherosclerosis disease (Watanabe Heritable Hyperlipidemic rabbit) and the 
practical size of the animal. Mice are also available with genetic disease 
background (ApoE knockout mice for example), but the smaller size of mice's 
vessels renders them difficult for catheter utilization and imaging technique and 
complicates the analysis of the imaging data. Pigs are also used for 
atherosclerosis studies, but the housing and maintenance are costly. For all 
these reasons, we think that Watanabe Heritable 
Hyperlipidemic rabbits (WHHL) and control New Zealand White rabbits (NZW) 
will be the most suitable model for imaging (MRI, Fluorescence) the target (αvß3 
integrin receptor) with an adequate resolution. 
 
3) We would like to study the effect of a contrast agent (integrin antagonist) on 
the visualization of early atherosclerotic plaque by different imaging techniques 
and then, compare this agent with other known contrast agents. To reach this 
goal, we include 18 rabbits for the optimization of the imaging technique: testing 
of imaging sequences, baseline testing with integrin contrast agent, baseline 
testing with other contrast agents (Gadofluorine-M, Feridex, etc.), imaging 
timeline, etc. 
 
For the study, we would like to use 6 Watanabe rabbits for each of the 3 
experimental conditions (fluorescence, MRI and dual imaging), in order to meet 
the requirements for journal publication. Also, we would like to use 2 normal NZW 
rabbits for each experimental technique (Fluorescence, MRI and dual imaging), 
to measure the efficiency of the contrast agent (no signal in the control animals 
without atherosclerotic plaque). Our rabbits requirements are based on two 
similar MRI studies that have shown greater signal enhancement in the rabbits 
injected with avß3 targeted particles1-2. 
 
 
In summary, for the first year, we would like to use a total of 32 rabbits for 
optimization of the experimental conditions and the fluorescence labeling study. If 
the results of these studies are promising, we would like to continue the imaging 
study with 14 rabbits during the second year (MRI) and 14 rabbits during the third 
year (dual imaging) for evaluating the potential of the new target molecule (avß3 
integrin antagonist) on the plaque visualization (See Table 1). 
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Please note that if at any point during the study, objectives have been 
accomplished, we may not need to use all rabbits that have been requested. 
Also, if during the study some preliminary results point out toward the failure of 
the project, we may stop the project immediately without using the remaining 
rabbits. 
 
Table 1 Number of Rabbits Required 
 
  Rabbits 
Watanabe 
rabbits injected 
with targeted 
particle 
Watanabe rabbits 
injected with non-
targeted particle 
NZW rabbits 
Types of 
Imaging         
Optimization   12 0 6 
Fluorescence Histology 6 6 2 
MRI In vivo 6 6 2 
MRI + 
Fluorescence In vivo 6 6 2 
 
Total Number WHHL Rabbits: 48  
Total Number NZW Rabbits: 12  
Total Number of Rabbits: 60  
 
References: 
1-Winter PM, Morawski AM, Caruthers SD, et al. Molecular imaging of 
angiogenesis in early- stage atherosclerosis with avß3-integrin-targeted 
nanoparticles. Circulation. 2003;108:2270-2274. 
 
 
2-Winter PM, Neubauer AM, Caruthers SD, et al. Endothelial avß3-integrin-
targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. 
Arterioscler Thromb Vasc Biol. 2006;26:2103-2109. 
 
________________________________________________________________________ 
F. DESCRIPTION OF EXPERIMENTAL DESIGN AND ANIMAL 
PROCEDURES: Briefly explain the experimental design and specify all animal procedures. This description should allow the 
ACUC to understand the experimental course of an animal from its entry into the experiment to the endpoint of the study. Specifically address 
the following: (Use additional sheets if necessary.) 
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S Injections or Inoculations (substances, e.g., infectious agents, adjuvants, etc.; dose, sites, volume, route, and schedules)  
S Blood Withdrawals (volume, frequency, withdrawal sites, and methodology)  
S Minor surgical procedures (that do not invade a body cavity)  
S Non-Survival Surgical Procedures (Provide details of major survival surgical procedures in Section G.) 
S Radiation (dosage and schedule)  
S Methods of Restraint (e.g., restraint chairs, collars, vests, harnesses, slings, etc.)  
S Animal Identification Methods (e.g., ear tags, tattoos, collar, cage card, etc.)  
S Other Procedures (e.g., survival studies, tail biopsies, etc.)  
S Potentially Painful or Distressful Effects, if any, the animals are expected to experience (e.g., pain or distress, ascites 
 production, etc.) For Column E studies provide: 1) a description of the procedure(s) producing pain and/or distress; 2) 
scientific justification why pain and/or distress can not be relieved. 
 S Experimental Endpoint Criteria (i.e., tumor size, percentage body weight gain or loss, inability to eat or drink, behavioral 
abnormalities, clinical symptomatology, or signs of toxicity) must be specified when the administration of tumor cells, 
biologics, infectious agents, radiation or toxic chemicals are expected to cause significant symptomatology or are potentially 
lethal. List the criteria to be used to determine when euthanasia is to be performed. Death as an endpoint must always be 
scientifically justified. 
 
Injections of Inoculations  
 
Fluorescence procedures: 
 
For the ex vivo fluorescence imaging, the rabbit will be brought to the 10/B1D221 
procedure room and injected with 0.3mmol/Kg of body weight of fluorescence-
labeled (FITC) αvβ3 integrin antagonist into the ear vein. The rabbit will then be 
anesthetized 2 hours later and immediately euthanized by the methods described 
in the section I and J. The rabbits will be dissected to excise portions of the 
coronary arteries and aorta for histological analysis using confocal fluorescence 
microscopy. 
 
MRI procedures: 
 
Rabbits will be delivered to the NMR center in rabbit transport box and kept in the 
box until anesthetized. For the experiments in which contrast agent should be 
administered in advance, they will be given IV into the rabbits auricular vein 
according to the table below, at the end of the section, for doses and timeline.  
For these experiments, a baseline scan could be done just before the contrast 
agent injection. Anesthesia will be induced using a ketamine 25-50mg/kg (usually 
30mg/kg) and xylazine 5mg/kg mixture. This will be administered subcutaneously 
(SC) or intramuscularly (IM) using a 25 gauge needle in the biceps femoris 
muscle of either hindleg. The eyes will be lubricated with sterile opthalmic 
petroleum ointment applied to the corneas. For anesthesia maintenance, the 
rabbit will be intubated with 1-3% isoflurane, with a mix of oxygen and medical 
air. 
 
MR safe conductive leads will be placed for the detection of ECG. Optimum 
positioning and composition of ECG leads is to be determined. A pressure 
transducer for respiratory detection will be placed on the abdomen. A fiber optic 
temperature probe (Model 1025 Monitoring & Gating System , SA Instrument Inc, 
NY) will be placed beneath the abdomen or a standard MR compatible rectal 
temperature probe can also be used. Lightly-adhesive tape may be used as 
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needed to stabilize the position of the body. The body of the rabbit will be 
supported on a platform and in order to maintain body temperature, a circulating 
warm water pad or a warm air blower at the magnet bore will be used. The 
respiration waveform and rate and ECG will be read on a computer 
monitoring/gating system. Respiration and temperature are monitored throughout 
the experiment for surveillance and maintenance of anesthesia. 
 
MRI studies of the aorta in the area of the aortic root and arch and/or thoracic 
and abdominal aorta will be performed on a 3T MR scanner (B1D200-202). A 
combination of black-blood, Gated Proton Density T1- and T2- weighted spin 
echo or gradient echo imaging of the chest will be performed as indicated, but not 
limited to these sequences. The imaging period will be approximatively 2 to 3 
hours. The animal is monitored continuously on the MRI monitor screen and any 
animal movement will become apparent on the images. At the end of the scan 
(except for the baseline scan), the rabbit will be immediately euthanized and 
dissected (the rabbit will never be woke up), to examine the tissues by 
histological and microscopical techniques. 
 
Catheterization procedure and Dual imaging: 
 
Rabbits will be brought to the NMR center and anesthetized and imaged 
according to the previously described procedure in the MRI section. The femoral 
artery will be punctured percutaneously (small incision) while the rabbit (already 
anesthetized) is still outside the MR scanner. If a suitable access to the femoral 
artery cannot be achieved percutaneously, we may use a cut down procedure 
and vessel exposure as an alternative technique for the cannula placement. 
 
Heparin (100 IU/kg body weight) will then be administered as an intravascular 
bolus. A canula will be used to access the femoral arteries. A catheter used for 
active MR imaging will then be advanced through the canula to reach the aorta. 
Standard guidewires may also be used when necessary. 
Catheterization will be performed during free breathing. Cardiac triggering may 
be used to obtain time-difference images. The intravascular devices will be 
visualized by active catheter technologies which make the catheter tip show up 
extremely bright in an image, or by the lack of signal present. 
 
For the catheterization, gadolinium (Gd) contrast material could be injected to 
confirm engagement and right positioning into the target region. Real-time 
images and the procedure time for each target region will be recorded. Real-time 
images will be utilized to confirm the tip position of the tracking devices on 
selected still-frame images. The catheter sheath will be coupled to a fluorescence 
imaging fiber optic apparatus which emits laser light at different colors. This 
apparatus permits the detection of fluorescence-labeled contrast agents and 
uses an computer located outside the MR scanner. At the end of the scan, the 
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anesthetized rabbit will be euthanized and dissected, to examine the tissues by 
histological and microscopical techniques. 
 
 
 
List of contrast agents that can be used for IV injection into the auricular vein: 
Gadolinium            0.1mmol/kg                        20min before MRI 
Gadofluorine-M    50µmol/kg                           24hrs before MRI 
Feridex                 15µmol/kg                          10min before MRI 
Resovist                0.45mmol                           24hrs before MRI  
 
 
Blood Withdrawals 
 
One or two mL of blood sample would be obtained via the auricular artery using a 
23 gauge butterfly catheter. This blood sample will be used for cholesterol, 
lipoprotein, and proteomic analysis. This will be done once, just before the scan 
and after the anesthesia to minimize pain. 
 
Animal Identification Methods 
 
The rabbits will be tattooed on either of the ears and then placed in cage 
identified by card. 
 
Resultant Effects, if any, the animals are expected to experience 
 
We do not expect any adverse effects with the contrast agents and with the 
Watanabe rabbits at this age. 
 
Experimental Endpoint Criteria 
 
At the end of the scan, the animals will be euthanized in order to dissect and 
excise portions of the coronary arteries and the aorta and further analyze tissues 
by histology. 
________________________________________________________________________
G. MAJOR SURVIVAL SURGERY - If proposed, complete the following: NoneX 
 
1. Identify and describe the surgical procedure(s) to be performed. Include the aseptic methods to 
be utilized. (Use additional sheets if necessary): 
 
2. Who will perform surgery and what are their qualifications and/or experience? 
 
3. Where will surgery be performed, Building and Room 
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4. Describe post-operative care required, including consideration of the use of post-operative 
analgesics, and identify the responsible individual: 
 
5. Has major survival surgery been performed on any animal prior to being placed on this study? 
Y/N If yes, please explain: 
 
6. Will more than one major survival surgery be performed on an animal while on this study? Y/N 
If yes, please justify: 
________________________________________________________________________
H. RECORDING PAIN OR DISTRESS CATEGORY - The ACUC is responsible for 
applying U.S. Government Principle IV. contained in Appendix 3: Proper use of animals, including the 
avoidance or minimization of discomfort, distress, and pain when consistent with sound scientific practices, is 
imperative. Unless the contrary is established, investigators should consider that procedures that cause pain or 
distress in human beings may cause pain or distress in other animals. Check the appropriate category(ies)and 
indicate the approximate number of animals in each. Sum(s) should equal total from Section B. 
 
IF ANIMALS ARE INDICATED IN COLUMN E, A SCIENTIFIC JUSTIFICATION IS REQUIRED TO 
EXPLAIN WHY THE USE OF ANESTHETICS, ANALGESICS, SEDATIVES OR TRANQUILIZERS 
DURING AND/OR FOLLOWING PAINFUL OR DISTRESSFUL PROCEDURES IS CONTRAINDICATED. 
FOR USDA REGULATED SPECIES, PLEASE COMPLETE THE EXPLANATION FOR COLUMN E 
LISTINGS FORM AT THE END OF THIS DOCUMENT. THIS FORM WILL ACCOMPANY THE NIH 
ANNUAL REPORT TO THE USDA. FOR ALL OTHER SPECIES, THE JUSTIFICATION FOR SUCH 
STUDIES MUST BE PROVIDED IN SECTION F. NOTE: THIS COLUMN E FORM, AND ANY 
ATTACHMENTS, e.g., THE ASP, ARE SUBJECT TO THE FREEDOM OF INFORMATION ACT. 
 
 
NUMBER OF ANIMALS USED EACH YEAR 
 
                                   Year 1 Year 2  Year 3 
            
   
[   ] USDA Column C - Minimal, Transient, or No Pain or Distress             
[X] USDA Column D - Pain or Distress Relieved By Appropriate Measures              32              14             14 
[   ] USDA Column E - Unrelieved Pain or Distress   
      ________    ________    ________ 
Describe your consideration of alternatives to procedures listed for Column D and E that may cause more 
than momentary or slight pain or distress to the animals, and your determination that alternatives were not 
available. [Note: Principal investigators must certify in paragraph N.5. that no valid alternative was 
identified to any described procedures which may cause more than momentary pain or distress, whether it 
is relieved or not.] Delineate the methods and sources used in the search below. Database references must 
include databases (2 or more) searched, the date of the search, period covered, and keywords used: 
 
Database: ILAR; search date: 6/9/2010; period covered: 1964-Present; 
Keywords: restraint, MRI, rabbit;  
No results found for rabbit 
 
Database: Pubmed; search date: 6/9/2010; period covered: 1966-Present; 
Keywords: restraint, MRI, rabbit; found only one paper in Magnetic Resonance in 
Medicine journal (Magn Reson Med. 2000 Sep;44(3):474-8).  
The title is fMRI of visual system activation in the conscious rabbit. They said that 
the rabbit is ideal for these experiments (conscious MRI) because of its natural 
tolerance for restraint. They acquired high spatial and temporal resolution 
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magnetic resonance images during long periods of restraint with conscious 
rabbits (no anesthesia). We will anesthetize rabbits for the MRI which should 
result in less stress and pain. 
________________________________________________________________________ 
I. ANESTHESIA, ANALGESIA, TRANQUILIZATION - For animals indicated in Section H, 
Column D, specify the anesthetics, analgesics, sedatives or tranquilizers that are to be used. Include the name of the agent(s), 
the dosage, route and schedule of administration. None____ 
 
Anesthesia will be induced using a ketamine 25-50mg/kg (usually 30mg/kg) and 
xylazine 5mg/kg mixture. This will be administrated subcutaneously (SC) or 
intramuscularly (IM) using a 25 gauge needle in the biceps femoris muscle of 
either hindleg. For anesthesia maintenance, the rabbit will be intubated with 1-3% 
isoflurane, with a mix of oxygen and medical air. Isoflurane will be used in an 
area approved by the Division of Health and Safety (DOHS) 
________________________________________________________________________ 
J. METHOD OF EUTHANASIA OR DISPOSITION OF ANIMALS AT END 
OF STUDY: Indicate the proposed method, and if a chemical agent is used, specify the dosage and route of 
administration. If the method(s) of euthanasia include those not recommended by the AVMA Panel Report on Euthanasia, 
provide justification why such methods must be used. Indicate the method of carcass disposal if not as MPW.   None ____ 
 
Pentobarbital IV at a dose of 85 to 150 mg/kg or injection of KCl (potassium 
chloride) IV at a dose of 1-2meq/Kg when animal is under isoflurane anesthesia. 
The carcass will then be disposed off in MPW box lined with two trash bags. 
________________________________________________________________________ 
K. HAZARDOUS AGENTS: Use of hazardous agents requires the approval of an IC safety specialist. 
Registration Documents for the use of recombinant DNA or potential human pathogens may be attached at the discretion of 
the ACUC. None ____ 
 
YES [X] NO [ ] List Agents and Registration Document Number (If Applicable) 
 
1.  Radionuclides           
2.  Biological Agent           
3.  Hazardous Chemical or Drugs   isoflurane      
4.  Recombinant DNA         
Study conducted at Animal Biosafety Level:  ABL-1  
Describe the practices and procedures required for the safe handling and disposal of contaminated 
animals and material associated with this study.  Use of volatile anesthetics requires a description of 
scavenging methods used.  Also describe methods for removal of radioactive waste and, if applicable, 
the monitoring of radioactivity. 
 
Gas anesthetics (e.g. isoflurane) will be scavenged using an approved anesthetic 
gas scavenging system, e.g., in-house vacuum, down-draft table, chemical fume 
hood, or ducted biosafety cabinet. 
 
Carcasses will be disposed of in a double-bagged Medical Pathological Waste 
(MPW) box, as described previously in Section J. 
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Additional safety considerations: 
________________________________________________________________________ 
L. BIOLOGICAL MATERIAL/ANIMAL PRODUCTS FOR USE IN ANIMALS 
(e.g., cell lines, antiserum, etc.): None X 
1. Specify Material________________________________________________________________ 
 
2. Source__________________________ Material Sterile or Attenuated ________Yes ________No 
 
3 If derived from rodents, has the material been MAP/RAP/HAP/PCR tested?__Yes (Attach copy of 
results)  No______  
     
4. I certify that the MAP/RAP/HAP/PCR tested materials to be used have not been passed through 
rodent species outside of the animal facility in question and/or the material is derived from the 
original MAP tested sample.  To the best of my knowledge the material remains uncontaminated 
with rodent pathogens. 
 
___________ Initials of Principal Investigator 
________________________________________________________________________ 
M. SPECIAL CONCERNS OR REQUIREMENTS OF THE STUDY - List any special 
housing, equipment, animal care (i.e., special caging, water, feed, or waste disposal, etc.). Include justification for exemption 
from participation in the environmental enrichment plan for nonhuman primates or exercise for dogs. None ____ 
 
The Watanabe Heritable Hyperlipidemic (WHHL) rabbits will be obtained from a 
NIH non- approved vendor (Brown Family Enterprises, LLC dba Gemini Research 
of Alabama) and housed in Building 14F. The Health Report from the vendor 
should be obtained by the animal program coordinator. 
 
 
________________________________________________________________________ 
N. PRINCIPAL INVESTIGATOR CERTIFICATIONS: 
 
1. I certify that I have attended an approved NIH investigator training course.  
Year of Course Attendance: 2005 Year(s) of Refresher Training: 2008; 2009 
 
2. I certify that I have determined that the research proposed herein is not unnecessarily duplicative of 
previously reported research. 
 
3. I certify that all individuals working on this proposal who have animal contact are participating in the 
NIH Animal Exposure Program (or equivalent, as applicable, for contract personnel). 
 
4. I certify that the individuals listed in Section A are authorized to conduct procedures involving animals 
under this proposal, have attended the course "Using Animals in Intramural Research: Guidelines for 
Animal Users" will complete refresher training as required, and received training in the biology, 
handling, and care of this species; aseptic surgical methods and techniques (if necessary); the concept, 
availability, and use of research or testing methods that limit the use of animals or minimize distress; 
the proper use of anesthetics, analgesics, and tranquilizers (if necessary); procedures for reporting 
animal welfare concerns. I further certify that I am responsible for the professional conduct of all 
personnel listed in Section A. 
 
5. FOR ALL COLUMN D AND COLUMN E PROPOSALS (see section H): I certify that I have 
reviewed the pertinent scientific literature and the sources and/or databases (2 or more) as noted in 
section H, and have found no valid alternative to any procedures described herein which may cause 
more than momentary pain or distress, whether it is relieved or not. 
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6. I will obtain approval from the ACUC before initiating any significant changes in this study (See PM 
3040-2, F.4.d.). 
 
Principal Investigator: Signature___________    ______Date______________ 
 
 
 
 
 
_______________________________________________________________________
O. CONCURRENCES: PROPOSAL NUMBER ___________ (LEAVE BLANK) 
 
Laboratory/Branch Chief: certification of review and approval on the basis of scientific merit. Scientific 
Director's signature required for proposals submitted by a Laboratory or Branch Chief 
Name   Ira W. Levin, Ph.D.  Signature   Date__________ 
 
Safety Representative: certification of review and concurrence (Required of all studies utilizing hazardous 
agents)  
 
Name  Diana Stadler   Signature    Date__________ 
 
Facility Manager: certification of resource capability in the indicated facility to support the proposed 
study  
 
Facility 14F  Name Dave Dorsey  Signature  Date__________ 
 
COMMENTS: 
 
Facility Veterinarian: certification of review  
 
Name JoanneSmith,D.V.M.   Signature                Date_____ 
 
Attending Veterinarian: certification of Review 
 
Name    Mark St. Claire, D.V.M.   Signature        Date__        
 
__________________________________________________________________________________________ 
P. FINAL APPROVAL: 
 
Certification of review and approval by the NIDDK Animal Care and Use Committee Chairperson  
 
Chairperson Samuel W. Cushman, Ph.D.  Signature   Date____________ 
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INSTRUCTIONS FOR EMERGENCY ANIMAL TREATMENT AND 
CARE 
 
Principal Investigator: _____Ahmed Gharib___Date form completed:7/7/2010 
Protocol Number:_____ASP K037___ 
Office Phone: _____301-451-8982__ 
Home Phone:_____301-951-9537___ 
 
Protocol Title: __ αvß3-targeted imaging of early atherosclerosis in Watanabe Heritable 
Hyperlipidemia (WHHL) rabbits with a new integrin antagonist_______    
Use a separate form if care is different for each species 
 Species: ______ Watanabe rabbit _____________Species: ____________ 
 Species: ______New Zealand White rabbit ___     Species: ______________ 
 
Animal Housing Location:    Bldg __14F___________________ 
Use separate form if care differs by location 
        Bldg ________________________  
        Bldg ________________________ 
 
List of Procedures:  
(surgery, tumor implant, catheter)_ Auricular blood drawn, Contrast agent injection__  
Primary Point of Contact (P.O.C.) in Case of Emergency: Ahmed Gharib 
Work Tel: _301-451-8982_ Home Tel: _301-951-9537___ Pager or Cell #: 10212076 
Alternate Point of Contact in Case of Emergency: Julie Heroux 
Work Tel: _301-451-9092_ Home Tel: _240-751-4451____Pager or Cell #:  
Potential or Expected Complications: _____ N/A ______________________ 
Circumstances Requiring Contact: ________ Dead Animal ______________ 
 
Treatment (indicate appropriate response):  
Treatment determined by veterinarian: [ X ] Yes [ ] No 
  If NO, specify restrictions as follows: _______________________  
Specific treatment as follows: ________N/A_______________________  
What drugs are contraindicated? ______N/A____________________ 
 
Criteria for Euthanasia (indicate appropriate response)  
At Vet discretion if poor condition, severe pain or distress: [X] Yes [ ] No 
 If NO, specify treatments or restrictions: 
___________________________________________________________ 
 
Notify P.O.C. *[X] Yes [ ] No  
Requested euthanasia agent and route of administration: ______N/A______  
Specific criteria for euthanasia: ____N/A_____________________________ 
 
If Euthanasia is performed or animals are found dead: 
a. Contact P.O.C.       [X] Yes  [  ] No 
b. Refrigerate carcass      [  ] Yes  [X] No 
c. Dispose of carcass      [X] Yes  [  ] No 
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d. Submit to DVR for necropsy     [  ] Yes  [X] No 
CAN number to use for submission: _____8327125___________ 
 
Additional Comments: 
________________________________________________________________________ 
 
Principal Investigator: 
____________________________________________________________________ 
Signature                                                               
 Date 
________________________________________________________________________
_________________________ 
* The veterinarian will take the appropriate action in an emergency if no response 
from the PI/POC is received within 30 minutes after an attempt at notification is 
made. 
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Abstract
Purpose: A newly developed synthetic αvβ3 integrin targeted optical probe (ITOP) has been
demonstrated to target cancer cells, in vivo. Compared to the commercially available cyclic
peptide c[RGDfv], this optical probe has at least 20 times better binding affinity for the αvβ3
receptor. The present in vitro study was designed to investigate the possibility of detecting early
atherosclerotic plaque by using this ITOP.
Procedures: Experiments were performed on five Watanabe heritable hyperlipidemic rabbits and
two New Zealand White rabbits for control. Our ITOP was used for detecting the presence of
αvβ3 receptors in vitro.
Results: Segments of plaque accumulation from two distinct regions of ascending and
descending aortas were labeled in Watanabe rabbits. The signal was found principally in the
adventitia and proximal intima of the aortic vessel, corresponding directly to the expression
of integrin αvβ3 as determined by antibody assay. Moreover, there was a close association
between the level of labeling with the αvβ3 targeted probe and the thickness of the
adventitia.
Conclusions: This high-affinity ITOP identifies the site and extent of αvβ3 expression and
correlates with adventitial thickness. Recent evidence associates αvβ3 expression with the
inflammatory process in early vulnerable plaque, making this compound a promising potential
biomarker for early atherosclerotic disease.
Key words: Aorta, Atherosclerosis, αvβ3 integrin, Immunohistofluorescence, Molecular imaging,
Targeted optical probe, Watanabe heritable hyperlipidemic rabbits
Source of support: Intramural NIH funding
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Abbreviations FITC, Fluorescein isothiocyanate; NZW, New Zealand White; WHHL,
Watanabe heritable hyperlipidemic; ECM, Extracellular matrix; IC50, Inhibitory concentration;
ITOP, Integrin targeted optical probe; OCT, Optimal cutting temperature; H&E, Hematoxylin
and eosin; NI, Neointima; M, Media; Ad, Adventitia; DAPI, 4′,6-Diamidino-2phenylindole
Introduction
D espite all the recent technological and medicaladvances, cardiovascular disease remains the leading
cause of death in the Western World and needs to be
detected at an earlier stage [1]. With the understanding of
atherosclerosis as an inflammatory disease [2, 3], there is a
growing interest in the detection of components of the
inflammatory process as early biomarkers of this disease. One
potential promising molecular target for the detection of
atherosclerotic plaque is the αvβ3 receptor [4, 5], which is a
widely recognized target for the development of molecular
probes in pathological conditions [6, 7]. In addition, human
atherosclerosis lesions show extensive expression of αvβ3 [8],
which plays a role in thrombus formation [9], cell migration
[10], neovascularization [7, 11], as well as many other
processes. Although αvβ3 is expressed on a variety of cells,
its expression seems to be predominant in smooth muscle cells
and endothelial cells [8, 12]. Macrophages also express αvβ3
during foam cells formation [13]. Most interesting is the fact
that αvβ3 expression seems to be an early event in plaque
formation [5, 14] and is also correlated with plaque instability
[4, 15]. Additionally, previous studies have shown the great
potential of targeting αvβ3 integrin for the development of
contrast agents that enhance the detection of plaque [16, 17]
and for the delivery of therapeutic drugs [18].
Recently, an integrin targeted optical probe (ITOP) was
synthesized and has been shown to efficiently target the αvβ3
receptor with high affinity in an in vivo mouse model of cancer
[19]. The probe is a small non-peptidic carbamate integrin
antagonist (RGD mimic), which is fluorescently labeled and
targets the αvβ3 integrin. Compared to nanoparticles having
sizes of hundreds of nanometers (nm), this probe is much
smaller (G1 nm), which should translate into better clearance
from blood and better diffusion into the targeted tissue. In vitro,
this labeled compound has very high affinity for αvβ3 (IC50 of
3 nM) and greater selectivity towards αvβ3 compared to
αIIbβIIIa, αvβ5, and αvβ6 (IC50>100µM) [19]. This ITOP
has at least 20 times higher binding affinity for αvβ3
compared to the commercially available cyclic peptide c
[RGDfv] labeled with fluorescein isothiocyanate (FITC;
personal communication, Narasimhan Danthi). When intra-
venously injected in tumor bearing mice, the ITOP persisted
in the tumor for more than 4 h, while it disappeared from
most of the other tissues within an hour, demonstrating that
its biodistribution is conducive for use in imaging. Based on
these animal experiments [19], we have not seen immuno-
genic reactions associated with our ITOP. As a first step, in
this in vitro study, we have explored the utility of this ITOP
to probe the molecular processes involved in atherosclerotic
plaque formation, in a Watanabe rabbit model.
Materials and Methods
Integrin αvβ3 Targeted Optical Probe Synthesis
The αvβ3 ITOP 4-[2-(3,4,5,6-tetrahydropyrimidin-2ylamino)ethyl-oxy]
benzoyl-2-(S)-[N-(3-amino-neopenta-1-carbamyl)]-aminoethylsulfony-
lamino-β-alanine fluorescein thiourea (Fig. 5, suppl. data) was
synthesized as previously described. Briefly, ITOP was developed from
a potent fibrinogen receptor antagonist (3-amino-2(S)-arylsulfonylami-
nopropionic acid derivative) [20] with further structural modifications,
followed by conjugation to FITC. The conjugation of the fluorophore to
the integrin antagonist did not alter the binding affinity or selectivity to
integrin αvβ3. This compound represents the first example of a non-
peptidic integrin αvβ3 targeted optical probe. In the binding assays as
well as in the cell adhesion inhibition assays this compound showed
very high binding affinity (3nM) and selectivity to αvβ3 compared to
αIIbβIIIa, αvβ5, and αvβ6 [19].
Experimental Design
All experiments were performed on specimens taken from 3- to 12-
month-old Watanabe heritable hyperlipidemic (WHHL) rabbits, two
females and three males (n=5), fed a standard rabbit chow diet. The
animals were purchased from Brown Family Enterprises (Gemini
Research of Alabama, Odenville, Alabama, USA). Control aortic
tissues without atherosclerosis were taken from New Zealand White
(NZW) rabbits (n=2) and purchased from Zyagen (San Diego, CA,
USA). Prior to any experiments, rabbits were anesthetized with a
ketamine (30 mg/kg) and xylazine (5 mg/kg) cocktail administered
subcutaneously and then euthanized by intravenous pentobarbital
(100 mg/kg) injection while still under anesthesia. The aortic arch was
excised and cut into different sections prior to be quick frozen in
optimal cutting temperature (OCT) media for histological and
immunohistological experiments. All experiments were performed in
accordance with protocols approved by the Animal Care and Use
Committee of the National Heart Lung and Blood Institute.
Histology
OCT blocks from frozen aortic tissue were cut into 7–8-µm sections
with a cryostat and mounted onto slides. Routine hematoxylin and eosin
(H&E) straining was performed on the frozen sections. An antibody
against human αvβ3, anti-human integrin αvβ3, clone LM609
(Chemicon International, Temecula, CA, USA), was used to confirm
the presence of the integrin and as a reference for the localization of any
experimental fluorescence signal. This antibody was used in conjunc-
tion with an anti-mouse horseradish peroxidase detection kit, according
to the specifications of the company (Chemicon International).
Expression of αvβ3 integrin in the aortic wall was assessed by
immunohistofluorescence with the new ITOP. Sections were thawed
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for 15 min at room temperature, fixed for 10 min with cold acetone,
washed in phosphate buffer solution, and then incubated with the
targeted fluorescent probe for 1 h. After the incubation period, the slides
were washed again, mounted with VECTASHIELDmounting medium
containing DAPI (Vector Laboratories, Burlingame, CA, USA) and a
coverslip was applied. For signal specificity experiments, slides were
incubated with the unlabeled ITOP prior to the washing and mounting
steps. Images of staining or fluorescence signal were acquired under a
microscope (Nikon E1000 with a Nikon DXM-1200 color camera)
using a visible or ultraviolet light source, respectively.
Results
Plaque Labeling
Histological staining (H&E) of WHHL rabbit aortic tissue
demonstrated intimal thickening, which was absent in the
control. Examination of the aortic tissue incubated for 1 h
with the ITOP showed a strong fluorescent signal (Fig. 1a).
Aortic tissue that has been incubated with non-labeled ITOP
showed a loss of signal (Fig. 6, suppl. data). Signal
enhancement was predominately localized in the adventitia
and the neointima, though there was also some fluorescence
in the media. In contrast, the specific fluorescent signal of
the integrin targeted probe was absent in the control NZW
rabbits (Fig. 1b). There was some autofluorescence in the
aortic tissue, but it was negligible.
Signal Correlation with an Anti-αvβ3 Antibody
A transverse image of the ascending aorta of the WHHL
rabbit shows that the intimal thickening (neointima) of the
tissue is a component of the atherosclerotic plaque (Fig. 2).
Upon comparison, the immunohistological labeling of αvβ3
(Fig. 2, right panels) and the fluorescence signal of the
ITOP (Fig. 2, left panels) appear co-localized to the same
regions. Higher magnification (×100) of the neointimal
region (Fig. 2c, d) demonstrated corresponding strong
fluorescence and immunohistological signals near the
interface of the lumen and intima. The fluorescent and
immunohistological labeling are mostly localized in the
adventitia and proximal intima of the ascending aorta; a
similar distribution was shown in the descending aorta
sections (Fig. 1).
Adventitia Labeling
Higher magnification images of the adventitial sections
demonstrated co-localization between the ITOP signal and
the DAPI (4′,6-diamidino-2phenylindole) labeling of cell
nuclei, suggesting that the signal from the fluorescent
molecule is found close to the nucleus of the cell (Fig. 3).
Adventitial co-localization results also showed neovessel-
like structures, located around regions delineated by cells
labeled with fluorescent ITOP.
Labeling and Adventitia Thickness
Comparison between fluorescent staining with the αvβ3
targeted probe (Fig. 4, upper panel) and histological staining
(Fig. 4, bottom panel) of the corresponding descending aorta
section demonstrates a qualitative correlation between
fluorescent signal intensity and adventitial thickness. Thus,
a mild signal was present in plaques with a small adventitia
thickness (Fig. 4a, b, d, e), while a strong signal appeared on
plaque with marked adventitia thickness (Fig. 4c, f). There is
also some inverse correlation between the intensity of
fluorescence labeling and the organization level of the
plaque. Staining was very intense (Fig. 4c) when the media
was disorganized (Fig. 4f) and less intense (Fig. 4a, b) when
the media was well delineated (Fig. 4d, e).
Fig. 1. Fluorescence microscopy of Watanabe rabbit descending aorta sections (transverse cut) from tissue incubated with
FITC-αvβ3 targeted probe. a Image (×40 magnification) of slide exposed to FITC-αvβ3 targeted probe (2.8µM) for 1 h. b
Background fluorescence of the same region in slide from control NZW rabbit exposed to the fluorescent ITOP with the same
conditions (×100 magnification). Results indicate specific plaque labeling with the fluorescent targeted probe with a very small
amount of autofluorescence background from tissues. FITC fluorescein isothiocyanate, Ad adventitia, M media, NI neointima.
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Discussion
Integrin expression, particularly αvβ3, in atherosclerotic
plaque is a critical component of the inflammatory process
that can drive the plaque toward a more unstable state [21,
22] leading to plaque rupture [23–25]. Many processes
taking place during the initiation and progression of
inflammatory vascular lesions require αvβ3 expression,
including foam cell formation [13], smooth muscle cell
migration [26], and thrombus formation [9].
In this study, we describe the use of a novel synthetic
high affinity and high specificity αvβ3 integrin targeted
Fig. 3. Fluorescence microscopy of localization of the αvβ3 targeted-probe labeling inside the adventitia. This image (×400
magnifications) shows a composite image of the ITOP staining and DAPI staining (nucleus of cells) of the same aortic region.
Smaller inset image represents the targeted-probe labeling alone. The targeted-probe signal appears to be localized on the
surface of the cells, near the nucleus. There is presence of some structures similar to early neovessels that are labeled with
fluorescence. FITC fluorescein isothiocyanate, DAPI 4′,6-diamidino-2phenylindole.
Fig. 2. Co-localization study of αvβ3 expression on Watanabe rabbit ascending aorta sections labeled with fluorescence (a, c)
or immunohistochemistry (b, d). The upper panels display the whole aortic wall (×40 magnifications), while the bottom panels
are focused on the neointimal region (×100 magnifications). Both the fluorescence signal (a, c) and the immunohistological
labeling (b, d) are co-localized predominantly in the adventitia and proximal neointima. Arrowheads illustrate immunohisto-
logical staining. FITC fluorescein isothiocyanate, Ad adventitia, M media, NI neointima.
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optical probe and confirmed the in vitro specific labeling of
rabbit atherosclerotic plaques (Figs. 1 and 2). We also show
that the ITOP signal is localized near the nucleus of the cell
(Fig. 3), which indicates that fluorescence is correlated to
cells (αvβ3 receptors are membrane-bound) instead of
unspecific ECM labeling. One interesting observation in
the present work is that the fluorescent signal of the integrin
targeted optical probe seems to extend from the adventitia
toward the media of the aortic wall (Fig. 1a). The presence
of fluorescent signal in the media is correlated with strong
labeling and expansion of the adventitial layer (Figs. 1a and
3). This finding might be associated with the development of
the angiogenic processes that first begins within the
adventitia (vasa vasorum expansion) and then extends to
the media of the vessel wall [27]. Nevertheless, further
studies must be carried out to clarify the relationship
between our compound and the natural history of angio-
genesis in atheroma. Most importantly, there is a strong
correlation between the labeling of atherosclerotic plaque
with the integrin targeted probe and the thickness of the
adventitia (Fig. 4). Thus, adventitial thickness is character-
ized by a strong and widely distributed signal enhancement
with the probe, which may signal a more advanced
inflammatory state. Moreover, stronger αvβ3 labeling is
situated where the media is less organized, which is another
sign of the presence of inflammation.
In agreement with other studies [5, 8, 16], we also found
that the most significant accumulation of the αvβ3 receptor
was in the adventitia of the aortic wall, a privileged site for
the formation of neovessels. We also observed a character-
istic expansion of the adventitia, a process which has been
extensively described by others studies [5, 16, 28, 29]. This
expansion allows angiogenesis and will further attract more
inflammatory cells and lipids into the plaque, contributing to
plaque growth, instability, and rupture.
In addition to the adventitial localization of the signal, we
also observed fluorescence within the neointima of plaques,
close to the lumen. Previous studies have shown that
activated or proliferative endothelial cells express high
levels of αvβ3 [7, 11]. This integrin is critical for the
survival signal of these cells and is also recognized to
influence adhesion and migration pathways [12]. Hence, it is
not surprising to observe evidence of αvβ3 within the intima.
With the broad development of nanoparticles in disease
detection [30, 31], we can extrapolate the use of this new
αvβ3 integrin targeted probe for imaging atherosclerosis in
combination with a variety of high-resolution molecular
imaging techniques [32, 33]. The synthetic nature of this
molecule makes it attractive for the development of various
nanoparticle structures incorporating this molecule to target
the plaque. For example, this ITOP was efficiently used in a
combined imaging/treatment system for targeted drug
Fig. 4. Intensity of fluorescence staining in Watanabe rabbit descending aorta sections (a, b, c) correlated with adventitia
thickness and plaque histology (d, e, f). In images (×100 magnifications) of aorta sections with relatively small adventitia (mild
thickening; d, e), the level of staining and the intensity of the αvβ3 targeted-probe signal is relatively mild (a, b). In a similar
direct correlation, for the aorta sections with large adventitia (marked thickening; f), the signal from the αvβ3 targeted probe is
marked (c). There was also an apparent inverse correlation between the intensity of labeling and the organization within the
plaque. Staining is very intense when the media appears disrupted (c) and less intense when the media is well delineated (a, b).
FITC fluorescein isothiocyanate, Ad adventitia, M media, NI neointima.
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delivery and imaging of cancer angiogenesis [34]. For
coronary atherosclerotic plaque assessment, we are working
on labeling this ITOP with near-infrared molecules as part of
a dual imaging system, which may allow MRI-guided
catheter to detect fluorescent probes. This can lead to the
delivery of treatments into specific unstable area of the
plaque.
Relative to peptide-based molecules, this synthetic probe
provides easier production and purification. Moreover, its
affinity as a labeled probe for the αvβ3 receptor is higher
than the commercially available labeled cyclic peptide c
[RGDfv]. This should translate into a smaller injected dose
for the plaque detection and also a better sensitivity. In
addition, our ITOP is specific to αvβ3, whereas linear and
cyclic RGD peptide specificity is broader (αvβ3, αIIbβ3a,
αvβ5).
The physiochemical characteristics of this probe are also
important. As opposed to antibodies, this small synthetic
molecule (G1 nm) has less potential to induce an immune
response and has important advantages related to the blood
clearance and its diffusion into the targeted atherosclerotic
tissue. Moreover, unlike antibodies, the probe is very
suitable for further derivatives or structure modifications.
However, future in vivo studies will be necessary to evaluate
the labeling efficiency and kinetic uptake properties of this
new optical probe.
Conclusions
This in vitro work demonstrates that a new high-affinity
ITOP identifies the presence of αvβ3 expression associated
with early atherosclerotic plaque development in the aortas
of Watanabe rabbits. The studies further suggest that the
αvβ3 expression identified by this probe corresponds to the
degree of adventitial thickening. As such, this new probe
holds promise for meeting the challenge of detecting early
atherosclerotic lesions and identifying vulnerable plaque.
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ABSTRACT 
 
Purpose The detection of early atherosclerosis, before the development of its later 
sequelae of myocardial infarction, angina or stroke, constitutes an important challenge in 
current diagnostic medicine. Despite all the recent technological advances, cardiovascular 
disease remains the leading cause of death in the Western World and needs to be detected 
at an earlier stage to allow for more timely therapeutic intervention. This study is 
focusing on the detection of atherosclerosis or more specifically plaque vulnerability with 
the help of molecular imaging and pathological observation. Effectively, to predict 
plaque rupture, molecular imaging has emerged as a powerful diagnostic tool, consequent 
to the development of a growing number of new probes with affinity for key molecular 
targets. As a result, such selective molecules with high affinity for overexpressed targets 
in plaque formation, as αvβ3 integrin, should hold promises as probes for imaging 
atherosclerosis. With the help of molecular imaging combined with pathological 
observations, we can better comprehend, predict, and detect plaque vulnerability and 
rupture.  
Objectives The overall objective of this study was to evaluate different molecular 
tools to predict the vulnerability of the atheromatous plaque. The major objective of the 
research was to investigate the possibility of detecting atherosclerotic plaques by using a 
newly developed synthetic αvβ3 integrin targeted optical probe (ITOP) showing 
particularly high affinity and specificity for αvβ3 receptors. We also investigate the 
relationship between this probe and pathological observation of atherosclerotic plaques 
from WHHL animal model and different human samples. 
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Procedures and Results For this study, experiments were performed on 12 
Watanabe heritable hyperlipidemic (WHHL) rabbits and 1 New Zealand White (NZW) 
rabbit for control. First, our ITOP labeled with fluorescein isothiocyanate was used for 
detecting the presence of αvβ3 receptors in vitro and ex vivo on a Watanabe rabbit model. 
Fluorescence microscopy demonstrated a strong labeling of atherosclerotic plaques, 
which was absent in tissue from normal NZW rabbits. Segments of plaque accumulation 
from two distinct regions of ascending and descending aortas were labeled in each 
rabbits. The signal was found principally in the adventitia and proximal intima of the 
aortic vessel, corresponding directly to the expression of integrin αvβ3 as determined by 
antibody assay. Moreover, there was a close association between the level of labeling 
with the αvβ3 targeted probe and the thickness of the adventitia. Secondly, the ITOP was 
evaluated on human atherosclerotic samples, and was found to efficiently labeled 
atherosclerotic plaques. Moreover, we observed the same tendency as in the Watanabe 
rabbit: the ITOP intensity correlated with the degree of adventitial thickening. Finally, we 
tested the ITOP on AD-HIES coronary arteries, and have been able to detect a plaque 
corresponding to the first type of advanced atherosclerosis (type IV). We also found a 
relationship between plaque morphology and predisposition to aneurysms in AD-HIES. 
Conclusions αvβ3 expression is related to inflammatory and stenotic processes. 
Our ITOP can efficiently label in vitro the first type of advanced atherosclerotic plaques. 
In combination with noninvasive imaging techniques that evaluates stenosis, it has great 
potential for the detection of vulnerable plaques. 
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RESUMÉ 
 
But La détection précoce de l’athérosclérose, avant le développement de ses séquelles 
pathologiques, comme l’infarctus du myocarde, l’angine ou l’accident cérébraux-
vasculaire (ACV), représente un important défi au niveau de la médecine diagnostique 
actuelle. En dépit de toutes les récentes avances technologiques, les maladies 
cardiovasculaires demeurent la principale cause de décès dans les pays occidentaux et la 
détection à un stage plus précoce s’avère nécessaire pour permettre une intervention 
thérapeutique adéquate. Notre étude se concentre sur la détection de l’athérosclérose ou 
plus spécifiquement la vulnérabilité de la plaque, grâce à l’imagerie moléculaire et 
l’observation pathologique. Effectivement, pour prédire la rupture de la plaque, 
l’imagerie moléculaire a émergé comme outil diagnostique puissant suite au 
développement croissant de nouvelles sondes ayant de l’affinité pour les molécules cibles 
du processus d’athérosclérose. Comme résultantes, ces molécules sélectives possédant 
une forte affinité pour des cibles surexprimées durant le processus de formation de la 
plaque, comme l’αvβ3 par exemple, devrait représentées des sondes prometteuses pour la 
détection de l’athérosclérose. Avec l’aide de l’imagerie moléculaire combinée à 
l’observation pathologique, nous pourrons mieux comprendre et prédire la vulnérabilité 
et rupture de la plaque.  
Objectif L’objectif global de notre étude était d’évaluer et de prédire la 
vulnérabilité de la plaque d’athérome à l’aide de différents marqueurs moléculaires. Le 
principal objectif de notre recherche était d’évaluer la possibilité de détecter précocement 
la plaque  en utilisant une ITOP (integrin targeted optical probe). Cette sonde synthétique 
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nouvellement développée et ciblant l’intégrine αvβ3 avait déjà démontré une affinité et 
spécificité particulièrement élevée pour le récepteur de l’αvβ3 dans le cancer. Nous 
avons également exploré la relation entre cette sonde et l’observation pathologique des 
plaques d’athéromes sur le modèle animale WHHL et sur des plaques humaines 
provenant de différents patients. 
Procédure et Résultats Pour cette étude, les expériences ont été réalisées sur un 
total de 12 lapins Watanabe hyperlipidémiques de souche WHHL (Watanabe heritable 
hyperlipidemic) et 1 lapin contrôle NZW (New Zealand White). Premièrement, notre 
ITOP, marquée avec la fluorescéine isothiocyanate (FITC), a été utilisée pour détecter in 
vitro et ex vivo la présence du récepteur de l’αvβ3. La microscopie à fluorescence a 
révélé un important marquage de la plaque d’athérome, lequel était absent dans les tissus 
provenant des lapins contrôles NZW. Le marquage a été détecté au niveau de segments 
de plaques provenant de deux régions distinctes de l’aorte ascendante et descendante dans 
chaque lapin. Le signal a été détecté principalement au niveau de l’adventitia et de 
l’intima proximale des vaisseaux aortiques, correspondant directement à l’expression de 
l’intégrine αvβ3, déterminée par essai immunochimique avec un anticorps contre l’αvβ3. 
De plus, une forte association s’est révélée entre le niveau de marquage de la sonde 
ciblant l’αvβ3 et l’épaisseur de l’adventitia. Deuxièmement, nous avons évalué notre 
sonde sur des échantillons humains affectés par l’athérosclérose et comparé les résultats 
avec l’évaluation morphologique de la plaque. Nous avons remarqué la même tendance 
que chez le lapin, soi un marquage plus important lorsque l’adventitia s’épaissi. 
Finalement, nous avons testé la sonde sur des artères coronaires provenant d’une autopsie 
d’un patient affecté par le AD-HIES et comparé les résultats avec l’évaluation 
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morphologique de leurs artères coronaires. Nous avons trouvé un lien entre la 
morphologie de la plaque et la prévalence d’anévrysmes coronaires chez ces patients. 
Conclusion L’expression de l’αvβ3 est reliée à la foi aux processus inflammatoires et 
à la sténose. Notre ITOP à marqué efficacement in vitro le premier type de plaque 
d’athérome classé comme avancé (type IV) et pouvant produire des manifestations 
cliniques. En combinaison avec l’imagerie noninvasive détectant la sténose, il pourrait 
s’avéré utile dans la détection de la plaque vulnérable. 
 
